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ABSTRACT OF DISSERTATION

PROTEOMICS AND PHOSPHOPROTEOMICS OF BRAIN: (1) ANALYSES OF
THE PINK1 KNOCKOUT MODEL OF PARKINSON DISEASE; (2) INSIGHTS
INTO THE PROGRESSION OF ALZHEIMER DISEASE; AND (3) THE NAKED
MOLE RAT MODEL OF SALUBRIOUS AGING
Proteomics is the field of science in which proteins produced by an
organism (the proteome) are identified. The level of a particular protein can vary
with time and the influence of cellular stressors. The study of phosphoproteomics
is vital because tyrosine, serine and threonine phosphorylation modulate protein
structure and function and is a crucial regulator of cellular signaling pathways.
Dysregulation of protein and phosphorylation levels has been reported in multiple
neurodegenerative disorders including Parkinson disease (PD) and Alzheimer
disease (AD).
PINK1 is a mitochondrial serine/threonine kinase that polices
mitochondrial integrity. Mutations in this protein are associated with familial earlyonset PD. PD is characterized by accumulated Lewy bodies, largely composed of
aggregated alpha-synuclein, and progressive dopaminergic neuronal
degeneration in the substantia nigra. In this dissertation study, proteomics
identified differences in protein expression and protein phosphorylation levels in
the brains of PINK1 knockout mice. The observed changes suggest that
perturbed metabolism, diminished proteostasis, decreased neuronal plasticity,
and aberrant cellular signaling are implicated in familial PD pathogenesis.
AD is characterized by senile plaques, neurofibrillary tangles and synapse
loss. Previously, multiple AD brain proteins were reported from our laboratory as
abnormally phosphorylated, indicating that deregulated phosphorylation may play
a key role in AD pathogenesis. In this dissertation study, quantitative
phosphoproteomic analyses were conducted on the inferior parietal lobule from
three different clinical stages of AD, i.e., late-stage AD, amnestic mild cognitive
impairment (MCI) and preclinical AD (PCAD). The differential phosphoproteins
identified provide insights into underlying mechanisms promoting the

preservation of memory in PCAD with expansive AD pathology, while uncovering
early aberrant phosphorylation events in MCI that conceivably may be involved in
the progressive cognitive decline leading to dementia.
Aging is a primary risk factor for development of neurodegenerative
disorders, including AD and PD. The naked mole-rat (NMR), which can live for 32
years, is currently under investigation to gain insights into extending human
lifespan and healthspan. In this dissertation research, age-related alterations of
the brain proteome and phosphoproteome of the NMR were identified, revealing
key proteins involved in neuronal plasticity, energy metabolism, autophagy, and
the ubiquitin-proteasome system that may contribute to salubrious longevity.
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CHAPTER 1
Introduction
The studies described in this work utilize proteomics and
phosphoproteomics techniques to gain a greater understanding of underlying
biochemical mechanisms that contribute to pathology and clinical presentation of
Alzheimer and Parkinson diseases. Additionally, changes in the brain proteome
and phosphoproteome that occur with age in the naked mole-rat (NMR) are
probed to examine mechanisms that may be central in maintaining an
exceptionally long, healthy lifespan. Further, proteomic insights into key proteins
involved in promoting/hindering neurodegenerative disease mechanisms may
provide biomarkers to aid in early detection and development of effective,
targeted therapeutics.
Many neurodegenerative diseases share common characteristics
including: changes in energy metabolism, diminished proteostasis networks,
increased oxidative stress, altered cellular signaling, and reductions in
neuroplasticity, neurotransmission and cellular structure (Beal 1992, Butterfield
and Kanski 2001, Palop, Chin et al. 2006, Rubinsztein 2006). Parkinson disease
(PD) and Alzheimer disease (AD) are the two most common age-related
neurodegenerative diseases. Although these disorders usually appear later in
life, mutations in key genes can induce early onset, inheritable forms of the
disease. In this dissertation research, we examined the proteome and
phosphoproteome of the PINK1 (phosphatase and tensin homologue induced
kinase1) knockout mouse model of PD at the earliest inception of disease
1

presentation (6 months-old). Further, we analyzed changes in the
phosphoproteome in the inferior parietal lobule from three different pathological
stages of AD: preclinical AD (PCAD), amnestic mild cognitive impairment (MCI),
and AD to evaluate mechanisms involved in disease progression from MCI to AD
as well as understanding underlying mechanisms that preserve memory and
cognitive function despite the presence of expansive senile plaque (SP) and
neurofibrillary tangle (NFT) pathology typical to AD brains.
Even though the greatest single risk factor for neurodegeneration is aging
(Lin and Beal 2006), most neurodegenerative research is conducted on shortlived species. However, by examining the age-related changes in the proteome
and phosphoproteome of the longest-lived rodent, the NMR, may provide
superior insights into proteins that may play critical roles in mechanisms that
resist neurodegeneration and facilitate cellular proteostasis for healthy cognitive
aging and improved quality of life.
The overall hypothesis of this dissertation research is that the underlying
biochemical changes, as evident by evaluation the proteome and
phosphoproteome of neurodegenerative brain, contribute to disease progression,
pathogenesis, and clinical presentation and how proteomic investigations of the
NMR could possibly identify key proteins that contribute to mechanisms
promoting salubrious longevity. To support the overall hypothesis, this
dissertation addresses the following:

2

1. What changes occur in the proteome and phosphoproteome of brain from
PINK1-KO mice at the earliest stage of PD-like pathology?
2. Which proteins exhibit altered phosphorylation states in the inferior
parietal lobule (IPL) of amnestic MCI and are they harbingers of AD?
3. What are the differences in the phosphoproteome of IPL of PCAD and AD
subjects and how does a brain heavy with SPs and NFTs negate cognitive
impairment?
4. What are the underlying mechanisms promoting a long healthspan and
lifespan in the NMR?
a. What are the biochemical changes in brain metabolism as these
animals age?
b. Which proteins are implicated in maintaining robust proteostasis
networks throughout their long lives?
c.

Are there alterations in levels or activity of proteins associated with
neuroplasticity, neurotransmission, or structure which may
contribute to the extraordinary traits of the NMR?

Copyright © Judy Carol Triplet 2015
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CHAPTER 2
BACKGROUND

2.1 Neurodegeneration overview
Neurodegenerative diseases are a collection of disorders characterized by
selective, progressive loss of neuronal structure and function. Oftentimes, these
diseases share certain common characteristics, including: alterations in energy
metabolism, mitochondrial dysfunction, increased oxidative stress, failing
proteostasis networks, aggregation of misfolded proteins, and neuronal cell death
(Beal 1992, Butterfield and Kanski 2001, Lin and Beal 2006, Palop, Chin et al.
2006). Since aging is the greatest risk factor for developing a neurodegenerative
disease, a potential global therapy may conceivably lie in targeting key proteins
in one or more of these common neurodegenerative pathways to ameliorate
disease severity and promote a healthy lifespan.
2.1.1 Parkinson disease (PD)
2.1.1.1 PD overview
PD is the most common neurodegenerative movement disorder that
affects approximately 1-2% of the population over the age of 65 and 3-5% of the
population over 85 years-old (Fahn 2003). Additionally, 5-10% of PD patients
may have an early-onset form of the disease with symptom onset occurring
before the age of 50 (Alves, Forsaa et al. 2008). Except for incidences of PD
caused by inheritable DNA mutations, the etiology of PD remains unclear, though
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a number of contributing factors (in addition to age) have been implicated:
exposure to environmental toxic metals or pesticides (Priyadarshi, Khuder et al.
2001), having a family member with PD (Kurz, Alves et al. 2003), mitochondrial
dysfunction and oxidative stress (Henchcliffe and Beal 2008, Bueler 2009), and
failure of proteostasis networks (McNaught, Olanow et al. 2001, Lynch-Day, Mao
et al. 2012).
2.1.1.2 PD Pathology and physiology
PD is characterized by the aggregation of phosphorylated α-synuclein
(Ser-129) within Lewy bodies and by the catastrophic death of the majority of
dopaminergic (DA) neurons in the pars compacta region of the substantia nigra,
although other neuronal types have been reportedly depleted as well (Braak, Del
Tredici et al. 2003, Anderson, Walker et al. 2006). Significant DA neuron loss can
result in one or more of the four cardinal motor symptoms of PD: resting tremor,
bradykinesia, muscular rigidity, and postural instability (Jankovic 2008). The
vulnerability of DA neurons has been linked to their reportedly reduced
mitochondrial reserve as compared to that of other neuronal types (Matsuda,
Kitagishi et al. 2013). Without an ample reserve of mitochondria, DA neurons are
more susceptible to apoptosis during periods of acute energy crisis,
mitochondrial dysfunction and oxidative stress (Hauser and Hastings 2013, Van
Laar and Berman 2013). Other typical non-motor PD symptoms, which include
anosmia, constipation, depression, hallucinations, REM sleep disorder, and
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cognitive decline (Chaudhuri, Healy et al. 2006) may appear many years before
the onset of motor-related symptoms.
2.1.1.3 PINK1
2.1.1.3.1 PINK1 function
Mutations in PTEN induced kinase 1 (PINK1), a mitochondrial
serine/threonine kinase, are associated with autosomal recessive-inherited early
onset PD (Kawajiri, Saiki et al. 2011). PINK1 is short-lived neuroprotective
protein that polices mitochondrial integrity (Narendra, Jin et al. 2010). When
mitochondria are functioning in a healthy steady-state, PINK1 is imported to the
inner mitochondrial membrane where it is immediately cleaved by proteases,
including PARL (presenillins-associated rhomboid-like protein), and retrotranslocated to the cytosol for proteasomal degradation (Figure 2.1) (Deas, PlunFavreau et al. 2011).
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Figure 2.1 PINK1 in healthy mitochondria. Cleavage of PINK1 at the inner
mitochondrial membrane in healthy mitochondria.
However, when mitochondria become dysfunctional and depolarize (Figure 2.2),
PINK1 import into the mitochondria is blocked and PINK1 accumulates on the
outer mitochondrial membrane where it recruits and phosphorylates Parkin, an
E3 ligase, to initiate mitophagy for disposal of the damaged organelle (Matsuda,
Sato et al. 2010).
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Figure 2.2 Pink1 in damaged mitochondria. PINK1 accumulating on the outer
membrane of damaged mitochondria, recruiting Parkin for mitophagy.
With malfunctioned PINK1, damaged mitochondria accumulate and disrupt
energy and calcium homeostasis (Heeman, Van den Haute et al. 2011).
2.1.1.3.2 PINK1 knockout (KO) PD mouse model
PINK1 KO mice do not develop α-synuclein-containing Lewy bodies,
nigrostraital neurodegeneration or manifestation of the four cardinal motor
symptoms; however, pre-motor symptoms are present, including anosmia and
gait disturbances (Glasl, Kloos et al. 2012). Consequently, PINK1 KO mice are a
good model to study early PD development and early biomarkers (Glasl, Kloos et
al. 2012). Further, PINK1 KO mice reportedly have decreased dopamine release,
reduced synaptic plasticity (Kitada, Pisani et al. 2007), progressive weight loss
and motor disturbances that correlate to reduced dopamine (Gispert, Ricciardi et
al. 2009). Further, in the brain of PINK1 KO mice, mitochondria exhibit functional
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defects as they have decreased ATP production (Gispert, Ricciardi et al. 2009),
reduced capacity for Ca2+ storage (Akundi, Huang et al. 2011) and increased
sensitivity to oxidative stress (Gautier, Kitada et al. 2008).
2.1.1.4 Mitochondria and superoxide
2.1.1.4.1 Mitochondria
The mitochondrial respiratory chain, located on the inner mitochondrial
membrane, is composed of five multisubunit protein complexes, which generate
ATP by electron (e-) mediated coupling of H+ and O2 to form H2O. The majority of
energy generated by oxidative phosphorylation is spent maintaining ion
gradients, propagating action potentials, releasing and recycling
neurotransmitters; therefore, mitochondrial dysregulation can be detrimental to
neuronal survival (Attwell and Laughlin 2001).
2.1.1.4.2 Superoxide
Up to 2% of oxygen consumed in this process is converted to superoxide
(.O2-) due to e- leakage from the ETC (primarily from complex I and II) and
transference to O2 (Chouchani, Pell et al. 2014). Superoxide can lead to
oxidative damage in a number of ways: (i) by direct damage by free radical chain
reactions; (ii) by reaction with nitric oxide to form peroxynitrite leading to protein
nitration; and (iii) indirectly by conversion to H2O2 by superoxide dismutase
(SOD), which though Fenton reactions can oxidize H2O2 producing a hydroxide
anion and a hydroxyl radical leading to lipid peroxidation and protein oxidation
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(Figure 2.3). The hydroxyl radical is considered to be one of the most toxic free
radical reactive oxygen species due to high reactivity and irreversible lipid,
protein and DNA modifications (Halliwell 2007).

Figure 2.3 Consequences of superoxide production. Pathways to protein
nitration, lipid peroxidation and protein oxidation.
2.1.2 Alzheimer disease (AD)
2.1.2.1 AD overview
AD, the most common neurodegenerative disease, afflicts 11% of the
population over the age of 65 and 32% of people over 75 (Hebert, Weuve et al.
2013). Interestingly, about two-thirds of the 5.2 million Americans with AD are
women (Hebert, Weuve et al. 2013). Since the greatest risk factor for developing
AD is age; and to date, no significant difference has been found between men
and women who develop AD (Hebert, Scherr et al. 2001), except for the longer
average lifespan of women. Other proposed AD contributing factors include: Aβ
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toxicity, oxidative stress, dysfunctional energy metabolism, and inflammation
(Butterfield and Kanski 2002, Hynd, Scott et al. 2004, Tuppo and Arias 2005).
2.1.2.2 AD pathology and physiology
Neuropathological hallmarks of AD include the extensive distribution of
extracellular senile plaques (SPs), intracellular neurofibrillary tangles (NFTs),
amyloid β-peptide (Aβ) oligomers, and loss of synapses, which results in
increased neuronal death. SPs are insoluble, fibrous Aβ-containing aggregations
that are often surrounded by dystrophic neurites. NFTs are insoluble aggregates
containing hyperphosphorylated tau proteins that have uncoupled from
microtubules, leading to disassembly of the microtubules and decimation of
neuronal infrastructure and axonal transport. Severity of AD clinical symptoms
tends to correlate with the quantity and distribution of SPs, NFTs and lost
synapses (Braak and Braak 1995, Thal, Rub et al. 2002). The pathology and
underlying biochemical mechanisms lead to escalating memory loss and
cognitive dysfunction that culminates in severe dementia.
2.1.2.3 AD progression
2.1.2.3.1 Amnestic mild cognitive impairment (MCI)
MCI is considered to be a transition between normal cognition and AD as
the MCI brain generally displays levels of SPs, NFTs, neuronal loss, and
oxidative stress that are intermediate to levels in AD (Morris, Storandt et al.
2001); however, SP density and abundance can vary widely (Villain, Chetelat et

11

al. 2012). A more reliable indicator that correlates with increased cognitive
impairment and synapse loss is the measurement of Aβ oligomers, of which
Aβ(1-42) is most toxic (Butterfield and Kanski 2002, Pham, Crews et al. 2010).
Additionally, MCI subjects have non-age-related cognitive deficits but exhibit no
signs of dementia or hindrance in performing every-day tasks (Petersen 2004).
MCI is divided into two specific categories: amnestic MCI, which involves
memory loss, and non-amnestic MCI, which does not affect memory (Portet,
Ousset et al. 2006). Moreover, amnestic MCI is considered to be a preferential
harbinger of AD (Portet, Ousset et al. 2006) and the conversion rate to AD is
approximately 10-15% per annum (Maioli, Coveri et al. 2007). Proteomic
research into this disease stage may conceivably uncover biomarkers to facilitate
early AD detection and increase understanding of early mechanisms involved in
disease progression.
2.1.2.3.2 Preclinical AD (PCAD)
Individuals with PCAD display no cognitive deficits, however, at
postmortem, they exhibit extensive distribution of SP and NFT pathology (ErtenLyons, Woltjer et al. 2009). PCAD brains are not only uncommon but also
possess some remarkable traits including: minimal or no loss of neurons (Price,
Ko et al. 2001), increased synaptic plasticity (O'Brien, Resnick et al. 2009), levels
of oxidative stress similar to control brain (Aluise, Robinson et al. 2010, Aluise,
Robinson et al. 2011), increased neuronal hypertrophy (Iacono, O'Brien et al.
2008), and alterations to proteins involved in anion transport (Lyubartseva, Smith

12

et al. 2010). Identifying neurochemical mechanisms that inhibit cognitive decline
despite heavy SP and NFT burden may provide critical clues towards therapeutic
interventions stopping progressive memory loss.
2.1.3. Oxidative stress
Oxidative stress is implicated in multiple neurodegenerative disorders
(Uttara, Singh et al. 2009). Oxidative stress occurs in a system when levels
reactive oxygen species (ROS) and reactive nitrogen species (RNS) overwhelm
antioxidant defenses (Dasuri, Zhang et al. 2013). An oxidatively-stressed
environment leads to damaged biomolecules, such as lipid membranes and
proteins, and can induce post translational modifications that may result in
altered protein structure and function, protein unfolding and aggregation, among
others (Butterfield and Lauderback 2002).
2.1.3.1 Reactive oxygen species (ROS) and reactive nitrogen species (RNS)
ROS and RNS are toxic species and free radicals that include:
superoxide, hydroxyl radical, hydrogen peroxide, nitric oxide, and peroxynitrite,
among others. ROS and RNS are tightly controlled by antioxidant enzymes, e.g.,
superoxide dismutase (SOD), biliverdin reductase, glutathione peroxidase,
peroxiredoxins, catalase, and many heat shock proteins, and molecules, such as
glutathione, vitamins C, D and E, and lipoic acid, to maintain the cellular redox
state (Gilgun-Sherki, Melamed et al. 2001). An imbalance in this system can lead
to oxidative damage to lipids, proteins and DNA (Halliwell 2007).
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2.1.3.3 Lipid peroxidation and 4-hydroxy-2-nonenal (HNE)
Lipid peroxidation occurs in three stages: initiation, propagation and
termination. Initiation occurs when an allylic hydrogen is removed from the lipid
leaving a carbon-centered radical that can react with O2 to form a peroxyl radical.
Propagation occurs as a radical-radical chain reaction leads to further allylic
hydrogen abstraction, which can cause production of reactive alkenals, loss of
lipid asymmetry and apoptosis (Castegna, Lauderback et al. 2004, Butterfield,
Bader Lange et al. 2010). Lipid peroxidation of arachidonic acid leads to the
formation of 4-hydroxy-2-nonenal (HNE). HNE can render proteins dysfunctional
by binding to His, Lys and Cys residues via a Michael’s addition reaction, thereby
altering the protein’s structure and function (Butterfield, Bader Lange et al. 2010).
2.1.3.4 Tyrosine nitration
Tyrosine nitration occurs when a nitro group is added to tyrosine at the 3position. The presence of this nitrite group sterically blocks tyrosine kinasemediated phosphorylation, causing altered protein activity (Tangpong, Cole et al.
2007). Further, increased levels of tyrosine nitration elevate the likelihood of
proteasomal degradation of the protein and can lead to neuronal death (Gow,
Duran et al. 1996, Mattson, Goodman et al. 1997).
2.1.3.5 Protein carbonyl (PC)
PCs are the most wildly measured marker of oxidative stress (DalleDonne, Scaloni et al. 2005). PCs can be formed on proteins through a variety of
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mechanisms, including: Michael addition reactions with lipid peroxidation
products, direct oxidation of amino acid side chains, peptide backbone scission,
and glycooxidation (Aksenov, Aksenova et al. 2001).
2.2 The naked mole-rat (NMR)
The NMR is arguably best known due to their unusually long healthspans
and hold the world record as the longest lived rodent (Buffenstein 2005, Grimes,
Reddy et al. 2014). Though being the size of a mouse, NMRs can live up to 32
years while maintaining normal body function and activity for 75-80% of their
lifespan (Buffenstein 2008, Edrey, Park et al. 2011). These remarkable NMRs
are not only resistant to cellular senescence, but they do not develop cancers, as
there are no indications of spontaneous neoplasia and only one route to tumor
development with experimentally-induced tumorigenesis (Buffenstein 2008,
Liang, Mele et al. 2010, Tian, Azpurua et al. 2013), while other typical lab rodents
develop cancers. It was recently discovered that malignant transformation of cells
could occur in NMR cell culture if high-molecular-mass hyaluronan (HMM-HA)
was removed (Tian, Azpurua et al. 2013). The mass of NMR HMM-HA is over 5
times that of a mouse or human analog and is implicated in mechanisms of early
contact inhibition (Tian, Azpurua et al. 2013). The role that HMM-HA plays in
mediating NMR cancer resistance is currently under investigation. Because of
these extraordinary traits, the NMR genome was sequenced and released in
2011 to help decipher underlying mechanisms that promote a long and healthy
lifespan.
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2.2.1 NMR: Habitat and behavior
The naked mole-rat (NMR; Heterocephalus glaber; sand puppy) is a
subterranean burrowing rodent indigenous to the hot and arid sub-Saharan
region of North East Africa. NMRs live in large colonies that average 75-80
individuals, but can be as large as 300 NMRs (Brett 1991).
NMRs are the only known eusocial mammals, a social structure akin to
that of bees or termites. Each colony has one dominate, breeding female (the
queen) that consorts with up to 3 breeding males (Lacey and Sherman 1991). All
other members of the community are somewhat smaller in size and
reproductively repressed; however, these subordinates can become reproductive
if removed from the colony (Holmes, Goldman et al. 2008). Interestingly,
subordinate males and females exhibit a remarkable lack of differences in
anatomy and behavior (Edrey, Park et al. 2011). Furthermore, a NMR colony has
a strict division of labor of communal tasks, including: gathering of food, defense
against predation, juvenile caretaking, and excavating of tunnel systems (Jarvis
1981).
Living in a deep and thermally stable ecological niche, NMRs have
evolved several remarkable traits. This sealed underground environment is highly
hypoxic, yet NMRs manage to cope with low oxygen levels, where in many
vertebrates, only a few minutes of oxygen deprivation leads to irreparable
neurological injury (Larson, Drew et al. 2014). Notably, as with most
subterranean endothermic species, NMRs have low basal metabolism rates and
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NMRs can greatly reduce their metabolism during periods of starvation
(O'Connor, Lee et al. 2002). Additionally, NMRs are thermoconformers and
therefore expend no energy in regulating their body temperature. Instead, NMRs
huddle together or retreat deeper into burrows for warmth.
2.2.2 NMR and oxidative stress
Surprisingly, NMRs have been shown to produce high levels of ROS
compared to mice (Lambert, Boysen et al. 2007). Even at an early age, NMRs
reportedly have high levels of oxidative damage; however, these global levels do
not increase and oxidized proteins do not accrue with age (Andziak and
Buffenstein 2006, Lewis, Andziak et al. 2013). High levels of oxidative damage
typically affect multiple cellular processes and contribute to age-related decline
(Morimoto and Cuervo 2009). But clearly, NMRs have seemingly evolved
mechanisms to repair or eradicate oxidative damage accumulation, since even
young NMRs are more resistant to resultant oxidative stress damage than mice
(Labinskyy, Csiszar et al. 2006). Antioxidants are a key ROS combatant;
however, when levels of selected antioxidants (SOD 1 & 2, catalase and
glutathione peroxidase) were measured in the NMR, they were not elevated
compared to shorter-lived species (Andziak, O’Connor et al. 2005), suggesting
that a superior antioxidant defense system is not the primary contributing factor
for NMR resistance to oxidative stress.
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2.2.3 Proteostasis in the NMR
NMRs are extremely resilient to cellular stress as their proteins are
resistant to unfolding (Perez, Buffenstein et al. 2009). In most species, damaged
proteins accumulate with age and is one of the hallmarks of aging (Zwickl,
Seemuller et al. 2001). These proteins can aggregate and cause damage, such
as the clogging proteasomes, disrupting cellular homeostasis. NMRs are an
exception to this age-related accumulation of damaged proteins (Perez,
Buffenstein et al. 2009). This resistance to oxidative stress in the NMR is
hypothesized to be a result of their ability to maintain proteostasis through
mechanisms assisting in protein repair or elimination (Rodriguez, Wywial et al.
2011).
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CHAPTER 3
METHODS
3.1 Tissue homogenization
For all studies in this dissertation, selected brain tissues were prepared
using a Wheaton glass homogenizer (~40 passes) with ice-cold isolation buffer
[0.32 M sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/ml PMSF, 4
µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml aprotinin and 10 µg/ml phosphatase
inhibitor cocktail 2]. Homogenates were vortexed and then sonicated on ice for
10 s at 20% power, two times resting the sample for 20 s in-between, using a
Fisher 550 Sonic Dismembrator (Pittsburgh, PA, USA). Protein concentrations of
the homogenates were determined by the Pierce BCA method (Rockford, IL,
USA) (Smith, Krohn et al. 1985).
3.2 Bicinchoninic acid (BCA) protein assay
Global protein concentrations of all samples in this dissertation research
were determined using the bicinchoninic acid (BCA) protein assay. The first step
of this assay utilizes the Biuret reaction for the reduction Cu 2+ to Cu+ by the
chelation of nearby peptide bonds. The second step is the formation of a
chelating complex containing 2 BCA molecules in a 4-coordination complex with
one Cu+ (Figure 3.1). A greater amount of protein will result in a darker purple
solution (absorbing at 562nm) as there would be a greater number of
chomophoric BCA complexes in solution. Bovine serum albumin (BSA) was used
as the protein standard and Beer’s law was used for calculations of protein
concentration.
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Figure 3.1 Formation of the BCA/Cu+ Complex. Reduction of Cu2+ for
chelation to bicinchoninic acid (BCA).
3.3 Measurement of global oxidative stress markers
The slot blot method was used to determine levels of global makers of
oxidative stress: protein carbonyls, 3-nitrotyrosine (3NT) and protein-bound 4hydroxy-2-nonenal (HNE). The slot blot process involves preparation of samples
(described below), loading samples in duplicate onto a nitrocellulose membrane
utilizing the slot blot apparatus, blocking the membrane, detecting the desired
modification with a primary antibody, labeling the primary antibody with a
secondary antibody for detection and the quantification of the data using BioRad
Image Lab software.
3.4 Detection of oxidative stress markers
3.4.1 Quantification of protein carbonyls
Global levels of protein carbonyls (PC) were determined in naked mole-rat
brain. First, 5 µL of homogenized sample, combined with 5 µL of a 12% sodium
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dodecyl sulfate (SDS) solution was derivatized with 10 µL of a 2,4dinitrophenylhydrazine (DNPH) solution [1:10 dilution with a 1x PBS, a
phosphate buffer solution with sodium chloride and mono and dibasic sodium
phosphates] to form dinitrophenylhydrazone Schiff bases. The solution was
incubated for 20 min at 22˚C. Next, 7.5 µL of a neutralization buffer [2 M Tris, pH
6.8, in 30% (v/v) glycerol] was added to react with the remainder of the DNPH
solution. Utilizing the BCA data, the solution is further diluted with phosphate
saline buffer (PBS) solution (10 mM, pH 8 with 0.88% NaCl) for a final protein
concentration of 1 ng/µL. The protein-bound hydrazone-adducts were transferred
to a nitrocellulose membrane using the slot blot apparatus and then detected
immunochemically.
3.4.2 Determination of 3-nitrotyrosine and protein-bound HNE
To measure global levels of 3-NT and protein-bound HNE, 5 µL of the
sample is added to 5 µL of the 12% SDS solution and 10 µL of a Laemmle buffer
[0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% glycerol] for 20 min, then
diluted to 1 ng/µL with PBS, transferred to a nitrocellulose membrane and
detected immunochemically.
3.4.3 Immunochemical development of nitrocellulose membrane
Nitrocellulose membranes were blocked in 3% BSA in Wash Blot solution
[150 mM sodium chloride, 3 mM monobasic sodium phosphate, 17 mM dibasic
sodium phosphate and 0.04% (v/v) Tween 20], with gentle rocking for 1.5 h at
22˚C. To this solution, the appropriate antibody was added (derivatized-PC
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(1:300 dilution), 3-NT (1:5000) and HNE (1:5000)) for 2 h. The membrane was
then rinsed and rocked in Wash Blot three times for 5, 5 and 10 min. Next, 2.5 µL
of an anti-rabbit IgG alkaline phosphatase conjugated secondary antibody in 20
mL of wash blot was added for exactly one hour. The membrane was rinsed and
rocked in Wash Blot again three times for 5, 10 and 10 min. The secondary
antibody was detected by adding 30 mL of an alkaline phosphatase (ALP) buffer
[0.5 M Tris, 0.1 M sodium chloride, 5 mM magnesium chloride hexahydrate, pH
9.5] with 99 µL of 5-bromo-4-chloro-3-indolyl phosphate dipotassium (BCIP) and
198 µL of nitrotetrazolium blue chloride (NBT). BCIP is hydrolyzed by ALP to
form 5-bromo-4-chloro-3-indole and inorganic phosphate and NBT is added as
an oxidizer to form an insoluble dark blue precipitate after being reduced for
colorimetric detection. Membranes were rocked in this developing solution until
colored slots appear. Relative color intensities are compared between the
samples, relating relative oxidation levels.
3.5 Proteomics
For all studies in this dissertation, significantly altered protein levels and
phosphorylation states were detected using a 2D-PAGE approach in conjunction
with protein-gel staining and protein identification by MS/MS.
3.5.1 Isoelectric focusing
Isoelectric focusing (IEF) is a technique for separation of proteins based
on their isoelectric point (pI). First, 200 µg of brain homogenate proteins were
shaken for 2 h at 22˚C in 200 µl of rehydration buffer [8 M urea, 2.0% (w/v)
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CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01% Bromophenol Blue].
Samples were sonicated for 10 s and applied to 11 cm ReadyStrip IPG strips, pH
3-10 (Bio-Rad, Hercules, CA, USA). The IPG strips were actively rehydrated at
20 °C for 18 h at 50 V and then isoelectrically focused at a constant temperature
of 20 °C beginning at 300 V for 2 h linearly, 500 V for 2 h linearly, 1000 V for 2 h
linearly, 8000 V for 8 h linearly, and finishing at 8000 V for 10 h rapidly, using a
Protean IEF cell (Bio-Rad). IPG strips were stored at -80 °C until second
dimension separation.
3.5.2 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
2-D-Page separates proteins based on their molecular weight and shape.
First, IPG strips were thawed for 10 min and equilibrated in buffer A [50 mM Tris–
HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5% dithiothreitol (DTT)]
for 10 min and then in buffer B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v)
SDS, 30% v/v glycerol, 4.5% iodoacetamide (IA)] for 10 min. IPG strips were next
placed into Linear Gradient (8-16%) Precast Criterion Tris–HCl polyacrylamide
gels, 11 cm (Bio-Rad). Precision Plus Protein All Blue (Bio-Rad) or
PeppermintStick (Invitrogen, Grand Island, NY, USA) molecular weight standards
were run with samples at a constant voltage of 200 V for approximately 65 min in
Tris-Glycine SDS running buffer.
3.5.3 Pro-Q Diamond phosphoprotein staining
Pro-Q Diamond phosphoprotein gel stain allows for the detection of
phosphoserine, phosphothreonine and phosphotyrosine protein residues; and the
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intensity of the resultant protein spot is correlated with the number of phosphate
groups attached. After completion of 2D-PAGE, gels were removed from their
casings and fixed in 50mLsolution [10% (v/v) acetic acid, 50% (v/v) methanol] for
30 min, two times, at 22˚C on a gently rocking platform. Gels were washed in
100mL of deionized (DI) water (3 times; 30 min each). Next, 60 mL of Pro-Q
Diamond stain was added to the gel in the dark and covered with aluminum foil
and rocked for 90 min. Gels were destained in 100 mL of destaining solution
[20% acetonitrile (ACN), 50 mM sodium acetate, pH 4] in the dark (4 times; 30
min each). The gels were then washed 3 times for 30 min each in 100 mL of DI
water in the dark. The gels, transported wrapped in aluminum foil, were scanned
at 580 nm using either a GE Healthcare Life Sciences Typhoon FLA 9500
scanner (PINK1 knockout project) or a BioRad ChemiDoc MP System Imager
(Alzheimer disease and naked mole-rat projects).
3.5.4 Sypro Ruby protein staining
Sypro Ruby gel protein stain allows for the detection and quantification of
total protein content. This staining method is also used in conjunction with Pro-Q
Diamond phosphoprotein stain to allow for normalization of the phosphorylated
proteins so that a highly abundant but lightly phosphorylated protein can be
distinguished from a lowly expressed but highly phosphorylated protein.
After scanning Pro-Q Diamond-stained gels, the gels were fixed in 50 mL
solution [7% (v/v) acetic acid, 10% (v/v) methanol] for 45 min. After removing the
fixing solution, 50 mL of Sypro Ruby stain was added for overnight staining (15
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hr) at 22˚C with gentle rocking. Gels were rinsed and transferred to 50 mL DI
water and scanned at 450 nm using the afore-mentioned scanners. Gels were
stored in DI water at 4 °C until protein spot excision.
3.5.5 Image analyses
For all proteomic and phosphoproteomic studies in this dissertation, spot
intensities from the Pro-Q Diamond and Sypro Ruby-stained 2D-gel images were
quantified densitometrically according to the total spot density using PDQuest 2D analysis software (Bio-Rad).
3.5.5.1 Differential protein expression
Spot intensities from Sypro Ruby-stained 2D-gel images of were
quantified by densitometry. Intensities of gel spot were normalized to the total gel
density. Protein spots of gels from a particular study were first manually matched
together and then matched by the PDQuest program using powerful
automatching algorithms for accurate spot-matching. Resultant data of
normalized intensity of each protein spot were compared between groups using
the appropriate statistical analysis. Figure 3.2 shows the method used to
determine differential protein levels in samples and provides an illustration of a
PDQuest gel map comparison.
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Figure 3.2 Proteomic methods. Flow chart depicting analysis sequence in 2-D
gel-based detection of differential protein levels.
3.5.5.2 Differential phosphorylation levels
Protein spots from Pro-Q Diamond-stained 2D-gel images were quantified
and matched together in the same manner as the Sypro Ruby-stained gels. Next,
two master gels, one from the Pro-Q Diamond images and one from the Sypro
Ruby stained images, were matched together in the same manner as described
above. Figure 3.3 shows the phosphoproteomics method for determining the
identity of proteins with differential protein phosphorylation levels. The PDQuest
software provided numerical data corresponding to the intensity of the protein
spot and the intensity of the phosphoprotein spot. The phosphoprotein spot
densities were then normalized to the Sypro Ruby spot densities and the
resultant normalized phosphoprotein spot densities were compared. Spots with a
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statistically significant difference based on appropriate statistical testing were
considered for in-gel trypsin digestion and subsequent identification.

Figure 3.3 Phosphoproteomic methods. Flow chart depicting analysis
sequence in 2-D gel-based detection of differential protein phosphorylation.
3.5.6 In-gel trypsin digestion
Significant protein spots were excised from 2D-gels with a clean, sterilized
razor blade or pipette tip and individually transferred to Eppendorf
microcentrifuge tubes. Gel plugs were incubated with 20 µL of 0.1 M ammonium
bicarbonate (NH4HCO3) for 15 min, and with 30 µL of ACN for 15 min. Gel plugs
were dried under a flow hood at RT for 30 min. Next, 30 µL of 20 mM DTT in 0.1
M NH4HCO3 was added at 56°C for 45 min. The DTT/NH4HCO3 solution was
then removed and replaced with 30 µL of 0.05 M IA in 0.1 M NH4HCO3 and
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incubated at 22˚C for 15 min. Next, the IA solution was removed and plugs
incubated for 15 min with 150 µL of 0.05 M NH4HCO3. Then, 200 µL ACN was
added to this solution and incubated for 15 min. Solvent was removed and gel
plugs were allowed to dry for 30 min under a flow hood. Plugs were rehydrated
with 10 µL modified trypsin solution (Promega, Madison, WI, USA) in 0.05 M
NH4HCO3 (enough to completely cover the gel plugs) and incubated with shaking
overnight at 37 °C.
3.5.7 Gel-peptide extraction and purification
The next day, the digest solution was transferred into a new Eppindorf
microcentrifuge tube. Next, approximately 20 µL of a 5% ACN, 0.1% formic acid
(FA) solution was added to the old tube containing the gel plug (twice the volume
necessary to submerge the gel), and sonicated in a bath for 15 min. To this, 30
µL of a solution containing 95% ACN, 0.1% FA and 0.001 M NH4CO3 was added
and sonicated for 15 min. This resulting solution was combined with the
supernatant digest solution in the new Eppendorf tube. Using a Speed Vac, the
samples were concentrated to a volume of 10 µl. Using C18 ZipTips (SigmaAldrich, St. Louis, MO, USA), salts and contaminants were removed from the
tryptic peptide solutions. To prepare the column in the ZipTip, 10 µL of 100%
ACN was aspirated into the tip and then expelled 5 times. Next, 10 µL of a 50%
ACN solution containing 0.1% FA was aspirated and expelled 5 times for column
equilibration. The trypsin digested solution was then slowly drawn up and pushed
gently out of the column 10 times for peptide adherence. Unwanted contaminants
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were removed from the peptides in the ZipTip by washing with 10 µL of a 5%
ACN and 0.1% FA solution 3 times. To elute the peptides from the column, 10 µL
of a 50% ACN and 0.1% FA solution was drawn up and then expelled into a new
Eppendorf tube. The eluant was drawn up and expelled 5 times to ensure
complete peptide removal from the column. Samples were stored at -80˚C until
MS/MS analysis.
3.5.8 NanoLC-MS
Samples desalted with C18 Zip Tips and reconstituted in 10 µL 5%
ACN/0.1% FA were analyzed by a nanoAcquity (Waters, Milford, MA)-LTQ
Orbitrap XL (Thermo Scientific, San Jose, CA) system in data dependent scan
mode. An in-house packed capillary column (0.1 x 130 mm column packed with
3.6 µm, 200Å XB-C18) and a gradient with 0.1% FA and ACN/0.1% FA at 200
nL/min were used for separation. The MS spectra were acquired by the orbitrap
at 30,000 resolution and MS/MS spectra of the six most intense ions in MS scan
were obtained by the orbitrap at 7,500 resolution.
3.5.9 Database interrogation and protein identification
Data files from all samples in this dissertation research were searched
against the most current version of the Swiss-Prot database by SEQUEST
(Proteome Discoverer v1.4, Thermo Scientific). At least two high-confidence
peptide matches were required for protein identification (false discovery rate
<1%). Proteins matched with the same peptides are reported as one protein
group. Exact peptide masses of digested proteins from the MS experiments were
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compared with theoretical peptide masses in the database to produce a list of
potential peptide matches. Proteins receive a confidence score based on the
number of peptides identified and the percentage of the protein’s amino acid
sequence covered. The data accompanying the identified protein includes the
expected molecular weight and isoelectric point. Preliminary verification of the
identified protein is made by comparing the position of the excised gel plug with
the expected position of the identified protein.
3.5.10 Immunoprecipitation
Brain proteins (250 µg) were suspended in 500 µL IP buffer [0.05% NP40, leupeptin 4 µg/mL, pepstatin 4 µg/mL, aproprotin 5 µg/mL, phosphatase
inhibitor cocktail 10 µg/mL in a phosphate buffer solution, pH 8 (8 M NaCl, 0.2 M
KCl, 1.44 M Na2HPO4, 0.24 M KH2PO4, pH adjusted with NaOH)] and allowed to
shake for 30 min at 4˚C. Next, 50 µL of Protein A/G beads (per sample) were
washed and centrifuged at 2500 RPM (5 min; 4˚C). The washed beads were
added to pre-clear the samples of non-specific protein A/G artifacts (90 min;
4˚C). Samples were centrifuged at 2500 RPM (5 min; 4˚C) and the supernatant
was transferred to new Eppendorf tubes with an antibody (1:50 dilution) and
shaken overnight at 4˚C. The next morning, 50 µL of protein A/G beads were
washed as and incubated with the protein samples (90 min; 4˚C). The
supernatant was removed and the beads were washed in IP buffer with shaking
(5 times; 10 min each). Beads were preserved for 1D-PAGE experiments.
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3.5.11 One-dimensional polyacrylamide gel electrophoresis (1-D PAGE)
Whole brain homogenates (50 µg) were suspended in 4X sample loading
buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% β-mercaptoethanol,
0.01% Bromophenol Blue] diluted to 1X with distilled water, heated at 95 °C for 5
min and cooled on ice. Samples and Precision Plus Protein All Blue Standards
were loaded into a Criterion precast (4-12%) Bis-Tris polyacrylamide 12 well gels
and run at RT in a Criterion Cell vertical electrophoresis buffer tank (Bio-Rad)
filled with a 1X dilution of XT MOPS running buffer at 80 V for 15 min to ensure
proper protein stacking. The voltage was then increased to 120 V for
approximately 100 min at RT for the duration of the electrophoretic run.
3.5.12 Western blotting
1D-gels were directly transferred to nitrocellulose membranes (0.2 nm)
using a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V for 30 min. After the
transfer, membranes were blocked with 3% bovine serum albumin (BSA) in
Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM NaHPO4 and 0.04% (v/v)
Tween 20] or TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20] for 1.5 h.
Primary antibodies were added to blocking solution for 2 h. Blots were rinsed two
times for 5 min each and one time for 10 min in either Wash Blot or TBS-T,
followed by a 1 h incubation with a secondary antibody. Blots were rinsed three
times for 5, 10 and 10 min each in Wash Blot or TBS-T and developed
chemiluminescently using Clarity Western ECL Substrate (Bio-Rad). After
developing for 5 min at RT in the dark, blots were scanned using a Bio-Rad
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ChemiDoc XRS+ imaging system and quantified using Image Lab software (BioRad). Blots were then typically rinsed with Wash Blot or TBS-T (5 min, two times)
and then stripped with Re-Blot Plus Strong solution (GE Healthcare, Pittsburgh,
PA, USA) for 10 min at RT, followed by two 5 min rinses with Wash Blot or TBST for re-probing with additional antibodies.
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CHAPTER 4
QUANTITATIVE EXPRESSION PROTEOMICS AND PHOSPHOPROTEOMICS
PROFILE OF BRAIN FROM PINK1 KNOCKOUT MICE: INSIGHTS INTO
MECHANISMS OF FAMILIAL PARKINSON DISEASE
4.1 Overview
Parkinson disease (PD) is an age-related, neurodegenerative motor
disorder characterized by progressive degeneration of dopaminergic neurons in
the substantia nigra pars compacta and presence of α-synuclein-containing
protein aggregates. Mutations in the mitochondrial Ser/Thr kinase PTEN-induced
kinase 1 (PINK1) are associated with an autosomal recessive familial form of
early-onset PD. Recent studies have suggested that PINK1 plays important
neuroprotective roles against mitochondrial dysfunction by phosphorylating and
recruiting Parkin, a cytosolic E3 ubiquitin ligase, to facilitate elimination of
damaged mitochondria via autophagy-lysosomal pathways. Loss of PINK1 in
cells and animals leads to various mitochondrial impairments and oxidative
stress, culminating in dopaminergic neuronal death in humans. Using a 2-D
PAGE proteomics approach, the differences in expressed brain proteome and
phosphoproteome between six month-old PINK1-deficient mice and wild-type
mice were identified. The observed changes in the brain proteome and
phosphoproteome of mice lacking PINK1 suggest that defects in signaling
networks, energy metabolism, cellular proteostasis and neuronal structure and
plasticity are involved in the pathogenesis of familial PD.
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4.2 Introduction
Parkinson disease (PD) is the most common neurodegenerative
movement disorder. The relative risk of developing PD increases with age and
approximately 1-2% of the population above 65 years is affected (Twelves,
Perkins et al. 2003, Pilsl and Winklhofer 2012). PD is characterized by the
accumulation of Serine-129 phosphorylated α-synuclein aggregates (Anderson,
Walker et al. 2006) within Lewy bodies and the loss of the majority of
dopaminergic (DA) neurons in the substantia nigra pars compacta, causing
drastically diminished dopamine release in the striatum (Braak, Tredici et al.
2003). In addition to the cardinal motor symptoms (resting tremor, bradykinesia,
rigidity, postural instability), PD patients frequently suffer from a variety of nonmotor symptoms that may occur decades earlier and include cognitive decline,
depression, hallucinations, REM sleep disorder and anosmia (Chaudhuri, Healy
et al. 2006, Jankovic 2008). Although the precise cause of PD remains elusive,
significant contributing factors are believed to include exposure to environmental
toxins, oxidative stress, inflammation, mitochondrial dysfunction, and failure of
proteostasis networks associated with protein aggregation (Henchcliffe and Beal
2008, Bueler 2009, Tansey and Goldberg 2010).
While the majority of PD cases are sporadic, an estimated 5-10% of
patients develop PD as a result of inheritable mutations in one of several genes
(Gasser, Hardy et al. 2011). Mutations in Pink1 are the second most common
cause of autosomal recessive familial early onset PD (Valente, Abou-Sleiman et
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al. 2004, Bonifati, Rohe et al. 2005, Bonifati 2012). PINK1 is a mitochondrial
kinase consisting of 581 amino acids that encode for a mitochondrial targeting
sequence, a transmembrane domain and a Ser/Thr kinase domain. PINK1 is
believed to confer neuroprotection by policing mitochondrial integrity (Narendra,
Jin et al. 2010, Jin and Youle 2012), and a growing amount of research links
dysfunction of mitochondrial dynamics with PD (Heeman, Van den Haute et al.
2011, Hauser and Hastings 2013, Van Laar and Berman 2013). DA neurons may
be particularly vulnerable to mitochondrial dysfunction and oxidative stress due to
reduced mitochondrial reserve compared to other types of neurons and the
reliance on calcium influx for pace-making (Liang, Wang et al. 2007, Surmeier,
Guzman et al. 2011). In normal cells with healthy mitochondria, PINK1 is
imported to the inner mitochondrial membrane where the N-terminal
mitochondrial targeting sequence is cleaved by the mitochondrial protease,
PARL (Deas, Plun-Favreau et al. 2011, Meissner, Lorenz et al. 2011).
Subsequently, PINK1 is retro-translocated to the cytosol where it is degraded by
the proteasome (Yamano and Youle 2013). However, a proportion of PINK1
remains in the cytoplasm (Haque, Thomas et al. 2008, Lin and Kang 2008) and
cytosolic PINK1 has been implicated in the regulation of various pathways,
including AKT signal transduction and cell survival, synaptic plasticity, DA
synthesis and mitophagy (Haque, Thomas et al. 2008, Murata, Sakaguchi et al.
2011, Akundi, Zhi et al. 2012, Fedorowicz, de Vries-Schneider et al. 2014, Zhou,
Refai et al. 2014). Import of PINK1 to the inner mitochondrial membrane is
blocked when the mitochondrial electron transport chain becomes dysfunctional
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and membrane potential (ΔΨm) is decreased (Matsuda, Sato et al. 2010, Amo,
Sato et al. 2011). PINK1 then accumulates on the outer mitochondrial membrane
where it phosphorylates Ser65 in the ubiquitin-like domain of the E3 ligase,
Parkin, to initiate mitophagy (Kazlauskaite, Kondapalli et al. 2014). When PINK1
kinase activity is inactivated in mice and flies via gene ablation, mitochondrial
dysfunction ensues and structurally abnormal mitochondria accumulate in cells
(Park, Lee et al. 2006, Exner, Treske et al. 2007, Gautier, Kitada et al. 2008,
Akundi, Huang et al. 2011, Heeman, Van den Haute et al. 2011, Gautier, Giaime
et al. 2012, Akundi, Zhi et al. 2013). Further, mutations in PINK1 cause a
decrease in mitochondrial complex I activity and ATP production, as well as
elevated production of reactive oxygen species (Yuan, Guo et al. 2010, Deas,
Plun-Favreau et al. 2011, Koh and Chung 2012, Morais, Haddad et al. 2014).
In this study, we utilized a 2-D PAGE proteomics approach to identify
proteins with differential expression levels and phosphorylation states in the
brains of PINK1 knockout (KO) mice versus wild-type controls to further study the
molecular mechanisms of PINK1-related PD.
4.3 Materials and Methods
4.3.1 Materials
All chemicals used in these studies were purchased from Sigma-Aldrich
(St. Louis, MO, USA) with noted exceptions: Criterion precast polyacrylamide
gels, ReadyStrip IPG strips, TGS and XT MOPS electrophoresis running buffers,
0.2 nm nitrocellulose membrane, Precision Plus Protein All Blue Standards,
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Sypro Ruby Protein Stain, mineral oil, dithiothreitol, iodoacetamide, biolytes, and
urea were purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond
phosphoprotein stain, PeppermintStick phosphoprotein molecular weight marker,
and anti-phosphoserine, anti-phosphothreonine and anti-phosphotyrosine
antibodies raised in rabbits were purchased from Invitrogen (Grand Island, NY,
USA). Anti-HSP70 and anti-aldolase A antibodies raised in rabbits were
purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-MAPK1/2
polycolonal antibody raised in rabbits, C18 ZipTips, and Re-Blot Plus Strong
stripping solution were purchased from Millipore (Billerica, MA, USA). Calmodulin
polyclonal antibody raised in rabbits was purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). Amersham ECL rabbit IgG horseradish
peroxidase (HRP)-linked secondary antibody, protein A/G beads and ECL-Plus
Western blotting detection reagents were purchased from GE Healthcare
(Pittsburgh, PA, USA). Modified trypsin solution was obtained from Promega
(Madison, WI, USA).
4.3.2 Animals and brain tissue
The generation and characterization of the PINK1-deficient mice used in
this study has been described previously (Akundi, Huang et al. 2011). The animal
housing facility regularly underwent serological testing to certify a healthy, virus
and pathogen free facility. Subjects were fed Richland Laboratory Rodent Diet
5001 and water ad libitum. The animal rooms were maintained with a 12 hour
light:12 hour dark cycle (lights on at 0600) at 20-22˚C. For the experimental
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groups of animals, n=6 per group, whole brains were isolated from mice rendered
unconscious by CO2 inhalation and euthanized by cervical dislocation using
procedures approved by the UK Institutional Animal Care and Use Committee.
Dissected brains were flash-frozen in liquid nitrogen and stored at -80˚C until
use.
4.3.3 Sample preparation
Mouse brains were thawed and individual homogenates were prepared
using a Wheaton glass homogenizer (~40 passes) with ice-cold isolation buffer
[0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES, 0.2µg/ml PMSF,
4µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml aprotinin and 5 µg/ml phosphatase
inhibitor cocktail 2]. Homogenates were vortexed on ice and then sonicated on
ice for 10 s at 20% power, two times, with a Fisher 550 Sonic Dismembrator
(Pittsburgh, PA, USA). Protein concentrations of the homogenates were
determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al.
1985).
4.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
Isoelectric focusing (IEF). IEF was performed as described previously
(Sultana, Boyd-Kimball et al. 2007). Briefly, brain homogenate proteins (200 µg)
were shaken for 2 h at RT in 200 µl of rehydration buffer [8 M urea, 2.0% (w/v)
CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01% Bromophenol Blue].
Samples (200 µl) were applied to 11 cm pH 3-10 ReadyStrip IPG strips (linear
gradient). Strips were actively rehydrated at 20 °C for 18 h at 50 V. Next, the
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samples were isoelectrically focused at a constant temperature of 20 °C
beginning at 300 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 8000 V for 8 h, and
finishing at 8000 V for 10 h. IPG strips were stored at -80 °C until second
dimension separation (SDS PAGE).
SDS PAGE. IEF strips were thawed and equilibrated with buffer A and
buffer B (buffer A [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v
glycerol, 0.5% DTT], buffer B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS,
30% v/v glycerol, 4.5% iodoacetemide]). IPG strips were next placed into
Criterion precast linear gradient (8–16%) Tris–HCl polyacrylamide gels, 1 IPG +
1 Well Comb, 11cm. Invitrogen PeppermintStick molecular weight marker and
samples were run at a constant voltage of 200 V for approximately 65 min in TrisGlycine SDS running buffer.
4.3.5 Gel staining
Proteins and phosphoproteins were detected using SYPRO Ruby and
Pro-Q Diamond phosphoprotein gel stain according to manufacturer’s directions
and as previously described (Di Domenico, Sultana et al. 2011). Briefly, gels
were fixed in solution [10% (v/v) acetic acid, 50% (v/v) methanol] (50 mL) and
washed in deionized water. Next, 60 mL of Pro-Q Diamond stain was added with
gentle rocking for 90 min. Gels were then destained 4 times for 30 min each in
100 mL of destaining solution [20% acetonitrile, 50mM sodium acetate, pH 4].
The gels were washed in deionized water and scanned at 580 nm using a GE
Healthcare Life Sciences Typhoon FLA 9500 scanner. The gels were then
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stained overnight with 50 mL of Sypro Ruby gel stain. Gels were rinsed and
placed in deionized water. Gels were scanned at 450 nm and then stored at 4 °C
until protein spot excision.
4.3.6 Image analysis
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2Dgel images of wild-type (WT) and PINK1 KO samples were quantified by
densitometry using PDQuest 2-D Analysis Software (Hercules, CA, USA).
Intensities of each gel were normalized to the total density of each gel. Protein
spots were manually and automatically matched with the PDQuest program. Spot
densities in KO and WT samples were compared and spots with a statistically
significant difference based on a Student’s two-tailed t-test (p<0.05) were
considered for in-gel trypsin digestion and subsequent identification.
Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel
images of PINK1-/- and WT samples were quantified and matched together in the
same manner as the SYPRO Ruby-stained gels. Next, two master gels were
chosen, one from the Pro-Q Diamond images and one from the Sypro Ruby
stained images. The phosphoprotein master image was then matched to the
master Sypro Ruby stained image in the same manner as described above. The
PDQuest software provided numerical data corresponding to the intensity of the
protein spot. The phosphoprotein spot densities were then normalized to the
Sypro Ruby spot densities and the resultant normalized phosphoprotein spot
densities in KO and WT samples were compared and spots with a statistically
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significant difference based on a Student’s two-tailed t-test (p<0.05) were
considered for in-gel trypsin digestion and subsequent identification.
4.3.7 In-gel trypsin digestion/peptide extraction
Protein spots were excised from 2D-gels with a clean, sterilized razor
blade and individually transferred to Eppendorf microcentrifuge tubes for trypsin
digestion as previously described (Thongboonkerd, McLeish et al. 2002). Gel
plugs were incubated with 20 µL of 0.1 M ammonium bicarbonate (NH4HCO3) for
15 min, and with 30 µL of acetonitrile for 15 min. Gel plugs were dried under a
flow hood at RT for 30 min. Next, 30 µl of 20 mM DTT in 0.1 M NH4HCO3 was
added at 56°C for 45 min. The DTT/NH4HCO3 solution was then removed and
replaced with 30 µl of 0.05 M iodoacetamide (IA) in 0.1 M NH4HCO3 and
incubated at RT for 15 min. Next, the IA solution was removed and plugs
incubated for 15 min with 150 µl of 0.05 M NH4HCO3 at RT. Then, 200 µl
acetonitrile was added to this solution and incubated for 15 min at RT. Solvent
was removed and gel plugs were allowed to dry for 30 min at RT under a flow
hood. Plugs were rehydrated with modified trypsin solution in 0.05 M NH4HCO3
(enough to completely cover the gel plugs) and incubated with shaking overnight
at 37 °C. The next day, the salts and contaminants were removed from the tryptic
peptide solutions using C18 ZipTips in accordance with manufacturer’s directions.
Samples were stored at -80˚C until MS/MS analysis.
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4.3.8 NanoLC-MS with Data Dependent Scan
Samples desalted with C18 Zip Tips were reconstituted in 10 µL 5%
ACN/0.1% FA and analyzed by a nanoAcquity (Waters, Milford, MA)-LTQ
Orbitrap XL (Thermo Scientific, San Jose, CA) system in data dependent scan
mode. An in-house packed capillary column (0.1 x 130 mm column packed with
3.6 µm, 200Å XB-C18) and a gradient with 0.1% FA and ACN/0.1% FA at 200
nL/min were used for separation. The MS spectra were acquired by the orbitrap
at 30,000 resolution and MS/MS spectra of the six most intense ions in MS scan
were obtained by the orbitrap at 7,500 resolution. Data files from each sample
were searched against the most current version of the Swiss-Prot database by
SEQUEST (Proteome Discoverer v1.4, Thermo Scientific). At least two highconfidence peptide matches were required for protein identification (false
discovery rate <1%). Proteins matched with the same peptides are reported as
one protein group.
4.3.9 Immunoprecipitation and Western blotting validations
Immunoprecipitation (IP). Whole brain homogenized protein extracts (250
µg) were suspended in 500 µL IP buffer [0.05% NP-40, leupeptin 4 µg/mL,
pepstatin 4 µg/mL, aproprotin 5 µg/mL, phosphatase inhibitor cocktail 10 µg/mL
in a phosphate buffer solution, pH 8 (8 M NaCl, 0.2 M KCl, 1.44 M Na 2HPO4,
0.24 M KH2PO4, pH adjusted with NaOH)] and allowed to shake for 30 min at
4˚C. Next, 50 µL of Protein A/G beads (per sample) were washed and
centrifuged at 2500 RPM for 5 min at 4˚C. The washed beads were added to the
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individual protein samples to pre-clear of non-specific protein A/G artifacts for 90
min at 4˚C. Samples were then centrifuged at 2500 RPM for 5 min at 4˚C and the
supernatant was transferred to new Eppendorf tubes with either anti-MAPK1
antibody (1:50 dilution) or anti-calmodulin antibody (1:50) and shaken overnight
at 4˚C. The next morning, 50 µL of protein A/G beads were washed as and
incubated with the protein samples for 90 min at 4˚C. After removing the
supernatant, the beads were again washed 5 times with IP buffer with 10 min of
shaking in IP buffer between centrifugations. The beads were preserved for a
1D-PAGE experiment.
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Whole
brain homogenates (50 µg) or beads from immunoprecipitation experiments were
suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8%
SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue] diluted to 1X with
distilled water, heated at 95 °C for 5 min and cooled on ice. Samples and
Precision Plus Protein All Blue Standards were loaded into a Criterion precast (412%) Bis-Tris polyacrylamide 12 or 18 well gels and run at RT in XT MOPS
running buffer at 80 V for 15 min. The voltage was then increased to 120 V for
approximately 100 min at RT for the duration of the electrophoretic run.
1D-Western blotting. 1D-gels were directly transferred to nitrocellulose
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad,
Hercules, CA, USA). After the transfer, membranes were incubated in a blocking
solution of 3% bovine serum albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM
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NaH2PO4, 17 mM NaHPO4 and 0.04% (v/v) Tween 20] at RT for 1.5 h. Each
protein of interest was detected by incubation with a primary antibody (1:8000
dilution), in blocking solution at RT with gentle rocking for 2 h. Blots were rinsed
two times for 5 min each and one time for 10 min in Wash Blot, followed by a 1 h
incubation with a horseradish peroxidase (1:3000) secondary antibody at RT with
gentle rocking. Blots were rinsed three times for 5, 10 and 10 min each in Wash
Blot and developed chemiluminescently using Clarity Western ECL substrate.
After developing for 5 min at RT in the dark, blots were scanned using a Bio-Rad
ChemiDoc XRS+ imaging system and quantified using Image Lab software
(Hercules, CA, USA). Blots rinsed and then stripped with Re-Blot Plus Strong
solution for exactly 10 min at RT, followed by three 5 min rinses with Wash Blot.
The membranes were then blocked once again in 3% BSA for 1.5 h. Next, an
anti-tubulin antibody (1:20000) or anti-phosphoserine, anti-phosphothreonine and
anti-phosphotyrosine antibodies (1:10000) were added to the Wash Blot solution
with 2 h more of gentle rocking at RT. Membranes were then washed, incubated
with a secondary HRP-conjugated antibody, washed, developed
chemiluminescently and scanned.
4.3.10 Statistical analysis
All statistical analyses were performed using a two-tailed Student’s t-test,
in which p<0.05 was considered statistically significant for Western blot and
PDQuest analysis. Fold-change values of easily discernible protein spots were
determined by dividing the average, normalized spot intensities in the knockout
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gels by the average, normalized spot intensities of the wild-type gels. Only spots
with a 1.25 fold change or greater in normalized spot density were considered for
MS/MS analysis. Protein and peptide identifications obtained with the SEQUEST
search algorithm with p<0.01 were considered to be statistically significant.
4.4 Results
4.4.1 PDQuest and MS/MS analysis
Proteomic analyses of the isolated brain proteins were conducted using a
2D-PAGE approach with Sypro Ruby and Pro-Q Diamond staining in conjunction
with MS/MS analysis. Protein spot intensities were compared between PINK1(-/-)
and PINK1(+/+) control mice to determine differentially expressed and
phosphorylated proteins. Figure 4.1 shows representative examples obtained
from SYPRO Ruby-stained 2-D gel images of the isolated proteins from 6 month
old PINK1(-/-) and PINK1(+/+) mice with significant differentially expressed proteins
labeled. Figure 4.2 shows typical images of Pro-Q Diamond-stained gels with
protein spots showing altered phosphorylation states labeled in the images.
Graphs displaying normalized phosphorylation intensity of each sample are also
provided.
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Figure 4.1 Sypro Ruby-stained gels of PINK1 KO and WT mice.
Representative 2-D gel images of isolated proteins from the brains of 6
month-old WT mice and PINK1 KO mice (n=6). Proteins whose
expression was significantly altered are labeled in the images and NFL
spot is enlarged to demonstrate differential levels (p<0.05). Used by
permission of John Wiley and Sons.
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Figure 4.2 Pro-Q Diamod-stained PINK1 KO and WT gels. Representative
images of Pro-Q Diamond-stained 2-D gels with protein spots showing altered
phosphorylation states labeled in the images. Bar graphs displaying normalized
phosphorylation intensity (Pro-Q Diamond spot density divided by SYPRO Ruby
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spot density) of each of n=6 WT (blue) and n=6 KO (red) samples [total of 12
individual gels] are also provided (p-value<0.05). Used by permission of John
Wiley and Sons.
PDQuest analysis of all of the 2-D images found 29 protein spots suitable
for extraction and whose expression or phosphorylation state was significantly
altered in the brains of PINK1(-/-) mice as compared to the WT controls. After ingel trypsin digestion and peptide extraction, MS/MS analysis coupled to
interrogation of protein databases was utilized to determine the identity of the
proteins. Tables 4.1 and 4.2 list the proteins in the brains of PINK1(-/-) mice that
showed significantly altered expression or phosphorylation states. Other
information listed in the tables include: the spot number as labeled by the
PDQuest program, the SwissProt accession number, percentage of the protein
sequence covered by matching peptides, the number of peptide sequences
identified by the MS/MS analysis, the protein confidence score, the expected
molecular weight and isoelectric point of the identified protein, as well as the foldchange levels and p-values obtained from the PDQuest analysis. Regarding foldchange values, a ↑1.33-fold means the protein expression in the KO brain is 33%
more than in WT brain. A ↓0.0885-fold means protein expression in the KO brain
is 91.15% less than in WT brain. All proteins were identified by more than one
peptide sequence. Further, identified protein spots were visually compared
against the theoretical molecular weights and isoelectric points from the mass
spectrometry analysis.
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Table 4.1 Proteins with altered expression in brain of PINK1 KO mice.
PDQuest and MS/MS results of brain proteins with significantly altered
expression in the PINK1 KO mice versus WT mice. Fold calculated by dividing
average KO protein spot intensity by WT protein spot intensity.

The 23 brain proteins with significantly altered expression were identified as:
neurofilament light peptide (↓0.580-fold), V-type proton ATPase subunit F
(↓0.725-fold), prohibitin (↓0.464-fold), dihydropyrimidinase-related protein 2
(DRP2, also called collapsing response mediated protein 2, CRMP2) (↓0.018649

fold), heat shock-related 70 kDa protein 2 (↓0.213-fold), acyl-protein thioesterase
1 (↓0.0130-fold), carbonyl reductase [NADPH] 3 (↓0.0244-fold), proteasome
subunit alpha type-2 (↓0.0898-fold), hypoxanthine-guanine
phosphoribosyltransferase (↓0.0885-fold), malate dehydrogenase, cytoplasmic
(↓0.0121-fold), actin-related protein 2/3 complex subunit 2 (↓0.0110-fold),
voltage-dependent anion-selective channel protein 2 (↓0.607-fold), isocitrate
dehydrogenase [NADPH] cytoplasmic (↓0.226-fold), vesicle-fusing ATPase
(↓0.0396-fold), elongation factor 2 (↓0.411-fold) and peptidyl-prolyl cis-trans
isomerase A, also known as cyclophilin A (↓0.181-fold), gamma-enolase (↑1.24fold), T-complex protein 1 subunit epsilon (↑1.33-fold), D-3-phosphoglycerate
dehydrogenase (↑3.69-fold), isoform 3 of dynamin-1 (↑1.41-fold), transgelin-3
(↑1.47-fold), fructose-bisphosphate aldolase A (↑2.99-fold) and transketolase
(↑1.52-fold).
The six proteins found to have differential phosphorylation states were:
calmodulin (↓0.418-fold), 14-3-3 protein epsilon (↓0.480-fold), neurofilament
medium polypeptide (↓0.275-fold), V-type proton ATPase catalytic subunit A
(↓0.313-fold), dual specificity mitogen-activated protein kinase kinase 1 (↑2.34fold), and mitogen-activated protein kinase 1 (↑3.39-fold).

50

Table 4.2 Proteins with altered phosphorylation levels in brain of PINK1 KO
brain. PDQuest and MS/MS results of proteins with significantly altered
phosphorylation states in the brain of PINK1 KO mice versus WT mice.

4.4.2 Immunoprecipitation and Western blot validation experiments
To validate the changes in protein expression and phosphorylation as
determined by the PDQuest analysis of the 2-D gels, immunochemistry and 1-D
Western blotting analysis of PINK1(-/-) and WT samples was performed. Figures
4.3 A and B show the Western blot images from the immunoprecipitation
experiments after probing with anti-phosphoserine, anti-phosphothreonine and
anti-phosphotyrosine antibodies where the immunoprecipitated protein, MAPK1
and calmodulin, respectively, was used as the loading control. Figures 4.3 C & D
display the corresponding histogram plot representations of the data.
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Figure 4.3 MAPK1 and CaM differential phosphorylation levels in brain of
PINK1 KO mice. Western blot validations and corresponding bar graph
representations from immunochemistry experiments of (A & C) the significant
increase in the phosphorylation of MAPK1 and (B & D) the significant decrease in
the phosphorylation of Calmodulin (CaM) in the brains of PINK1 KO mice as
compared to WT mice using the corresponding IP antibody as the loading control
(n=5, p-value<0.05). Antibodies detected by chemiluminescence. Used by
permission of John Wiley and Sons.
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Figure 4.4 HSP70 and aldolase A expression in PINK1 KO brain. Western
blot validations and corresponding bar graph representations of (A & C) the
down-regulation of HSP70.2 and (B & D) the up-regulation of aldolase A in the
brains of PINK1 KO mice as compared to WT mice using tubulin as a loading
control (n=6, p-value<0.05). Antibodies detected by chemiluminescence. Used by
permission of John Wiley and Sons.
The findings from these analyses confirmed a significant increase in the
phosphorylation of MAPK1 (p=0.045) and a decrease in the phosphorylation of
calmodulin (p=0.032) in the brain of PINK1(-/-) mice. Figures 4.4 A & B present
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the Western blot images of PINK1(-/-) and control samples after probing with
antibodies for HSP70 protein 2 and aldolase A, respectively, where tubulin was
used as the loading control. Figures 4.4 C& D are the corresponding bar graphs
of the results. The results of the Western blot analyses confirmed a significant
decrease in the expression of HSP70 protein 2 (p=0.047) and a significant
increase in the expression of aldolase A (p=0.049) in the PINK1(-/-) model. The pvalues of most of these results are slightly higher than the values obtained from
the 2-D proteomic studies. These differences may be attributed to the sensitivity
of the Sypro Ruby staining of the 2-D images as compared to the range
limitations of the chemiluminescent development of the 1-D Western blots.
4.5 Discussion
This current study focuses on protein expression and phosphorylation
changes in the brains of 6 month-old PINK1(-/-) mice compared to PINK1(+/+) mice.
Six month-old mice were selected based on the observation that at this age
PINK1(-/-) mice begin to exhibit a PD phenotype, including reduced dopamine
levels, providing a model to study early changes occurring in brains with PINK1related disease progression (Akundi, Huang et al. 2011). Proteomics studies
revealed twenty-nine proteins with significantly altered expression or
phosphorylation levels in the brains of PINK1 knockout mice (versus control
mice). These proteins can be subdivided into the following categories that are
discussed separately below: cellular signaling, energy metabolism, proteostasis
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networks, oxidative stress, and neuronal plasticity, neurotransmission and
structure.
4.5.1 Cellular signaling
Regulation of protein phosphorylation status by protein kinases and
protein phosphatases is essential in the control of cellular signaling pathways.
Ablation of the kinase PINK1 in mice revealed deregulated downstream
phosphorylation events in the brain that may contribute to familial PINK1-related
PD pathogenesis. Interestingly, lack of PINK1 is associated with increased
phosphorylation of both MAP kinase kinase 1 (MEK1) and its downstream target
MAPK1 that modulate vital functions including cell cycle, immunity, autophagy,
apoptosis, and cell survival (Dzamko, Zhou et al. 2014). Interestingly, it has been
reported that PINK1 deficiency resulted in increased p38 phosphorylation leading
to dysfunction of astrocytes (Choi, Kim et al. 2013). In many neurodegenerative
disorders, MAPKs display increased activity and can produce substantial
physiological effects with only modest changes in their phosphorylation state
(Zhu, Guo et al. 2003, Di Domenico, Sultana et al. 2011). Phosphorylated
MAPKs have been shown to aggregate in the halo region of Lewy bodies and
may have an early pathogenic role in PD (Zhu, Kulich et al. 2002).
Two additional ubiquitous signaling proteins were found to have
decreased phosphorylation states in the brains of PINK1(-/-) mice: calmodulin
(CaM) and 14-3-3 protein epsilon. CaM has been identified as a regulator of
more than 100 proteins involved in numerous pathways regulating apoptosis,
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neuronal plasticity, cytoskeletal organization, neurotransmitter release, cellular
growth and proliferation and is a vital regulator of calcium homeostasis
(DeLorenzo 1980, Benaim and Villalobo 2002, Xia and Storm 2005). 14-3-3
proteins are known to interact with more than 200 ligands including: kinases,
phosphatases and transmembrane receptors and have been implicated in
numerous neurological disorders (Fu, Subramanian et al. 2000, Foote and Zhou
2012). Aberrant phosphorylation of either of these identified proteins has the
potential to cause a myriad of deleterious downstream effects.
Prohibitin (PHB), another ubiquitously expressed pleiotropic modulator of
signaling pathways, was found to have significant down-regulated expression in
the brains of PINK1 KO mice. One of PHB’s more interesting functions is as a
chaperone in the assembly of the electron transport chain, and reduced
production of ATP has been noted with the loss of PINK1 (Theiss and Sitaraman
2011). Additionally, PHB also has been reported to play a defensive role against
oxidative stress, and decreased expression of PHB has been correlated to the
aging process (Robinson, Joshi et al. 2011), both risk factors or mediators of PD.
Further supporting the results of this study, PHB has been shown to be
significantly decreased in brains of subjects with PD (Ferrer, Perez et al. 2007,
Zhou and Qin 2013).
Decreases in expression were also found in acyl-protein thioesterase 1
(APT1) and peptidyl-prolyl cis-trans isomerase A (PPIaseA). APT1 catalyzes the
removal of palmitate at CYS residues from the cytosolic surface of membrane
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proteins (Dekker, Rocks et al. 2010). APT1 regulates protein-protein interactions,
cell signaling, membrane localization, subcellular trafficking, vesicle transport and
lysosomal degradation (Tian, McClafferty et al. 2012, Kong, Peng et al. 2013).
PPIaseA, also known as cyclophilin A, is a multifunctional proteins that catalyzes
the cis-trans isomerization at proline residues, playing a role in cellular signaling,
inflammation response and protein trafficking (Lang, Schmid et al. 1987,
Takahashi, Hayano et al. 1989).
4.5.2 Energy metabolism
A significant number of proteins identified as having altered expression
are involved in energy metabolism pathways. We and other groups have shown
that PINK1 deficiency impairs mitochondrial respiration, triggering metabolic
adaptations including increased glycolysis (Diedrich, Kitada et al. 2011, Yao,
Gandhi et al. 2012, Akundi, Zhi et al. 2013, Requejo-Aguilar, Lopez-Fabuel et al.
2014). The results of previous discoveries combined with the results of this
current investigation provide a more detailed molecular mechanism for the
increase of glycolysis noted in PINK1-related PD. Specifically, from this current
study, we observed an up-regulation of several proteins related to glycolysis in
PINK1-deficient mice. These include fructose-bisphosphate aldolase A (ALDOA),
gamma-enolase (ENO2), D-3-phosphoglycerate dehydrogenase (3-PGDH), and
transketolase (TK). Not only are ALDOA and ENO2 substrates directly involved
in the glycolytic pathway, but ENO2 has been shown to be neuroprotective when
up-regulated in microglial cells (Butterfield and Lange 2009, Hafner, Glavan et al.
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2013). Further, 3-PGDH is an oxidoreductase that catalyzes the transition of 3phosphoglycerate to 3-phosphohydroxypyruvate, the first step in the serine
biosynthesis pathway. L-serine is a crucial neurotrophic factor in the CNS as it is
a precursor for nucleotides, neurotransmitters, sphingolipids, phosphatidylserine
and L-cysteine (Ren, Qiang et al. 2013). Moreover, the increased levels of
neuronal-specific ENO2 and 3-PGDH are likely a cellular stress response to
prevent cell death in the absence of PINK1 (presence of mitochondrial
dysfunction), consistent with the finding that blocking glycolysis in PINK1deficient mouse embryonic fibroblasts led to rapid death of these cells (Akundi,
Zhi et al. 2013). Additionally, TK is an enzyme that catalyzes two key reactions
in the pentose phosphate pathway (PPP), resulting in the production of
glyceraldehyde-3-phosphate and fructose-6-phosphate. Up-regulation of TK
provides for more of these essential substrates to be fed into the glycolytic
pathway. Moreover, the PPP provides NADPH, which is needed to reduce
oxidized glutathione (GSSG) to reduced glutathione (GSH). Loss of GSH is
arguably the earliest neurochemical alteration in PD brain.
Dopaminergic (DA) neurons are reportedly more reliant upon
mitochondrial energy metabolism than other types of neurons due, in part, to
their reduced mitochondrial reserve (Kingsbury, Cooper et al. 2001, Van Laar
and Berman 2013). In PD, depletion of ATP is major factor in the cascade
leading to the neurodegeneration of these DA neurons (Mallajosyula, Chinta et
al. 2009). Significant decreased levels of cytoplasmic malate dehydrogenase
(MDHc), and hypoxanthine-guanine phosphoribosyltransferase (HPRT) were
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observed in the brain homogenates of PINK1 KO mice. MDHc is a metabolic
protein of the malate-aspartate shuttle that aids in the transfer of reducing
equivalents of NADH into the mitochondria for consumption by complex I of the
electron transport chain. A reduction of this key enzyme would result in impaired
mitochondrial ATP synthesis. Moreover, reduced MDHc expression is a plausible
contributor to the reduction of complex I activity that is reported in PD and PINK1
model organisms (Gautier, Kitada et al. 2008, Liu, Acin-Perez et al. 2011), as
cytosolic NADH cannot cross the outer mitochondrial membrane without the
enzymatic action of MDHc.
HPRT is another metabolic enzyme that is an essential player in the
purine salvage pathway for the generation of purine nucleotides (Sculley,
Dawson et al. 1992). Increasing nucleotide metabolism is essential for
mitochondrial biogenesis fission events to maintain a pool of healthy
mitochondria and has been shown to be neuroprotective in PINK1 models of PD
(Tufi, Gandhi et al. 2014). Interestingly, HPRT deficiency is reported to
dysregulate neurogenesis (Guibinga, Hsu et al. 2010), which in adults is
responsible for generating new neurons for the olfactory bulb (Altman 1969) and
the subgranular zone of the hippocampus (Eriksson, Perfilieva et al. 1998).
Consistent with this observation, PINK1 deficient mice have anosmia (Glasl,
Kloos et al. 2012). And, in PD, impaired olfaction occurs 2-7 years before onset
of motor symptoms in over 75% of patients (Lang 2011). Furthermore, HPRT
knockout mice were shown to have decreased levels of dopamine that correlated
with age (Micheli, Camici et al. 2011). Thus, we suggest that decreased
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expression of HPRT could quite possibly be a candidate as an early PD
biomarker.
4.5.3 Proteostasis networks
Disruption of two intracellular degradation systems, the ubiquitinproteasome system and autophagy-lysosome pathway, has been shown to play
central roles in PD pathology (Lim 2007, Pan, Kondo et al. 2008). Dysregulation
of these pathways causes accumulation and aggregation of abnormal proteins
and damaged organelles, leading to cellular toxicity, dysfunction and
neurodegeneration (Pan, Kondo et al. 2008). Without functional PINK1,
mitophagy fails, resulting in accumulated dysfunctional mitochondria and
elevated apoptotic rates (Lenzi, Marongiu et al. 2012). In this current study of
PINK1 KO mouse brain, two subunits of V-type proton ATPase were found to be
altered in either phosphorylation or expression: V-ATPaseA and V-ATPaseF. VATPase is a membrane transport protein whose function is to establish a proton
gradient, creating an acidic environment in many intracellular compartments,
including lysosomes (Beyenbach and Wieczorek 2006). Previously, we have
shown that C. elegans expressing mutant α-synuclein and tau have altered VATPase and decreased autophagy (Di Domenico, Sultana et al. 2012). Further,
when the function of V-ATPase is inhibited, autophagy may become
dysfunctional because the acidic environment in lysosomes required for
enzymatic hydrolysis cannot be generated (Pan, Kondo et al. 2008). Additionally,
with diminished lysosomal function, more α-synuclein can accumulate and impair
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cellular trafficking which may lead to neurodegeneration in PD (Dehay, MartinezVicente et al. 2013). The catalytic subunit A (V-ATPaseA) was found to have
decreased phosphorylation. V-ATPaseA is known to be phosphorylated by
protein kinase A at Ser-175; and, in liver cells, phosphorylation of subunit A leads
to a decreased activity (Alzamora, Thali et al. 2010), possibly due to decreased
binding affinity of ATP to V-ATPaseA. The F subunit of V-type proton ATPase (VATPaseF) was identified as having decreased expression, suggesting an overall
decrease in vacuolar acidification and autophagy.
Additional proteins involved in the proteostasis network that were found to
have significantly decreased expression were: proteasome subunit alpha type-2
(PSA2), heat shock-related 70 kDa protein 2 (HSP70.2), and voltage-dependent
anion-selective channel protein 2 (VDAC-2). PSA2 proteins compose the end
rings of the 20S proteasome, an ATP dependent multi-protein assembly that is
known to degrade oxidized proteins (Davies 2001). Hence, elevated oxidatively
modified proteins in PD conceivably could be due in part to diminished function of
the 20S proteasome. Moreover, since the 20S proteasome comprises the core of
the 26S proteasome, the overall protein degradation abilities of ubiquitinproteasome system could conceivably be diminished. Consistent with these
results, decreased proteasomal function and expression has been noted in PD
patients and PD animal models (Bukhatwa, Zeng et al. 2010, Ebrahimi-Fakhari,
Wahlster et al. 2012, Martins-Branco, Esteves et al. 2012).
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HSP70 is an ubiquitously expressed molecular chaperone that mediates
the folding of newly translated proteins, stabilizes proteins against aggregation,
aids in clathrin mediated endocytosis, exocytosis (including synaptic vesicles)
and is an important mediator for relaying targeted proteins to the ubiquitinproteasome system and autophagy-lysosomal pathways (Meimaridou, Gooljar et
al. 2009, Alvarez-Erviti L and et al. 2010, Redeker, Pemberton et al. 2012). We
have previously demonstrated that viral gene transfer of HSP70 protects against
toxin-induced dopaminergic neuron loss in a sporadic model of PD in mice
(Dong, Wolfer et al. 2005). In addition, HSP70 suppressed α-synuclein toxicity in
a transgenic Drosophila model of familial PD (Auluck, Chan et al. 2002).
Therefore, the finding of reduced HSP70 expression is intriguing and is
consistent with the notion of an increased vulnerability of dopaminergic neurons
to mitochondrial and proteotoxic stressors in the absence of PINK1.
VDAC2 is a mitochondrial membrane porin that opens at low or zero
membrane potential, and allows diffusion of small hydrophilic molecules and ions
and thus plays a role in mitochondrial metabolic processes (Blachly-Dyson and
Forte 2001, Shoshan-Barmatz and Gincel 2003). VDACs are also involved in
mitochondrial autophagy, possibly by recruiting Parkin to docking sites in
defective mitochondrial membranes, tagging the organelles for degradation by
lysosomes (Sun, Vashisht et al. 2012). A decrease in the expression of this
protein in PD would inhibit the removal of malfunctioning mitochondria,
contributing to an increase of cellular detritus and subsequent neuronal
dysregulation.
62

4.5.4 Oxidative Stress
Increased levels of reactive oxygen species have been noted in PD and
PD model organisms (Jenner 2003, Heeman, Van den Haute et al. 2011, Di
Domenico, Sultana et al. 2012, Varcin, Bentea et al. 2012). Not only does
aberrant mitochondrial function and dysfunction of proteostasis networks impact
oxidative stress, but loss of neurotropic factors contributes as well. Consistent
with this observation, two additional neuroprotective enzymes were found in the
present study to have decreased expression in in the brain of the PINK1 KO
mouse: carbonyl reductase [NADPH] 3 (CBR3) and cytoplasmic isocitrate
dehydrogenase [NADP+] (IDHc). CBR3 is an oxidoreductase that reduces
oxidative stress by catalyzing the reduction of carbonyls to their corresponding
alcohols (Miura, Nishinaka et al. 2008). This reduction of oxidative stressmediated carbonyls leads to the creation of a less toxic species (Oppermann
2007). IDH also plays a defensive role combating oxidative damage as it
contains a tagging sequence that can direct damaged proteins to peroxisomes
for degradation (Xu, Zhao et al. 2004). Additionally, IDHc, utilizing NADP+ as a
cofactor, generates NADPH, which noted above is an important cofactor for
maintaining reduced glutathione, a key antioxidant. Supporting our data,
knockdown studies of IDHc in PC12 cell lines demonstrated changes in cellular
redox status, increased oxidative damage and apoptotic cell death (Yang and
Park 2011). Further, cell lines that expressed lower levels of IDHc were shown to
have increased lipid peroxidation, peroxide generation and oxidative damage to
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DNA (Lee, Koh et al. 2002). Consequently, we opine that these proteins may
contribute to the oxidative stress observed in PD brain.
4.5.5 Neuronal plasticity, trafficking and structure
Mitochondrial dysfunction is implicated in various neuronal degenerative
diseases, leading to decreased neuroplasticity and neurite outgrowth (Cheng,
Hou et al. 2010). Furthermore, PINK1 has previously been reported to be a
possible contributor in the regulation of neurite outgrowth, and its deficiency
causes dysregulation of this process (Samann, Hegermann et al. 2009). In the
present study, we uncovered a significant decrease in two proteins involved in
neurite outgrowth: elongation factor 2 (EF2) and dihydropyrimidase-related
protein 2 (DRP2; CRMP2). EF2 mediates ribosomal translocation of peptidyltRNA from the A to the P site during protein translation, which has been shown to
regulate neurite outgrowth in advancing growth cones (Nairn and Palfrey 1987,
Iketani, Iizuka et al. 2013). When EF2 is down-regulated or inhibited by EF2
kinase, protein synthesis driving the growth cone is blocked; therefore, formation
of new neuronal connections are inhibited (Sutton, Taylor et al. 2007).
Furthermore, down-regulation of global protein synthesis has been linked to
impaired chaperone and proteasome activity as cells lower protein synthesis
when protein folding and/or degradation pathways are impaired to reduce the
burden of aggregated and misfolded proteins (van Oosten-Hawle and Morimoto
2014), consistent with the observed decreases of HSP70 and proteasomal
subunit expression in this study. Moreover, reducing protein synthesis has shown
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to be beneficial in a Drosophila PINK1 model (Liu and Lu 2010). Thus, while
reduced expression of EF2 may affect neurite formation it may also be an
adaptive, overall neuroprotective response.
DRP2, also called CRMP2, is a signaling protein that interacts with binding
partners and carries out multiple functions, some of which include: neurite
outgrowth and retraction, growth cone guidance, kinesin-dependent axonal
transport, neurotransmitter release, endocytosis, vesicular cycling, synaptic
assembly, Ca2+ homeostasis, organization of the dendritic field and neuronal
differentiation (Hensley, Venkova et al. 2011, Khanna, Wilson et al. 2012, Tan,
Ma et al. 2013). Even though DRP2 expression decreases with age, higher levels
remain in areas of neurogenesis and neuroplasticity (Charrier, Reibel et al.
2003). Consequently, PINK1(-/-) mice deficient in CRMP2 would have severely
diminished capacity in their brains to change and adapt.
In PD, multiple neuronal networks experience altered neurotransmission,
a condition that is exacerbated by α-synuclein overexpression (Barone 2010,
Nemani, Lu et al. 2010). In the PINK1(-/-) model in particular, there is a significant
reduction in the neurotransmitter dopamine. Decreased expression of V-ATPase
in the PINK1 KO mouse is a probable contributor in the breakdown in
neurotransmission. Working in conjunction with the H+/neurotransmitter
antiporter, V-ATPase assists in the concentration of neurotransmitters into
synaptic vesicles (Beyenbach and Wieczorek 2006). Disruption of this process
leads to decreased levels of neurotransmitters in the synaptic cleft. Further,
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synaptic vesicle trafficking at the presynaptic cleft is maintained by a cycle of
protein complex assembly and disassembly of the SNARE complexes; failure of
this cycle can lead to loss of neuronal structure and function (Esposito, Ana Clara
et al. 2012). A central protein involved in this process, vesicle-fusing ATPase,
also known as N-ethylmaleimide-sensitive fusion protein (NSF), was found in the
present study to be significantly decreased in the PINK1(-/-) brain. NSF is a
membrane trafficking chaperone required for intracellular membrane fusion and
vesicle-mediated transport (Whiteheart, Rossnagel et al. 1994, Bomberger,
Parameswaran et al. 2005). Specifically for neurotransmission, NSF facilitates
membrane fusion of SNARE complexes (in conjunction with SNAP) for synaptic
exocytosis, subsequent disassembly of the complex and mobilization of the
reserve neurotransmitter pool (Neuwald 1999, Lin and Scheller 2000, Whiteheart,
Schraw et al. 2001), while also promoting re-sensitization of surface receptors on
the plasma membrane (Bomberger, Parameswaran et al. 2005). Knockout of
NSF leads to an accumulation of synaptic vesicles at the axon terminals and at
the docking site (Whiteheart, Schraw et al. 2001). Consistent with our results and
the above notion, PINK1 deficient Drosophila neurons show that rapid stimulation
of synaptic vesicles is defective (Morais, Verstreken et al. 2009).
Loss of neuronal scaffolding is accompanied by decreased expression of
structural proteins. In this study we found two structural proteins to be
significantly decreased in the PINK1 KO brain: neurofilament light peptide (NFL)
and actin-related protein 2/3 complex subunit 2 (ARPC2). NFL is a component in
Lewy bodies and a major structural element in neurons, forming the backbone for
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other neurofilaments (Fuchs and Cleveland 1998). In the substantia nigra of PD
subjects, reduced levels of NFL and NFL mRNA were found and correlated with
the severity of the disease (Hill, Arai et al. 1993, Liu, Xie et al. 2011). ARPC2 is
part of a structural protein complex that plays a role regulating the polymerization
and branching of actin filament networks (Gournier, Goley et al. 2001, Spillane,
Ketschek et al. 2012). Furthermore, in the current study, the phosphorylation
state of neurofilament medium polypeptide (NFM) also was found to be
significantly decreased. NFM is a structural protein that supports axonal caliber,
and altered levels of NFM phosphorylation affect the function of larger
neurofilaments. Additionally, phosphorylation of NFM produces inter-filament
cross bridges that increase axonal structure; therefore, a decrease in NFM
phosphorylation would be predicted to lead to a decrease in axonal caliber
(Mukai, Toshimori et al. 1996). Thus, defects in neuronal structural proteins may
contribute to the pathogenesis of recessive familial PD.
In conclusion, ablation of PINK1 in mice results in differential expression
and altered phosphorylation states of multiple brain proteins with critical functions
involved in early changes in cellular signaling pathways, energy metabolism,
proteostasis networks, oxidative stress, neurotransmission and neuronal
structural plasticity (Figure 4.5).

67

Figure 4.5 Summary of PINK1 KO proteomics and phosphoproteomics.
Schematic diagram summary of expression proteomics and phosphoproteomics
profiles of the PINK1 KO mouse brain. We hypothesize that such changes
contribute to the reputed and known changes in PD. Used by permission of John
Wiley and Sons.
Our findings provide a starting point for future investigations of the impact that
these differentially expressed and phosphorylated proteins and their regulated
pathways may have on the pathogenesis of PD; particularly the role of potential
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environmental triggers that interact with mutated PD susceptibility gene. In
addition, further studies are required to determine if the proteins identified here
may serve as therapeutic targets to interfere with the progression of PD or as
part of a panel of potential biomarkers for PD.

Copyright © Judy Carol Triplet 2015

69

CHAPTER 5
QUANTITATIVE PHOSPHOPROTEOMIC ANALYSES OF THE INFERIOR
PARIETAL LOBULE FROM THREE DIFFERENT PATHOLOGICAL STAGES
OF ALZHEIMER DISEASE
5.1 Overview
Alzheimer disease (AD), the most common age-related neurodegenerative
disorder, is clinically characterized by progressive neuronal loss resulting in loss
of memory and dementia. AD is histopathologically characterized by the
extensive distribution of senile plaques and neurofibrillary tangles, and synapse
loss. Amnestic mild cognitive impairment (MCI) is generally accepted to be an
early stage of AD. MCI subjects have pathology and symptoms that fall on the
scale intermediately between ‘normal’ cognition with little or no pathology and
AD. A rare number of individuals, who exhibit normal cognition on psychometric
tests but whose brains show widespread postmortem AD pathology, are
classified as ‘asymptomatic’ or ‘preclinical’ AD (PCAD). In this study, we
evaluated changes in protein phosphorylation states in the inferior parietal lobule
of AD, MCI, PCAD, and control brain using a 2-D PAGE proteomics approach in
conjunction with Pro-Q Diamond phosphoprotein staining. Statistically significant
changes in phosphorylation levels were found in 19 proteins involved in energy
metabolism, neuronal plasticity, signal transduction, and oxidative stress
response. Changes in the disease state phosphoproteome may provide insights
into underlying mechanisms for the preservation of memory with expansive AD
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pathology in PCAD and the progressive cognitive decline in MCI that escalates to
the dementia and the characteristic pathology of AD brain.
5.2 Introduction
Alzheimer disease (AD) is neuropathologically characterized by the
increasing accumulation of extracellular senile plaques (SPs), intracellular
neurofibrillary tangles (NFTs), synapse loss, and increased neuronal cell death.
SPs are insoluble fibrous material containing deposits of amyloid-β-peptide (Aβ)
along with other proteins and dystrophic neurites. NFTs are formed following tau
hyperphosphorylation, which leads to tau uncoupling from microtubules and
aggregating with other proteins, thereby significantly hindering axonal transport.
Distribution and quantity of SPs and NFTs and loss of synapses tend to correlate
with disease severity (Thal, Holzer et al. 2000, Thal, Rub et al. 2002). Clinically,
the pathology and underlying biochemical mechanisms bring about escalating
memory loss and worsening cognitive function that culminates with severe
dementia.
Mild cognitive impairment (MCI) is considered to be an intermediate
disease state between persons with no cognitive impairment and individuals with
AD (Petersen 2004). Clinically, MCI-diagnosed patients have non-age-related,
failing cognition, yet do not exhibit signs of dementia, as primary day-to-day
functional abilities are not overtly affected (Morris, Storandt et al. 2001). The
amnestic MCI subtype, in particular, is considered to be a potential, preferential
harbinger of AD (Portet, Ousset et al. 2006). Histopathologically, the MCI brain
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tends to have intermediary quantities of NFTs, neuronal loss and atrophy than is
associated with a control or AD brain (Gomez-Isla, Price et al. 1996, Kordower,
Chu et al. 2001). Differences in SP deposition and density are generally
intermediate to AD pathology, but this can widely vary (Morris, Storandt et al.
1996, Markesbery 2010, Villain, Chetelat et al. 2012). However, levels of Aβ
oligomers, in particular Aβ(1-42), which is the most toxic Aβ (Butterfield and
Kanski 2002, Klein, Stine et al. 2004), are reported to correlate more reliably to
severity of cognitive impairment and loss of synaptic biomarkers (Pham, Crews
et al. 2010). Diagnosis of disease stage must not only consider NFT and SP
pathology and global cognition evaluations, but also biochemical changes which
may relate to either cognitive decline or a compensatory disease response.
Insights into underlying mechanisms of disease progression at earliest detectable
stages may be critical in slowing disease progression.
While advanced SP distribution can be present at any stage of cognition,
extensive distributions of NFTs are a rarity in people who are considered
cognitively intact (Arriagada, Growdon et al. 1992, Erten-Lyons, Woltjer et al.
2009). These subjects, whose brains exhibit considerable SP and NFT
pathology postmortem, yet were asymptomatic with no signs of failing cognition
antemortem, are referred to as having preclinical AD (PCAD) (Abner, Kryscio et
al. 2011). Interesting characteristics of PCAD brains include: larger brain
volumes than in MCI or AD (Erten-Lyons, Woltjer et al. 2009), little or no neuronal
loss (Price, Ko et al. 2001), increased neuronal hypertrophy (Iacono, O'Brien et
al. 2008), overall increase in synaptic plasticity (O'Brien, Resnick et al. 2009),
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and changes in proteins involved in Zn transport (Lyubartseva, Smith et al.
2010). Insights into neuroprotective mechanisms that prevent cognitive deficits
despite heavy SP and NFT load may provide key insights into halting mental
decline that leads to dementia.
Proposed contributing factors of AD include: oxidative stress, Aβ-induced
toxicity, inflammation, and dysfunction of energy metabolism (Markesbery 1997,
Butterfield and Kanski 2002, Hynd, Scott et al. 2004, Ho, Drego et al. 2005,
Tuppo and Arias 2005). Accumulating evidence suggests that free radicals
produced during oxidative stress play a key role in AD and other
neurodegenerative diseases (Browne, Ferrante et al. 1999, Butterfield 2002,
Zwerschke, Mazurek et al. 2003, Lin and Beal 2006, Triplett, Zhang et al. 2015).
Oxidative stress may lead to post translational modifications of proteins such as
carbonylation, nitration and 4-hydroxyl-2-nonenal (HNE) adducts that change
protein structure and can result in loss of function, protein unfolding and
aggregation (Butterfield and Lauderback 2002, Butterfield, Reed et al. 2007). In
AD, oxidative stress appears to be an early event as global levels of carbonyls,
3-nitrotyrosine and HNE are significantly increased in MCI brain; however, these
global markers of oxidative stress in PCAD were generally similar to levels in
control brains (Butterfield, Reed et al. 2006, Butterfield, Reed et al. 2007, Aluise,
Robinson et al. 2010, Bradley, Markesbery et al. 2010, Aluise, Robinson et al.
2011).
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Protein phosphorylation is a fundamental mechanism mediating diverse
cellular functions that is strictly regulated by kinases and phosphatases; aberrant
phosphorylation of neuronal proteins is a characteristic of several
neurodegenerative diseases (Humbert and Saudou 2003, Hasegawa, Arai et al.
2008, Di Domenico, Sultana et al. 2011, Triplett, Zhang et al. 2015). Evaluating
phosphorylation states in proteins in the three different pathological stages of AD
may provide valuable insights into the biological pathways that contribute to or
impede neurodegeneration in AD. In the current study, global protein
phosphorylation levels in the inferior parietal lobule (IPL) were determined using
2-D PAGE in conjunction with a multiplexed proteomics technology (Steinberg,
Agnew et al. 2003). By comparing the phosphoproteome of control, PCAD, MCI,
and AD brain, 19 proteins were found with significant differential phosphorylation
levels in the disease states. These proteins are involved in are involved in
underlying biochemical processes that contribute to disease pathology and
clinical presentation.
5.3 Materials and Methods
5.3.1 Materials
All chemicals used in this study were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless otherwise noted. ReadyStrip IPG strips (pH 3-10),
Criterion precast polyacrylamide gels (8-16% Tris/HCl or 4-12% Bis/Tris), TGS
and MOPS electrophoresis running buffers, Precision Plus Protein All Blue
Standards, mineral oil, Sypro Ruby protein stain, dithiothreitol (DTT),
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iodoacetamide (IA), biolytes, urea, and nitrocellulose membranes were
purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond phosphoprotein
stain and anti-phosphoserine, anti-phosphotyrosine, and anti-phosphothreonine
antibodies were obtained from Invitrogen (Grand Island, NY, USA). Re-Blot Plus
Strong stripping solution and C18 ZipTips were purchased from Millipore
(Billerica, MA, USA). Amersham ECL IgG peroxidase-linked secondary
antibodies, ECL Plus Western blotting reagents, and Protein A/G beads were
purchased from GE Healthcare (Pittsburgh, PA, USA). Pierce BCA protein assay
reagents were purchased from Thermo Scientific (Waltham, MA, USA). Modified
trypsin digestion solution was obtained from Promega (Madison, WI, USA). AntiCRMP2 and anti-SMP30 (senescence marker protein-30; regucalcin) antibodies
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
5.3.2 PCAD, MCI, AD, and control subjects
Frozen IPL tissue specimens from well-characterized PCAD, MCI, AD,
and respective age-matched control subjects (n=7 for each group) were obtained
from the University of Kentucky Rapid Autopsy Program of the Alzheimer
Disease Clinical Center, with an average post-mortem interval (PMI) of 2.62 h. All
the subjects underwent annual physical and neurological exams. Control and
PCAD subjects exhibited no history of dementia or other neurological disorders
and had MMSE test scores in the normal range. Criterial categorizing the stage
of disease progression has been previously described (Aluise, Robinson et al.
2011). Table 5.1 lists the relevant demographical data.
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Table 5.1 Demographic data of PCAD, MCI, AD and control subjects. Raw
and average data of subjects in this current dissertation study.

5.3.3 Sample preparation
IPL sample homogenates were prepared using a Wheaton glass
homogenizer (~40 passes) and diluted with ice-cold isolation buffer, pH 7.4 [0.32
M sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5
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µg/mL aprotinin, 4 µg/mL pepstatin, 4 µg/mL leupeptin, and 10 µL/mL
phosphatase inhibitor cocktail 2]. Protein concentrations of the homogenates
were determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et
al. 1985).
5.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
2-D PAGE experiments were performed as described previously (Sultana,
Boyd-Kimball et al. 2007). In short, 200 µg of each sample was suspended in
rehydration buffer [8 M urea, 2 M thiourea, 50 mM DTT, 2.0% (w/v) CHAPS,
0.2% Biolytes, 0.01% bromophenol Blue] (200 µL total volume), applied to IPG
strips and actively rehydrated for 18 h at 50 V and 20°C for 18 h. Next, proteins
were isoelectricly focused at 20°C starting at 300 V for 2 h, 500 V for 2 h, 1000 V
for 2 h, 8000 V for 8 h, and finishing at 8000 V for 10 h. IPG strips were
immediately stored at -80 °C.
For the second dimension, IEF strips were thawed, equilibrated for 10 min
in the dark with 4 mL of an equilibration buffer [50 mM Tris–HCl, pH 6.8, 6 M
urea, 1% (w/v) SDS, 30% v/v glycerol] containing 0.5% DTT, and then reequilibrated for 10 min in the dark with 4 mL of the same equilibration buffer
containing 4.5% IA. Next, the strips were rinsed and placed into 11 cm Criterion
precast polyacrylamide gels (8–16% Tris–HCl). Samples and Precision Plus
Protein All Blue molecular standards were run at 200 V for 65 min in TGS
running buffer.
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5.3.5 Pro-Q Diamond and Sypro Ruby gel staining
Phosphorylated proteins were detected and normalized using Pro-Q
Diamond and Sypro Ruby gel stains according to manufacturer’s directions. In
brief, gels were fixed in 50 mL of solution [10% (v/v) acetic acid, 50% (v/v)
methanol] (30 min, two times) and washed with 100 µL of deionized (DI) water
(30 min, three times). Next, gels were stained with 80 mL of Pro-Q Diamond for
90 min and then destained in 100 mL of solution [20% acetonitrile (ACN), 50 mM
sodium acetate, pH 4] (30 min, four times). The gels were washed in 100 µL of DI
water (30 min, three times) and scanned at 580 nm with ChemiDoc XRS+
imaging system (Bio-Rad, Hercules, CA, USA). Gels were then incubated in 50
mL of Sypro Ruby gel stain overnight (15 h). The Sypro Ruby stain was removed
and the gels were rinsed in DI water. The gels were scanned at 450 nm with the
ChemiDoc imager and then stored at 4 °C in DI water until protein spot
extraction.
5.3.6 Image Analysis
2D-gel images of the stained gels were quantified using PDQuest 2-D
analysis software (Bio-Rad), according to the manufacturer’s instructions. Briefly,
protein spots intensities were matched, measured, and normalized to the total
spot density in the gel for the Pro-Q Diamond-stained images and then for the
Sypro Ruby-stained images. Next, a high match analysis was conducted to
match each Pro-Q Diamond stained sample to the corresponding Sypro-Ruby
stained sample. The phosphoprotein spot densities were then normalized to the
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Sypro Ruby spot densities so that a highly abundant but lightly phosphorylated
protein could be differentiated from a lowly abundant but highly phosphorylated
protein. Only protein spots identified in the PCAD, MCI and AD gels as having
statistically significant, differential phosphorylation states from the control were
considered for in-gel trypsin digestion and protein identification by MS/MS.
5.3.7 In-gel trypsin digestion/peptide extraction
Protein spots in PCAD, MCI, and AD gels identified as being statistically
different from control group were excised, transferred to individual Eppendorf
microcentrifuge tubes, and trypsin digested as described previously
(Thongboonkerd, McLeish et al. 2002). Briefly, gels were incubated in 20 µL of
0.1 M ammonium bicarbonate (NH4HCO3) for 15 min. Next, 30 µL of ACN was
added and incubated for another 15 min. After removal of the solvents, the gel
plugs were dried under a flow hood and then incubated with 20 µL of 20 mM DTT
in 0.1 M NH4HCO3 for 45 min at 56°C. The DTT/NH4HCO3 solution was removed
and 20 µL of a 50 mM IA in 0.1 M NH4HCO3 solution was added for 15 min. The
IA/NH4HCO3 solution was removed and replaced with 150 µL of a 50 mM
NH4HCO3 solution for 15 min. Next, 200 µL of ACN was added for 15 min of
incubation. The gel plugs were dried under a flow hood after removal of the
solvents. The gel plugs were incubated with shaking at 37°C in 10 µL of modified
trypsin solution in 50 mM of NH4HCO3 overnight (16 h). C18 ZipTips were used to
remove salts and contaminants from the tryptic peptide solutions. Tryptic peptide
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solutions were reconstituted in 10 µL of 5% ACN/0.1% formic acid (FA) and
stored at -80˚C until MS/MS analysis.
5.3.8 NanoLC-MS with Data Dependent Scan
A nanoAcquity (Waters, Milford, MA)-LTQ Orbitrap XL (Thermo Scientific,
San Jose, CA) platform using a data dependent scan mode was implemented in
the analyses of the tryptic peptide solutions. An in-house packed capillary column
(0.1 x 130 mm column packed with 3.6 µm, 200Å XB-C18) with a gradient using
0.1% FA and ACN/0.1% FA at 200 nL/min was used for separation. The orbitrap,
operating at 30,000 resolution, was used to obtain MS spectra. For the MS/MS
spectra of the six most intense parent ions, the orbitrap was operated at 7,500
resolution. To identify the protein in each peptide sample, the latest version of the
Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, Thermo
Scientific) was used in the interrogation of data files. At least two high-confidence
peptide matches were used for protein identification, and the false discovery rate
was less than 1%. Proteins were reported as one protein group if they were
matched with the same peptides. Initial verification of the MS/MS data was
accomplished by the comparison of the expected molecular weight (MW) and
isoelectric point (PI) of the identified protein to MW and PI of the extracted gel
plug.
5.3.9 Immunoprecipitation and Western blotting validations
Individual brain homogenates (250 µg) were suspended in an IP buffer
solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na2HPO4, 0.24 M KH2PO4, 0.05%
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NP-40, aproprotin 5 µg/mL, leupeptin 4 µg/mL, pepstatin 4 µg/mL, and
phosphatase inhibitor cocktail 10 µL/mL] (500 µL total volume). Samples were
shaken with Protein A/G agarose beads for 1.5 h at 4˚C for preclearance of
endogenous antibodies. Each sample was agitated overnight in IP buffer at 4˚C
with either anti-SMP30 or anti-CRMP2 antibodies (1:50 dilution). Protein A/G
agarose beads were mixed with the sample for 1.5 h and washed with 500 µL of
IP buffer (10 min, 5 times). The beads were suspended in 4X sample loading
buffer [0.5 M Tris (pH 6.8), 40% glycerol, 8% SDS, 20% β-mercaptoethanol,
0.01% Bromophenol Blue] (diluted to 1X with DI water). Samples were heated at
95°C for 5 min and cooled before loading into Criterion precast 18 well
polyacrylamide gels (4-12% Bis-Tris). Using XT MOPS running buffer, samples
and Precision All Blue MW marker were run at 80 V for 15 min and then at 120 V
for 100 min. The in-gel proteins were transferred onto a nitrocellulose membrane
with a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V for 30 min. After the
transfer, membranes were blocked in solution (3% bovine serum albumin (BSA)
in TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h. Antiphosphoserine, anti-phosphothreonine, and anti-phosphotyrosine antibodies
were added to the blocking solution (1:8000 dilution) and incubated for 2 h. Next,
the blots were washed with TBS-T (5 min, three times) and incubated for 1 h with
a peroxidase secondary antibody in TBS-T (1:3000). The membranes were
washed in TBS-T (10 min, three times), developed with Clarity Western ECL
substrate, scanned using Bio-Rad ChemiDoc XRS+ imaging system, and
quantified using Image Lab software (Bio-Rad). The blots were then stripped with
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Re-Blot Plus Strong solution, rinsed with TBS-T (5 min, three times each),
probed with either anti-SMP30 or anti-CRMP2 antibodies (1:2000), developed
and scanned.
5.3.10 Statistical analysis
All data are presented as mean+SEM. A one-way ANOVA statistical test
with post hoc Tukey t-test was used in determining significance (p<0.05) in
PDQuest analyses. A Student’s t-test was used in Western blot analysis. Protein
spot fold-change values were calculated by dividing the average, normalized spot
intensities of the PCAD, MCI, or AD group by the average, normalized spot
intensities of the gels of the control group. Spot were extracted for MS/MS
analysis if the fold change of the normalized spot density was 50% or more,
whether elevated or decreased from controls. Proteins identified with the
SEQUEST search algorithm were considered to be statistically significant if
p<0.01.
5.4 Results
For the evaluation of phosphorylation levels of proteins in the IPL, the
average, normalized protein spot densities from the PDQuest analysis of control,
PCAD, amnestic MCI and AD samples were compared. Figure 5.1 shows
representative Sypro Ruby-stained 2-D gels, while Figure 5.2 shows the same
gels developed with Pro-Q Diamond phosphoprotein stain. Protein spots with
statistically significant altered phosphorylation levels are labeled in the
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appropriate gels. PDQuest analyses of all 2-D gels found 19 proteins whose
phosphorylation levels differed in at least one of the comparisons.

Figure 5.1 Sypro Ruby-stained gels of control, PCAD, amnestic MCI and AD
brain. Representative Sypro Ruby-stained 2-D gel images of isolated proteins
from the IPL of (A) control, (B) PCAD, (C) amnestic MCI, and (D) AD subjects.
Extracted protein spots of proteins whose phosphorylation levels were
significantly altered (p<0.05) in each group are labeled in the images.
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Figure 5.2 Pro-Q Diamond-stained gels of control, PCAD, amnestic MCI and
AD brain. Representative Pro-Q Diamond-stained 2-D gel images of isolated
proteins from the IPL of (A) control, (B) PCAD, (C), amnestic MCI, and (D) AD
subjects. Proteins with significantly altered (p<0.05) phosphorylation levels in
each group are labeled in the images.
Tables 5.2-5.4 summarize the PDQuest and MS/MS data and includes:
the protein spot number as labeled by PDQuest, the SwissProt accession
number, the percentage of the protein sequence identified by MS/MS analyses,
the number peptide sequences identified, the confidence score of the protein, the
expected molecular weight and predicted isoelectric point of the identified
protein, and the p-values and fold-change levels of phosphorylation.
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Table 5.2 Significantly altered phosphoproteins of the IPL of PCAD and control
subjects. PDQuest and MS/MS results of IPL proteins of control versus PCAD subjects
with significantly altered phosphorylation states as compared to control subjects.

Table 5.3 Significantly altered phosphoproteins of the IPL of MCI and control
subjects. PDQuest and MS/MS results of IPL proteins of control versus MCI subjects
with significantly altered phosphorylation states as compared to control subjects.
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Table 5.4 Significantly altered phosphoproteins of the IPL of AD and control
subjects. PDQuest and MS/MS results of IPL proteins of control versus AD subjects
with significantly altered phosphorylation states as compared to control subjects.

Proteins were identified with two or more peptide sequences. To ensure
correct identification of the proteins, the expected molecular weight and
isoelectric point of the identified protein were visually compared to the spot of the
extracted gel plug.
In comparing the IPL of PCAD and control brains (Table 5.2), 8 proteins
found to have significantly altered phosphorylation levels: Heat shock 70kDa
protein 12A (↑8.92-fold); isoform 2 of gelsolin (↓0.280-fold); regucalcin
(↓0.0170-fold); L-lactate dehydrogenase b-chain (↑28.7-fold); septin 2 (↑2.89fold); flavin reductase [NADPH] (↑8.86-fold); and isoform CNPI of 2’,3’-cyclic
nucleotide-3’-phosphodiesterase (↓0.0083-fold). Analysis of the IPL of MCI and
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control specimens (Table 5.3) revealed 5 proteins that had significantly different
phosphorylation levels: citrate synthase (↑3.88-fold); transitional endoplasmic
reticulum ATPase (↓0.0571-fold); isoform 2 of gelsolin (↓0.383-fold); regucalcin
(↓0.0262-fold); EF-hand domain-containing protein D1 (↓0.0710-fold). The
largest differences were observed in the comparison of the IPL of AD and control
brains (Table 5.4), in which 14 proteins exhibited significant differential levels of
phosphorylation. These 14 proteins were: voltage-dependent anion-selective
channel protein 1 (↓0.149-fold); isoform 2 of voltage dependent anion-selective
channel protein 2 (↓0.0829-fold); isoform 2 of gelsolin (↓0.179-fold); L-lactate
dehydrogenase b-chain (↑34.8-fold); dihydropyrimidinase-related protein 2 [also
called collapsing response mediator protein 2, CRMP-2] (↑3.51-fold); guanine
nucleotide-binding protein G(o) subunit alpha (↑6.11-fold); EF-hand domaincontaining protein D1 (↓0.0802-fold); transitional endoplasmic reticulum ATPase
(↓0.258-fold); Cu/Zn superoxide dismutase (↓0.0097-fold); peroxiredoxin 1
(↓0.0489-fold); regucalcin (↓0.108-fold); stathmin (↓0.0454-fold); syntaxinbinding protein 1 (↓0.177-fold); and carbonyl reductase 1 (↓0.392-fold). Some
of these proteins were found to have significantly different phosphorylation levels
in multiple group comparisons and their relationships are illustrated in the Venn
diagram of Figure 5.3.
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Figure 5.3 Significant differentially phosphorylated proteins of the IPL in
AD progression. Venn diagram of significant differentially phosphorylated IPL
proteins illustrating the overlapping proteins involved in the progression of AD.

To validate MS/MS results, immunoprecipitation experiments were carried
out. Figure 5.4 shows the images from the immunoprecipitation experiments after
probing with anti-phosphoserine, anti-phosphothreonine and antiphosphotyrosine antibodies in which the immunoprecipitated protein of each
experiment, SMP30 or CRMP2, was used as the loading control.
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Figure 5.4 SMP30 and CRMP2 phosphorylation in IPL from control, PCAD,
MCI and AD brain. Western blots and corresponding bar graph representations
from immunochemistry experiments evaluating changes in global
phosphorylation levels of SMP30 and CRMP2 in the IPL of control, PCAD,
amnestic MCI, and AD subjects (n=4 for each age group, *p<0.05).
Immunoreactivity with specific antibodies was detected by chemiluminescence.

The findings from the SMP30 analysis confirmed a significant decrease in
the global phosphorylation levels of SMP30 in the IPL in the following
comparisons: PCAD versus control (p=0.0371), MCI versus control (p=0.0489),
and AD versus control (p=0.00872). Analysis of the CRMP2 immunoprecipitation
experiment verified the increased phosphorylation of CRMP2 in the AD brain
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versus control, (p=0.00733). Additionally, global levels of phosphorylated CRMP2
were also significantly increased in the IPL of MCI, (p=0.0118).
5.5 Discussion
Neuropathologically, AD progression is quantified by increasing SPs,
NFTs, and synaptosomal loss. Clinically, the underlying biochemical mechanisms
contributing to these pathologies result in progressive cognitive deficits,
culminating in dementia. The PCAD brain is intriguing, as it possesses
accumulation of SPs and NFTs, but does not have loss of synapses, cognition, or
global changes in oxidative stress (Aluise, Robinson et al. 2011). In this current
study, the phosphoproteome of the IPL of control, PCAD, MCI, and AD brains
were compared to not only assess phosphorylation changes in brain proteins
involved in disease progression from control to MCI and AD, but also to evaluate
underlying biochemical pathways that may contribute to prevention of memory
loss in the presence of abundant AD pathology. Significant changes in
phosphorylation were found that may provide insights into clinical manifestations
of underlying pathology. These insights are discussed in areas concerning:
energy metabolism and mitochondrial dysfunction, oxidative stress and stress
response, and neuronal plasticity, neurotransmission and cellular signaling.
Energy metabolism and mitochondrial dysfunction
Cognitive decline in AD is associated with cortical atrophy, reduced
cerebral glucose metabolism and mitochondrial dysfunction and is reviewed in
(Ferreira, Resende et al. 2010, Kapogiannis and Mattson 2011). The majority of
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the energy generated by glucose oxidation is spent maintaining ion gradients,
propagating action potentials, and the release and recycling of neurotransmitters
(Attwell and Laughlin 2001). Therefore, regulating and maintaining high energy
production is essential for neuronal survival.
Lactate dehydrogenase (LDH) is a metabolic enzyme that catalyzes the
reversible production of lactate from pyruvate. Of the five different isoforms of
LDH, LDHB activity preferentially promotes the conversion of lactate to pyruvate
to provide a source of fuel (Newington, Harris et al. 2013). Lactate production
has been shown to be increased in both sporadic and familial AD (Sims, Finegan
et al. 1985, Hoyer, Oesterreich et al. 1988), especially in areas of AD pathology
(Kapogiannis and Reiter). In the current study, phosphorylation levels LDHB
were significantly increased in AD compared to control and MCI and also
increased in PCAD as compared to control. Though the effect of phosphorylation
of LDHB has yet to be determined, it is reasonable to speculate that
phosphorylation may conceivably decrease LDHB activity, as increased lactate
levels in AD brain have been confirmed by multiple groups (Sims, Finegan et al.
1985, Hoyer, Oesterreich et al. 1988). It is interesting that LDHB phosphorylation
is significantly increased in the IPL of brains with extensive SP and NFT
pathology, and it is reasonable to speculate that phosphorylation of LDHB could
be a potential neuroprotective mechanism to induce the Warburg effect in an
attempt to decrease mitochondrial throughput, thereby decreasing resultant ROS
production and oxidative stress.
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In the IPL of the MCI brain, on the other hand, citrate synthase (CS) had
significantly increased levels of phosphorylation compared to control.
Phosphorylation of CS has been reported to increase the enzymatic activity of
this enzyme (Kojima and Numata 2002). Since CS is considered to be the TCA
enzyme that drives the cycle (Wiegand and Remington 1986), the significant
increase of phosphorylated CS may be an attempt to increase availability of ATP
to meet cellular energy demands required to sustain functions in a deteriorating
environment. Additionally, in AD brain, it has been previously shown that there is
no change in the activity of CS (Canevari, Clark et al. 1999, Bubber, Haroutunian
et al. 2005). Consistent with these results, the phosphorylation levels of CS in the
AD brain in this current study were similar to control brain. Further, in contrast to
the PCAD and AD brain, the MCI brain does not contain as many SP and as
much NFT pathology. So perhaps, increasing energy production takes
precedence over minimizing ETC-related oxidative stress in the MCI brain,
though this is speculation at present.
Voltage dependent anion channels (VDACs) are the primary porins of the
outer mitochondrial membrane that are involved the regulation of metabolic flux
by modulating membrane permeability (Blachly-Dyson and Forte 2001, ShoshanBarmatz and Gincel 2003). VDACs are key participants in numerous processes
including: Ca2+ signaling, synaptic plasticity, apoptosis, and mitophagy (Murgia,
Giorgi et al. 2009, Sun, Vashisht et al. 2012). Therefore, dysregulation of VDACs
may result in a considerable shift in cellular metabolism and homeostasis that
promote neuronal dysregulation. Consistent with this notion, dysregulation of
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VDACs has been reported in multiple neurodegenerative diseases, including AD
(Ghosh, Pandey et al. 2007, Israelson, Arbel et al. 2010, Cuadrado-Tejedor,
Vilarino et al. 2011, Triplett, Zhang et al. 2015). In the current study,
phosphorylation levels of VDAC1 were decreased in PCAD and AD compared to
control and isoform 2 of VDAC2 was decreased in AD brain compared to control.
VDAC1, in particular, has been reported to be directly blocked by phosphorylated
tau and Aβ (Manczak and Reddy 2012), impeding mitochondrial influx. The most
abundant VDAC, VDAC1, has 11 known phosphorylation sites and VDAC2 has 4
known sites, but effects of phosphorylation at these sites remain largely
undetermined for VDAC1 and completely unknown for VDAC2 (reviewed in
(Kerner, Lee et al. 2012)). However, as both PCAD and AD brains contain high
amounts of Aβ and phosphorylated tau, it is reasonable to speculate that global
dephosphorylation of VDAC1 may serve to either enhance the interaction with Aβ
and phosphorylated tau to inhibit influx through the pore to limit oxidative
phosphorylation or to promote closure of the pore by phosphorylation itself to
constrain ETC-related oxidative stress. It is hypothesized that the different
isoforms of VDACs play distinct, although sometimes over-lapping roles
(Messina, Reina et al. 2012). VDAC2 has been reported to complex with BAK, a
pro-apoptotic protein, to inhibit the initiation of apoptosis (Cheng, Sheiko et al.
2003). And since phosphorylation of isoform 2 of VDAC2 was only significantly
decreased in the IPL of AD brain, it is interesting to speculate that decreased
phosphorylation of VDAC2 may diminish its affinity towards BAK, thereby
promoting cell death.
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Oxidative stress and stress response
Dysregulated energy metabolism and mitochondrial dysfunction can lead
to increased levels of reactive oxygen species, in particular, superoxide radical.
Cu/Zn superoxide dismutase (SOD1) catalyzes the conversion of superoxide to
H2O2 and O2. Analysis of APP transgenic mice showed decreased activity of
SOD1 which correlated to increased Aβ and contributed to increased oxidative
damage (Schuessel, Schäfer et al. 2005). Similarly, SOD1 activity was reported
to be significantly reduced in AD brain and is associated with increased oxidative
stress (Marcus, Thomas et al. 1998). In the current study, phosphorylation levels
of SOD1 in the IPL of AD brain were significantly decreased compared to control.
Although little is known about how phosphorylation affects any one of the 11
known phosphorylation sites, considering the reported decrease in SOD1 activity
in AD and the decrease in global SOD1 phosphorylation, it may be conceivable
that decreased SOD1 phosphorylation promotes decreased activity of this
important antioxidant, contributing to the increased oxidative stress reported in
AD (Butterfield and Lauderback 2002).
Peroxiredoxin 1 (PRDX1) is another antioxidant enzyme that had
decreased phosphorylation levels in the IPL of the AD brain compared to both
control and PCAD brains. PRDX1 regulates the cellular redox state by reducing
peroxides to water and the corresponding alcohol. By regulating H 2O2 levels,
PRDX1 may also play a role in cellular signaling by regulating TNFα-mediated
inflammation (Kang, Chae et al. 1998) and modulating the peroxide-dependent
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signaling of the ASK/p38 MAPK pathway (Jarvis, Hughes et al. 2012). Levels of
PRDX1 are reportedly increased in AD and DS brain (Kim, Fountoulakis et al.
2001). Further, phosphorylation on Thr90 has been shown to decrease
peroxidase activity by 80% and results in H2O2 accumulation (Chang, Jeong et
al. 2002). Additionally, phosphorylation on Tyr-194 has also been shown to
inactivate the protein (Woo, Yim et al. 2010). Therefore, the increased levels of
PRDX1 as well as the decrease in phosphorylation levels likely increases protein
activity as a compensatory response to the overwhelming levels of oxidative
stress in AD brain.
Levels of protein carbonyls are the most widely-used indicator of oxidative
stress as carbonyl levels are increased with age and age-related diseases
(Aksenov, Aksenova et al. 2001, Dalle-Donne, Scaloni et al. 2005). Carbonyl
reductase (CBR1) plays a protective role in an oxidative stress-induced
environment by catalyzing the reduction of carbonyl-containing compounds as
well as a variety of other substances, including HNE (Wermuth 1981, Forrest and
Gonzalez 2000, Doorn, Maser et al. 2004). Interestingly, CBR1 has been shown
to be oxidatively modified by HNE in the hippocampus of MCI brain (Reed,
Perluigi et al. 2008). Additionally, CBR1 is biologically important because it can
reduce the nitrosyl bond of S-nitrosoglutathione (GSNO) (Bateman, Rauh et al.
2008). GSNO plays an important function in NO signaling by acting as an
intracellular NO reservoir. Therefore, CBR1 is a mechanism that terminates NO
signaling that regulates many processes including: memory and learning,
inflammatory response, neuronal plasticity, and apoptotic mechanisms, among
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others (De La Monte, Sohn et al. 2000, Staab, Hartmanova et al. 2011).
Pathways involving NO have been implicated in AD and (Togo, Katsuse et al.
2004). Expression and activity of CBR1 is reported to be increased in AD and
DS, likely as a cellular stress response to increased carbonyls (Lemieux, Malfoy
et al. 1993, Balcz, Kirchner et al. 2001). In the current study, phosphorylation
levels of CBR1 were significantly decreased in AD as compared to both control
and MCI brains. Implications of CBR1 phosphorylation are presently unknown;
but, considering (i) PCAD brains exhibit SP and NFT pathology; (ii)
phosphorylation levels were decreased in AD but not PCAD; and (iii) global
measures of protein carbonyls have been shown to be similar in the IPL of
control and PCAD brains (Aluise, Robinson et al. 2011), while carbonyls are
increased in AD brain (Hensley, Hall et al. 1995, Aksenov, Aksenova et al. 2001),
it is reasonable to speculate that decreased phosphorylation of CBR1 likely
increases enzymatic activity as a stress response to carbonyl-related oxidative
stress.
Interestingly, flavin reductase (FR), also known as biliverdin reductase B
(BVR-B) (Shalloe, Elliott et al. 1996), was significantly increased in PCAD brain.
BVR-B is a NADPH-dependent enzyme that that catalyzes the reduction of
flavins including the conversion of biliverdin to bilirubin, an antioxidant-scavenger
of free radicals that promotes a reduced cellular state (Stocker, Yamamoto et al.
1987, Barone, Di Domenico et al. 2014). Moreover, both biliverdin and bilirubin
have been reported to prevent oxidative stress and apoptosis (Jansen, Hortmann
et al. 2010, Barone, Di Domenico et al. 2014). Further, BVR is a pleiotropic
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(Ser/Thr and Tyr) kinase with roles in modulating phosphatidylinositol-3-kinase
(PI3K) and MAPK signaling pathways which are involved in cell survival, synaptic
plasticity and memory consolidation, among others (Maines 2007, Kapitulnik and
Maines 2009). Phosphorylation is reportedly required for BVR activity (Salim,
Brown-Kipphut et al. 2001). Therefore, the increase in phosphorylation levels of
BVR-B in PCAD brain demonstrates a potential mechanism by which a brain,
heavy with SP and NFT pathology, may conceivably still be able to maintain
synaptic plasticity and normal cognitive function. In addition, another highly
conserved BVR isoform, BVR-A, is reported to be extensively modified by
oxidative stress, particularly by nitration, in AD brain (Barone, Di Domenico et al.
2011). Since phosphorylation and nitrosative modifications are in competition for
the same Tyrosine hydroxyl groups on proteins, a highly oxidative environment
such as exists in AD brain, could result in reduced activity of BVR, resulting in
decreased synaptic plasticity and memory consolidation.
Protein aggregation can result in increased cellular oxidative stress
leading to elevated expression of heat shock proteins and amplified intracellular
Ca2+ levels that can lead to cell death (Stefani and Dobson 2003). Hsp70
chaperone proteins can respond to cellular stress by refolding misfolded proteins
or leading them towards degradation, as well as obstructing apoptosis by
blocking recruitment of procaspase-9 to the apoptosome (Beere, Wolf et al.
2000). In the current study, Hsp70 protein 12A (hsp70A12A) showed significantly
increased phosphorylation in PCAD brain. The specific functionality of the
hsp70A12A isoform within the Hsp70 family is currently unknown. However,
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phosphorylation of Hsp70 by CK1, CK2 and GSK3β at the highly conserved Cterminal domain of Hsp70 reportedly inhibits binding to CHIP, a Ub-ligase that
mediates protein degradation or aggregation, and promotes binding affinity to cochaperone HOP, which promotes protein re-folding (Muller, Ruckova et al. 2013).
Binding effects due to phosphorylation by other co-chaperones are currently
being studied, but phosphorylation-dependent interactions with co-chaperones
are critical regulators of Hsp70 activities. Therefore, as SPs and NFTs cause
elevated Hsp70 production, the increased phosphorylation of the C-terminal
domain likely promotes protein refolding to prevent further protein aggregation.
Phosphorylation effects of other Hsp70 domains have yet to be elucidated;
however, since PCAD brains contain high SP and NFT pathology and have no or
low neuronal loss, global phosphorylation likely contributes to increased Hsp70
activity to promote proteostasis and cell survival.
The endoplasmic reticulum (ER) is sensitive to disturbances in cellular
homeostasis and can either initiate signaling cascades or unfolded protein
response to manage stress situations or induce apoptosis to save tissue from
necrotic injury (Salminen, Kauppinen et al. 2009). In AD, ER stress can also lead
to inflammation and AD pathology (Salminen, Kauppinen et al. 2009). The
transitional endoplasmic reticulum ATPase (aka valosin-containing protein; VCP)
is a pleiotropic protein involved in a wide array of cellular functions, including:
ER-associated degradation (ERAD), ubiquitin-proteasome mediated proteolysis,
autophagy, mediation of ER stress-induced apoptosis, vesicle transport and
fusion, activation of transcription factors, and peroxisomal assembly (Dai, Chen
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et al. 1998, Ogura and Wilkinson 2001, Wang, Song et al. 2004, Song, Wang et
al. 2007). VCP has been connected to protein misfolding and aggregation-linked
neurodegeneration (Weihl 2011). Previously, we showed VCP phosphorylation
levels to be significantly decreased in the hippocampus in AD (Di Domenico,
Sultana et al. 2011). In the current study, phosphorylation levels of VCP were
significantly decreased in MCI brain as compared to control and PCAD brain and
also decreased in AD brain relative to control. Phosphorylation of VCP has been
reported to promote UPS-related degradation and prevent apoptosis (Yu, Yang
et al. 2013). We opine that decreased VCP phosphorylation in MCI and AD IPL
may be indicative of a mechanism to eradicate cells that are too damaged to
rescue as a means to prevent necrosis. However, VCP has over 60 known
phosphorylation sites and putative consequences of phosphorylation of various
residues includes: ER assembly (Lavoie, Chevet et al. 2000), inhibition of ERGolgi transport (Kano, Tanaka et al. 2004), degradation of misfolded
glycoproteins (Li, Zhao et al. 2008), ERAD regulation (Klein, Barati et al. 2005),
and regulation binding with some of over 40 known adaptor proteins (Kano,
Kondo et al. 2005, Klein, Barati et al. 2005, Yeung, Kloppsteck et al. 2008,
Madsen, Seeger et al. 2009), and others reviewed in (Ewens, Kloppsteck et al.
2010).
Neuronal plasticity, neurotransmission and cellular signaling
Mitochondria can be found concentrated at the synapse and in dendrites
where they play key roles modulating Ca2+ and providind ATP, thereby regulating
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neuronal plasticity, cognition, and neuronal survival (Li, Okamoto et al. 2004).
Calcium is controlled by a variety of cellular mechanisms including: G proteins
and their receptors, Ca2+ binding proteins, transcription factors, organelle
reservoirs, and other systems. In AD, the presence of Aβ peptides excitotoxicity
and resultant dysregulated Ca2+ homeostasis can occur that can lead to impaired
synaptic transmission and plasticity, cell death, and associated cognitive
dysfunction (Mattson, Cheng et al. 1992).
Gelsolin (gsn) is a F-actin severing protein that remodels skeletal structure
throughout the CNS, but is especially concentrated in growth cones where it is
essential for Ca2+-dependent actin motility (Tanaka, Kira et al. 1993, Sun,
Yamamoto et al. 1999). Gsn is reportedly sequestered in an inactivated state by
phosphatidylinositol 4,5-bisphosphate (PIP2) and activated by Ca2+ (Janmey, Iida
et al. 1987). Gsn-PIP2 binding has been reported to enhance phosphorylation
(De Corte, Gettemans et al. 1997); and this phosphorylation hinders association
with actin filaments (De Corte, Demol et al. 1999). Further, gsn is cleaved by
caspase-3 during apoptosis and the resultant carboxyl-terminal fragment is
reportedly increased in AD brain, correlating with disease severity (Ji, Chauhan
et al. 2009). Additionally, gsn has been shown to bind to Aβ 1-40 and Aβ 1-42,
and this interaction is reported to be anti-amyloidogenic, sequestering Aβ thereby
inhibiting Aβ fibrillization and Aβ-induced apoptosis and neurotoxicity (Ray,
Chauhan et al. 2000, Qiao, Koya et al. 2005). In this study, phosphorylation
levels of gsn were decreased in the IPL of all three stages of AD progression
compared to control, suggesting decreased activity of the protein with
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consequent decreased Aβ sequestering, promoting SP pathology, and, in a
neuroprotective process, by removal neurotoxic Aβ oligomers. Such a scenario
implies a cellular response to Aβ elevation. Furthermore, considering the
absence of apoptosis in PCAD, gsn dephosphorylation may also promote
neuronal hypertrophy to maintain actin structure in place.
Regucalcin (human senescence marker protein 30; SMP30;
gluconolactonase) is a highly conserved, Ca2+ dependent protein that decreases
with age and plays a key role in Ca2+ homeostasis as an activator of Ca2+
membrane pumps (Fujita, Inoue et al. 1998). Since SMP30 is required for
synthesis of vitamin C, this protein also exhibits antioxidant properties (Kondo,
Inai et al. 2006). SMP30 deficiency has been reported to dysregulate Ca2+
dependent kinases and phosphatases, RNA and DNA synthesis (Yamaguchi and
Sakurai 1991, Morooka and Yamaguchi 2002, Morooka and Yamaguchi 2002,
Yamaguchi, Morooka et al. 2002), increase oxidative stress (Son, Zou et al.
2006), decreased insulin secretion leading to diminished glucose tolerance
(Hasegawa, Yamasaki et al. 2010), NF-κB activation, and increased
inflammatory response (Jung, Lee et al. 2014). Further, SMP30 has been
suggested to be a potential biomarker for AD and PD (Yamaguchi 2014) as
levels were reported to be significantly decreased in animal models (Kim, Lee et
al. 2012). In the current study, SMP30 phosphorylation levels were significantly
decreased in the IPL of PCAD, MCI and AD, all compared to age-matched
control brains. Implications of SMP30 phosphorylation have yet to be elucidated,
though seven known phosphorylation sites have been identified. However,
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considering the proposed functions of SMP30 and dysregulation of Ca 2+
signaling in AD progression, it may be reasonable to speculate that
dephosphorylation conceivably decreases SMP30 activity.
EF-hand domain-containing protein D1 (EFhd1; swiprosin 2) belong to the
EF-hand superfamily of Ca2+ binding proteins that participate in a myriad of Ca2+
dependent processes. EFhd1 exhibits pro-survival activity in neurons and may
act as a response to oxidative stress (Dutting, Brachs et al. 2011). Suppression
of EFhd1 by siRNA has been reported to suppress neurite outgrowth and
promote apoptosis (Tominaga, Kurihara et al. 2006). Based on these findings
and the evidence that EFhd1 associates with the inner mitochondrial membrane,
it is suggested that EFhd1 modulates mitochondrial functions (Tominaga,
Kurihara et al. 2006). Measured phosphorylation levels of EFhd1 were
significantly decreased in both MCI and AD brain as compared to control,
suggesting a decrease in its activity. The literature concerning this protein is
scarce and effect of phosphorylation is unknown, but considering what is known
to date with the decrease in phosphorylation in both MCI and AD, it is rational to
opine that dephosphorylation of EFhd1 decreases its activity.
Guanine nucleotide-binding protein G(o) subunit alpha (GNAO1), is a
component of G protein transmembrane signaling and is involved in a multitude
of cellular processes. Mutations in GNAO1 can result in epileptic
encephalopathy, a severe neurological condition characterized by impaired
behavior, progressive cognitive decline and cerebral atrophy (Nakamura, Kodera
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et al. 2013). Further, it was believed that these mutations resulted in an impaired
ability of the protein to localize to the plasma membrane (Nakamura, Kodera et
al. 2013), suggesting that abnormal GNAO1 signaling can lead to cognitive
decline. Earlier studies in G protein subunits showed that there was no difference
in GNOA1 levels in AD brain as compared to control (O'Neill, Wiehager et al.
1994). Previously, work from our laboratory showed that phosphorylation levels
of GNAO1 were significantly increased in the hippocampus of the AD brain (Di
Domenico, Sultana et al. 2011). In this current study, GNAO1 phosphorylation
was found to be significantly increased in the IPL of AD brains as compared to
both control and PCAD brains, suggesting that GNAO1 phosphorylation may
conceivably interfere with GTP binding, downstream coupling to beta and gamma
G proteins or result in aberrant cellular localization. Further studies deciphering
the particular residues phosphorylated, the kinases involved, and the impact on
GNAO1 structure and function are needed to determine the role that
phosphorylated GNAO1 may play in cognitive decline and dementia in the
progression of AD.
Dihydropyrimidinase-related protein 2 (DRP2; collapsin response mediator
protein 2, CRMP2) is a pleiotropic protein involved in: synaptic assembly, neurite
outgrowth, guidance and collapse of the growth cone, axonal growth,
neurotransmitter release, endocytosis, Ca2+ homeostasis, and organization of the
dendritic field (Goshima, Nakamura et al. 1995, Byk, Dobransky et al. 1996,
Uchida, Ohshima et al. 2005, Brittain, Piekarz et al. 2009, Hensley, Venkova et
al. 2011, Ju, Li et al. 2013). CRMP2 is phosphorylated by a number of kinases
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which result in breakdown of growth cones, neurite retraction, and hindrance of
axonal expansion and is reviewed in (Khanna, Wilson et al. 2012). Interestingly,
phosphorylated CRMP2 is a component found in NFTs (Uchida, Ohshima et al.
2005) and phosphorylation of CRMP2 has been suggested to be an early
occurrence in AD progression based on studies of rodent models (Cole, Noble et
al. 2007). In previous studies, we have shown that CRMP2 is oxidatively modified
in AD (Castegna, Aksenov et al. 2002) and that phosphorylation levels of CRMP2
are increased in the hippocampus of AD brain (Di Domenico, Sultana et al.
2011). In this current study, the phosphorylation levels of CRMP2 were
significantly increased in the IPL of AD brain as compared to control IPL. This
result suggests that the decrease in synapses in AD may be directly related to
the increased phosphorylation of CRMP2.
Septins are highly conserved cytoskeletal GTPases are involved in
various cellular processes and signaling pathways, including: DNA response to
cytoskeletal damage, protein scaffolding, membrane compartmentalization, cell
division, vesicle trafficking, exocytosis and apoptosis (Barral, Mermall et al. 2000,
Kremer, Adang et al. 2007, Spiliotis, Hunt et al. 2008, Hagiwara, Tanaka et al.
2011). It has also been suggested that 9 of the 14 known septins play a role in
maturation of the dendritic field, as they may be involved in spine dynamics,
synaptic transmission and connectivity (Tada, Simonetta et al. 2007, Xie, Vessey
et al. 2007). Previous studies have shown that Septins contain multiple
phosphorylation sights that are crucial in regulating functions of septin (Xue,
Wang et al. 2000, She, Huang et al. 2004, Meseroll, Occhipinti et al. 2013).
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Abnormal septin function has been noted in multiple neurological disorders such
as AD, Down syndrome, Parkinson disease and Schizophrenia (Kinoshita,
Kinoshita et al. 1998, Cheon, Fountoulakis et al. 2001, Barr, Young et al. 2004,
Ihara, Yamasaki et al. 2007). Septin 2, in particular, is associated with synaptic
vesicles and neurotransmitter release (Kinoshita, Kimura et al. 2004, Tokhtaeva,
Capri et al. 2015). Further, it has been reported that septin 2 may regulate
glutamate uptake by the excitatory amino acid transporter (EAAT1) in astrocytes,
a mechanism that aids in the prevention of excitotoxicity and resultant neuronal
death (Kinoshita, Kimura et al. 2004). In AD, septin 2 is associated with both
NFTs and SPs (Kinoshita, Kinoshita et al. 1998, Pissuti Damalio, Garcia et al.
2012). Phosphorylation levels of septin 2 were significantly upregulated in PCAD
as compared to all other groups, suggesting that increased phosphorylation of
septin 2 may promote increased plasticity and neurotransmission. Further,
maintaining normal synaptic activity, as in PCAD, has been suggested to protect
the synapse against Aβ toxicity (Tampellini, Rahman et al. 2009).
Stathmin is an essential protein that regulates microtubule dynamics,
playing key roles in neurite outgrowth, synaptic plasticity, learning, and memory
by preventing microtubule assembly, promoting disassembly, and sequestering
tubulin dimers (Belmont and Mitchison 1996, Jourdain, Curmi et al. 1997, Mori
and Morii 2002, Grenningloh, Soehrman et al. 2004, Felkl and Leube 2008).
Expression of stathmin is reportedly decreased in AD brain (Saetre, Jazin et al.
2011). Phosphorylation of stathmin decreases its binding affinity towards tubulin,
thereby promoting microtubule assembly (Amayed, Pantaloni et al. 2002). We
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found phosphorylation levels of stathmin significantly decreased in AD brain as
compared to age-matched controls, demonstrating a mechanism for decreasing
axon and synapse structure and decreasing LTP.
Syntaxin-binding protein 1 (stxbp1; Munc18) binds to syntaxin, thus
controlling formation of the SNARE complex and neurotransmitter release
(Misura, Scheller et al. 2000, Yang, Steegmaier et al. 2000). Additionally, stxbp1
has also been shown to regulate the filopodia of the growth cone to modulate
presynaptic plasticity (Broeke, Roelandse et al. 2010). Protein kinase C
phosphorylation on Ser-306 and Ser-313 has been reported to modulate
neurotransmission by increasing rapid vesicle cycling and vesicle release
(Barclay, Craig et al. 2003, Craig, Evans et al. 2003). In the current study, stxbp1
phosphorylation levels were significantly decreased in AD brain as compared to
control, which correlates to decreased synaptic efficiency and implicates
decreased stxbp1 phosphorylation in synapse loss in AD brain.
Protein levels of 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNP) are
mainly localized to oligodendrocytes and are considered to be a marker of
myelination, as it is suggested that CNPI plays a role in maintain the myelin
sheath (Thompson 1992, Lappe-Siefke, Goebbels et al. 2003). In AD, the activity
of CNP is reportedly decreased in the hippocampus and putamen and increased
in the parietal cortex, temporal cortex and parahippocampalis (Vlkolinsky, Cairns
et al. 2001). In this study of the IPL, phosphorylation levels of CNP isoform CNPI
were decreased in PCAD (with a near significant decrease in AD). Taken
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together, this suggests that dephosphorylation of CNPI may conceivably increase
the activity of the protein in an attempt to prevent synaptic and cognition loss.
In conclusion, this current study has identified significant changes in global
phosphorylation levels of proteins in the IPL of PCAD, amnestic MCI and AD
subjects, suggesting related alterations in protein activity to the underlying
mechanisms that may contribute to aberrant changes in: Ca 2+ signaling, energy
metabolism, neuronal plasticity, signal transduction, and oxidative stress
response. Further, we show how changes in phosphorylation may contribute to
the progressive cognitive decline in MCI that escalates to the dementia of AD.
Moreover, examination of the phosphoproteome of PCAD brain suggests
potential mechanisms that may play key roles in preserving cognitive functions
despite abundant AD pathology. The results are suggestive of changed activity of
differentially phosphorylated proteins in all the states of AD. Further activity
measurements are needed to confirm or refute these suggestions. Moreover,
targeting the kinases and phosphatases involved in the regulation of these
proteins may conceivably lead to promising treatment strategies to halt the
cognitive decline in AD progression.

Copyright © Judy Carol Triplet 2015
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CHAPTER 6: THE NAKED MOLE-RAT
CHAPTER 6.1
METABOLIC CLUES TO SALUBRIOUS LONGEVITY IN THE BRAIN OF THE
LONGEST-LIVED RODENT: THE NAKED MOLE-RAT
6.1.1 Overview
Naked mole-rats (NMRs) are exceptionally long-lived rodents that have
sustained healthspans, exhibiting negligible senescence and a pronounced
resistance to age-related disease. Uncovering insights underlying these
extraordinary traits involved in successful aging may conceivably provide crucial
clues to extend the human lifespan and healthspan. A prominent hallmark in agerelated diseases, such as neurodegeneration and cancer, is the impairment and
dysregulation of metabolic pathways. Using a 2-D PAGE proteomics approach,
alterations in levels and phosphorylation of metabolic proteins in the brains of
NMRs were evaluated in an age-dependent manner. We identified 14 proteins
with altered levels and/or phosphorylation states that play key roles involved in
metabolic functions. New insights into potential pathways involved in metabolic
aspects of successful aging have emerged.
6.1.2 Introduction
Most aging research focuses on investigating a few well-characterized
short-lived species including: Caenorhabditis elegans, Drosophila melanogaster,
Rattus norvegicus, and Mus musculus (Finch and Austad 2001). While models
with such short lifespans that provide the ability to perform experiments rapidly,
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restraining biomedical research to very few models of aging or longevity may limit
novel discoveries and scientific progression. Not surprisingly, there is a growing
call for new models that may better mimic human aging and provide better
translational predictability (Buffenstein, Nelson et al. 2014). Since humans are a
long-lived species on the basis of their body size (Hulbert, Pamplona et al. 2007),
it is hypothesized that species with naturally longer lives may yield better insights
into diseases that afflict humans later in life than do short-lived models that
commonly die before age-related diseases manifest. Such species likely also
have evolved mechanisms which allow for extended healthy life spans, in
contrast to those that do not, and as such provide more precise models for
human aging (Lewis, Mele et al. 2012). Unlike most other rodents that live
relatively short lives in absolute terms (as little as 2-3 months in the wild; 2-5
years in captivity), naked mole-rats (NMRs) live to exceedingly advanced ages
(4-17 years in the wild and up to 30+ years in captivity), unrivaled by any other
rodent species (Bobeck 1969, David and Jarvis 1985, Buffenstein 2008, Edrey,
Hanes et al. 2011). Perhaps even more extraordinary, NMRs exhibit a prolonged
healthspan, seemingly resistant to age-related deterioration well into old age
(Buffenstein 2008, Edrey, Hanes et al. 2011, Grimes, Reddy et al. 2014). Insights
into mechanisms facilitating sustained physiology and metabolism in NMRs may
have therapeutic implications for human aging and age-associated diseases.
NMRs are naturally found in the arid and semi-arid regions of the horn of
Africa (Kenya, Ethiopia and Somalia). Here, they lead an exclusive subterranean
existence, living in sealed burrows in large eusocial colonies of up to 300
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individuals with a strict division of labor culminating in the presence of only one
breeding female and 2-4 breeding males (Jarvis 1981). This extreme
environment coupled with their eusocial life-style has led to the evolution of
several adaptive traits including tolerance of variable oxygen and nutrient
availability and concomitant metabolic effects (Buffenstein and Yahav 1991,
Buffenstein and Yahav 1991, Larson and Park 2009).
NMRs present a number of unique phenotypes that may contribute to their
unusually long lives. NMRs maintain a low basal metabolic rate throughout their
lives (O'Connor, Lee et al. 2002). This is accompanied by low heart rates,
decreased cardiac output, and low fasting blood glucose levels (Ables, BrownBorg et al. 2014, Grimes, Reddy et al. 2014). Nevertheless, glucose tolerance
tests reveal that a large dose of glucose will cause a prolonged blood glucose
elevation, indicative of insulin insensitivity (Kramer and Buffenstein 2004). This
insensitivity is characteristic of induced-diabetic animal models, yet healthy
NMRs show no other signs of diabetic pathology (Dumm, Console et al. 1995,
Tokuyama, Sturis et al. 1995, Kramer and Buffenstein 2004). Rather, animals
appear to be extremely sensitive to insulin administration. Unlike mice treated in
an identical manner, glucose levels in blood not only precipitously drop following
treatment with human insulin but remain at these low levels for an extended
period (Dumm, Console et al. 1995, Tokuyama, Sturis et al. 1995, Kramer and
Buffenstein 2004). These findings suggest that in their normal daily lives they are
extremely sensitive to insulin signaling. Novel and tightly regulated glucose
management may play a critical role in lifespan extension as it has been shown
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that genetic control of insulin signaling through the insulin/insulin-like growth
factor signaling pathway may significantly expand the lifespan of an organism
(Guarente and Kenyon 2000).
In this study, we explored not only the age-dependence of levels of brain
proteins involved in energy metabolism, but also their global phosphorylation
status as a means of gathering insights into the active proteome of NMRs during
their life and development. The brain, in particular, is an essential organ on which
to study, as cerebral insulin signaling is crucial in maintaining energy and glucose
homeostasis, arguably key regulators of longevity and aging. Dysregulation of
these pathways is associated with neurodegenerative diseases and metabolic
syndromes leading to shortened lifespans and diminished quality of life
(Butterfield, Di Domenico et al. 2014).
By evaluating the NMR proteome and phosphoproteome, the results
obtained have yielded a number of insights on the salubrious aging process of
NMR with regards to glucose utilization, proteostasis networks, signaling
pathways, neuronal plasticity, and neuronal structure. A large number of brain
proteins altered in aging have been identified, too many to be efficiently
presented and discussed in a single manuscript. Accordingly, to facilitate the
discussion of the implications of altered protein expression and phosphorylation
and how they relate to the unusually long and healthy life spans of NMRs, we
approached this effort by use of functional class of identified proteins. Here, we
present the results related to metabolism.
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6.1.3 Materials and Methods
6.1.3.1 Materials
The chemicals used in these studies were purchased from Sigma-Aldrich
(St. Louis, MO, USA) unless otherwise noted. Criterion precast polyacrylamide
gels, ReadyStrip IPG strips (pH 3-10), TGS and MOPS electrophoresis running
buffers, 0.2 nm nitrocellulose membrane, Precision Plus Protein All Blue
Standards, Sypro Ruby Protein Stain, urea, biolytes, mineral oil, dithiothreitol,
and iodoacetamide were obtained from Bio-Rad (Hercules, CA, USA). Modified
trypsin solution was purchased from Promega (Madison, WI, USA). C18 ZipTips,
and Re-Blot Plus Strong stripping solution were purchased from Millipore
(Billerica, MA, USA). Pro-Q Diamond phosphoprotein stain, and antiphosphoserine, anti-phosphotyrosine, and anti-phosphothreonine antibodies
raised in rabbits were procured from Invitrogen (Grand Island, NY, USA).
Amersham ECL rabbit IgG horseradish peroxidase-linked secondary antibody,
ECL-Plus Western blotting detection reagents and protein A/G beads were
obtained from GE Healthcare (Pittsburgh, PA, USA). Anti-malate dehydrogenase
(cytosolic) and anti-lactate dehydrogenase antibodies were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). Anti-glucose-6-phosphate
dehydrogenase antibody was obtained from Cell Signaling Technology (Danvers,
MA, USA).
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6.1.3.2 Animals
The brains from naked mole-rats used in this study, aged 2-24 years, were
obtained from the colonies maintained by Dr. Rochelle Buffenstein at the
University of Texas Health Science Center, San Antonio. These wellcharacterized colonies (Buffenstein 2005) were housed in fabricated burrow
systems with climate conditions that mimicked their natural habitat (30˚C and 3050% relative humidity). Their diet consisted of fresh fruits and vegetables,
provided ad libitum, and supplemented with a high protein and vitamin enriched
feed (Pronutro, South Africa). NMRs were anesthetized with isofluorane and then
euthanized via cardiac exsanguination. Brains were immediately harvested and
flash frozen in liquid nitrogen. All animal procedures were approved by the
Institutional Animal Care and Use Committee at the University of Texas Health
Science Center at San Antonio, TX. The experimental groups of animals
consisted of both male and female breeding and non-breeding adults. For the
four age groups, n=5-9 individual brains.
6.1.3.3 Sample preparation
NMR brains were thawed and individual homogenates were prepared
using a Wheaton glass homogenizer (~40 passes) with ice-cold isolation buffer
[0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES, 0.2µg/mL PMSF,
4µg/mL leupeptin, 4 µg/mL pepstatin, 5 µg/mL aprotinin and 10 µg/mL
phosphatase inhibitor cocktail 2]. Homogenates were vortexed on ice and
sonicated for 10 s at 20% power with a Fisher 550 Sonic Dismembrator
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(Pittsburgh, PA, USA). Protein concentrations of the homogenates were
determined by the Pierce BCA method (Smith, Krohn et al. 1985).
6.1.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
Isoelectric focusing (IEF). 2-D PAGE experiments were conducted as
described previously (Sultana, Boyd-Kimball et al. 2007). Briefly, 200 µg of each
homogenate was shaken for 2 h at 22˚C in 200 µL of rehydration buffer [8 M
urea, 2.0% (w/v) CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01%
Bromophenol Blue]. Samples were then sonicated for and dispensed into wells
for application to 11 cm pH 3-10 ReadyStrip IPG strips for isoelectric separation
of the proteins. Strips were actively rehydrated at 20 °C for 18 h at 50 V using a
Bio-Rad Protean IEF Cell (Hercules, CA, USA). Isoelectrical focusing continued
at a constant temperature of 20 °C beginning at 300 V for 2 h, 500 V for 2 h,
1000 V for 2 h, 8000 V for 8 h, and finishing at 8000 V for 10 h. IPG strips were
then immediately stored at -80 °C.
SDS PAGE. IEF strips were thawed and then equilibrated for 10 min in the
dark with 4 mL of equilibration buffer A [50 mM Tris–HCl, pH 6.8, 6 M urea, 1%
(w/v) SDS, 30% v/v glycerol, 0.5% DTT]. Strips were then re-equilibrated for 10
min in the dark with 4 mL of equilibration buffer B [50 mM Tris–HCl, pH 6.8, 6 M
urea, 1% (w/v) SDS, 30% v/v glycerol, 4.5% IA]. The IEF strips were rinsed in a
1X dilution of TGS running buffer and placed into Criterion precast
polyacrylamide gels (8–16% Tris–HCl, linear gradient), 1 IPG + 1 Well Comb,
11cm. Precision Plus Protein All Blue molecular weight marker was added and
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the wells were overlaid with agarose gel. The gels were run at a constant voltage
of 200 V for approximately 65 min at 22˚C in 1X Tris/Glycine/SDS running buffer
using a Criterion Cell vertical electrophoresis buffer tank.
6.1.3.5 SYPRO Ruby and Pro-Q Diamond staining
Gel staining to detect proteins and phosphoproteins was carried out
according to manufacturer’s directions and as previously described (Triplett,
Zhang et al. 2015). In brief, gels were fixed, stained with Pro-Q Diamond,
scanned at 580 nm using a Bio-Rad ChemiDoc XRS+ imaging system (Bio-Rad,
Hercules, CA, USA), stained with Sypro Ruby, and then scanned again at 450
nm. Gels were stored in deionized water at 4 °C until extraction of the protein
spots.
6.1.3.6 Image Analysis
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2Dgel images of NMR samples were quantified by densitometry according to the
total spot density using PDQuest 2-D Analysis Software (Bio-Rd, Hercules, CA,
USA). Intensities of individual spots were normalized to the total density of the
gel. Spot densities of the three older age groups (4-6 year-olds, 7-12 year-olds,
and 15-24 year-olds) were independently compared to the spot densities from
the earliest age group (2-3 year-olds) using a Student’s two-tailed t-test and a
Mann-Whitney U statistical test, both at 95% confidence (i.e. p<0.05). Only spots
with a significant difference in both tests were considered for in-gel trypsin
digestion and subsequent identification.
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Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel
images of the NMR samples were quantified and matched together in the same
manner as the SYPRO Ruby-stained gels. Next, the master gel from the Sypro
Ruby matching and Pro-Q Diamond matching were used for a high match
analysis. The PDQuest software provided numerical data based on the intensity
of each protein spot. The phosphoprotein spot densities were then normalized to
the Sypro Ruby spot densities and the resultant normalized phosphoprotein spot
densities in the 3 older age groups were independently compared to the earliest
age group using a Student’s two-tailed t-test and a Mann-Whitney U statistical
test. Only spots that were significant (p<0.05) in both tests were considered for
in-gel trypsin digestion and subsequent identification.
6.1.3.7 In-gel trypsin digestion/peptide extraction
Significant spots were excised from 2D-gels and transferred to individual
Eppendorf microcentrifuge tubes for trypsin digestion as described previously
(Thongboonkerd, McLeish et al. 2002). Briefly, gels were washed with 0.1 M
ammonium bicarbonate (NH4HCO3) for 15 min, followed by incubation with
acetonitrile (ACN) for 15 min. The solution was removed and gel plugs were
allowed to dry under a flow hood. Next, the gel plugs were incubated in 20 mM
DTT in 0.1 M NH4HCO3 for 45 min at 56°C. The DTT/NH4HCO3 solution was
removed and 0.05 M IA in 0.1 M NH4HCO3 was added and allowed to incubate at
22˚C for 15 min. The IA solution was removed and 150 µL of 0.05 M NH 4HCO3
was added and incubated for 15 min at 22˚C. Next, 200 µL of ACN was added
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and allowed to incubate for 15 min at 22˚C. The solution was then removed and
the gel plugs were allowed to dry under a flow hood. Then, 10 µL of modified
trypsin solution in 0.05 M NH4HCO3 was added and incubated with shaking
overnight at 37 °C. Salts and contaminants were removed from the tryptic
peptide solutions using C18 ZipTips. Samples were stored at -80˚C until MS/MS
analysis.
6.1.3.8 NanoLC-MS with Data Dependent Scan
Tryptic peptide solutions were reconstituted in 10 µL 5% ACN/0.1% formic
acid (FA). MS/MS analysis was performed by a nanoAcquity (Waters, Milford,
MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) system using a data
dependent scan mode. A capillary column packed in-house (0.1 x 130 mm
column packed with 3.6 µm, 200Å XB-C18). For separation, a gradient with 0.1%
FA and ACN/0.1% FA at 200 nL/min was used. The MS spectra were obtained
by the orbitrap at 30,000 resolution. The MS/MS spectra of the six most intense
ions in MS scan were acquired by the orbitrap at 7,500 resolution. Using the
Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, Thermo
Scientific), data files of each sample were interrogated. For protein identification,
at least two high-confidence peptide matches were used (false discovery rate
<1%). Proteins that were matched with the same peptides were reported as one
protein group. Data from the MS/MS analysis was initially verified by comparing
the expected molecular weight and isoelectric point of the identified protein to
that of the extracted plug from the 2-D gel.
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6.1.3.9 Immunoprecipitation and Western blotting validations
Immunoprecipitation (IP). Whole brain homogenates (250 µg) were
suspended in 500 µL IP buffer [0.05% NP-40, leupeptin 4 µg/mL, pepstatin 4
µg/mL, aproprotin 5 µg/mL, phosphatase inhibitor cocktail 10 µg/mL] in a
phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na 2HPO4, 0.24 M
KH2PO4]. The samples were then precleared by incubation with Protein A/G agarose beads for 1.5 h at 4˚C and then incubated overnight with anti-malate
dehydrogenase antibody (1:50 dilution) at 4˚C. Samples were once again
incubated with Protein A/G – agarose beads for 1.5 h at 4˚C and then washed 5
times with IP buffer. The beads were preserved for a 1D-PAGE experiment.
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Whole
brain homogenized protein extracts (50 µg) or beads from immunoprecipitation
experiments were suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8,
40% glycerol, 8% SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue]
diluted to 1X with distilled water. Samples were then heated at 95 °C for 5 min,
cooled on ice, and loaded into a Criterion precast (4-12% Bis-Tris)
polyacrylamide 18 well gel. Gels were placed in a Criterion Cell vertical
electrophoresis buffer tank filled with XT MOPS running buffer and run at 80 V for
15 min and then at 120 V for approximately 100 min.
1D-Western blotting. 1D-gels were transferred to nitrocellulose
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad,
Hercules, CA, USA). After the transfer, membranes were blocked with 3% bovine
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serum albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM
NaHPO4 and 0.04% (v/v) Tween 20] at 22˚C for 1.5 h. The membrane was
incubated with a primary antibody (1:3000 dilution) in blocking solution with
gentle rocking for 2 h at 22˚C. After washing the blots three times for 5 min each,
the blots were incubated with a horseradish peroxidase (1:5000) secondary
antibody in Wash Blot at 22˚C with gentle rocking. The membranes were washed
three times in Wash Blot (10 min each) and developed chemiluminescently using
Clarity Western ECL substrate. After developing in the dark for 5 min at 22˚C,
membranes were scanned using Bio-Rad ChemiDoc XRS+ imaging system and
quantified using Image Lab software (Bio-Rad, Hercules, CA, USA). Blots were
then stripped with Re-Blot Plus Strong solution and washed three times with
Wash Blot (5 min each). The membranes were then blocked in 3% BSA for 1.5 h
and incubated with an anti-tubulin antibody (1:5000) or with anti-phosphoserine,
anti-phosphothreonine and anti-phosphotyrosine antibodies (1:6000) for 2 h. The
membranes were washed, incubated with a secondary antibody, and developed
as described above.
6.1.3.10 Statistical analysis
Initial statistical analyses of PDQuest data were performed conservatively
by using both a two-tailed Student’s t-test and the Mann-Whitney U statistical
test, comparing each age group independently to the earliest age group. A
protein spot was considered statistically significant if p<0.05 for both tests. A oneway ANOVA with post hoc Bonferroni t-test was used in determining significance
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(p<0.05) between age groups for PDQuest data and Western blot analysis. Foldchange values of protein spots were calculated by dividing the average,
normalized spot intensities of the gels of the older age group by the average,
normalized spot intensities of the gels of the younger age group in the
comparison. Spot extraction and MS/MS analysis was conducted only for spots
with a 40% fold change or greater in normalized spot density. Identifications of
proteins acquired with the SEQUEST search algorithm were considered to be
statistically significant if p<0.01. All data are presented as mean +SEM.
6.1.4 Results
To evaluate age-related protein changes in the brain, the NMR were
divided into four age groups: 2-3 year-olds (age group 1; young), 4-6 year-olds
(age group 2; intermediate), 7-12 year-olds (age group 3; old) and 15-24 yearolds (age group 4; oldest). The average protein spot intensities from each age
cohort were compared to determine significant differentially expressed and
phosphorylated proteins.
Figure 6.1.1 shows representative examples obtained from SYPRO-Rubystained 2-D gel images of the isolated proteins from these four age groups with
significant differentially expressed proteins labeled and Figure 6.1.2 shows
characteristic 2-D gels of the isolated protein spots stained with Pro-Q Diamond
showing significantly altered phosphorylation states identified in each age group.
PDQuest and MS/MS analyses of all the significant proteins found 14 metabolic
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proteins whose expression and/or phosphorylation states were significantly
altered in NMR brains with age. These results are summarized in Table 6.1.1.

Figure 6.1.1 Sypro Ruby-stained 2-D gels of NMR metabolism-associated
proteins with altered expression in brain with age. Representative Sypro
Ruby-stained 2-D gel images of isolated proteins from the brains of NMRs, aged
2-3 years (A), 4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins whose
expression was statistically significantly altered in the particular age group are
labeled in the images (p<0.05).
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Figure 6.1.2 Pro-Q Diamond-stained 2-D gels of NMR metabolism-associated
proteins with altered expression in brain with age. Representative Pro-Q Diamondstained 2-D gel images of isolated proteins from the brains of NMRs, aged 2-3 years (A),
4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins with statistically significantly
altered phosphorylation states in the particular age group are labeled in the images
(p<0.05).
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Table 6.1.1 Metabolic proteins with significantly altered levels and/or
phosphorylation states with age in the NMR brain. PDQuest and MS/MS
results of NMR metabolic brain proteins with significant altered expression and/or
phosphorylation states as a function of age.

Additional information provided in the table includes: the PDQuest spot
number, the SwissProt accession number, percentage of the protein sequence
covered by matching peptides, the number of peptide sequences identified by the
MS/MS analyses, the confidence score of the protein, the expected molecular
weight and isoelectric point of the identified protein, the age groups compared
with the corresponding p-values, and fold-change levels of expression and
phosphorylation obtained from the PDQuest analyses. Two or more peptide
sequences were used in the identification of all proteins; and the identified
protein spots were visually compared against the expected molecular weights
and isoelectric points to further ensure correct protein identification. The 14
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metabolic proteins found to have differential expression and/or phosphorylation
states in one or more age groups were: pyruvate kinase, pyruvate kinase PKM;
glucose-6-phosphate 1 dehydrogenase; glucose-6-phosphate isomerase; malate
dehydrogenase (both cytosolic and mitochondrial); L-lactate dehydrogenase b
chain; cytosolic acyl CoA thioester hydrolase (2 different isoforms); fructosebisphosphate aldolase; alpha enolase; cytosolic isocitrate dehydrogenase;
aspartate aminotransferase; and ATP synthase subunit alpha (isoform 2).
To validate the identification of these proteins, immunoprecipitation and
Western blot validation experiments were undertaken. Figure 6.1.3 shows the
Western blot images using tubulin as a loading control verifying the age-related
changes in expression of lactate dehydrogenase (LDH) and glucose-6-phosphate
dehydrogenase (G6PD) with corresponding bar graph representations of the
data. The results of the Western blot analyses of the expression of LDH
confirmed a significant increase in the oldest age group as compared to the
intermediate age group (p=0.0003) and to the old age group (p=0.0003).
Additionally, the Western blot analysis also showed a statistically significant
increase (p=0.024) in the oldest age group as compared to the youngest age
group. Western blot analysis of G6PD confirmed a significant increase in the
level of G6PD in the brains of the oldest age group as compared to the
intermediate (p=0.0103) and old age group (p=0.014).
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Figure 6.1.3 LDH and G-6-P dehydrogenase expression in brain of NMR
with age. Western blot and corresponding bar graph representations from the
validation experiments of the changes in the expression of lactate
dehydrogenase (A & C) and glucose-6-phosphate dehydrogenase (B & D) in the
brains of NMRs (n=4 for each age group, *p<0.05, ***p<0.001). Immunoreactivity
with specific antibodies was detected by chemiluminescence.

Figure 6.1.4 shows the images from the immunoprecipitation experiments
after probing with anti-phosphoserine, anti-phosphothreonine and antiphosphotyrosine antibodies in which the immunoprecipitated protein, cytosolic
malate dehydrogenase (MDH1), was used as the loading control.
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Figure 6.1.4 Reduced MDH1 phosphorylation in NMR brain with age.
Western blot and corresponding bar graph representation from immunochemistry
experiments of the validation of the significant decrease in the phosphorylation of
cytosolic malate dehydrogenase in the brains of NMRs (n=4 for each age group,
*p<0.05). Immunoreactivity of anti-MDH1 antibody was detected by
chemiluminescence.
The findings from this analysis confirmed a significant decrease in the
phosphorylation of MDH1 in the NMR brain for the old age group (p=0.044) and
in the oldest age group (p=0.03), both as compared to the youngest age group.
6.1.5 Discussion
Numerous alterations of metabolism are evident in a number of agerelated diseases such as Alzheimer, Huntington and Parkinson diseases, cancer,
atherosclerosis, and type 2 diabetes mellitus, to name but a few (Berg, Combs et
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al. 2002, Kahn 2003, Hsu and Sabatini 2008, Cai, Cong et al. 2012, Butterfield,
Di Domenico et al. 2014). Many of these metabolic diseases directly impact upon
brain function for the brain is an organ with a high rate of metabolism. The brain
consumes up to 20% of total glucose and 30% of inspired oxygen to maintain
neuronal resting potentials, propagate action potentials, release
neurotransmitters, and other energy-requiring processes (Madsen, Cruz et al.
1999). With age, energy metabolism in the brain undergoes a gradual decline
and the efficacy of these essential brain functions correspondingly diminishes,
thereby contributing to age related cognitive deficits (Petit-Taboué, Landeau et
al. 1998, Poon, Shepherd et al. 2006, Navarro and Boveris 2007, Swerdlow
2007). Not only do changes in metabolism impact upon brain function and
healthspan, but conversely, aging as well as many age-associated diseased
states dramatically impact upon metabolism (Finkel, Serrano et al. 2007). For
example, in cancer, activation of oncogenes and loss of tumor suppressor activity
alters metabolism by inducing the Warburg effect, promoting glycolysis to support
cancerous cell growth and survival (Dang 2012). Therefore, examining the agerelated changes in metabolic proteins in the brains of the NMR and
understanding the mechanisms that contribute to the resistance of senescencerelated diseases in NMRs conceivably may provide crucial clues to metabolic
mechanisms that promote successful aging and increased healthspan.
This current proteomics study revealed fourteen metabolic proteins with
significantly altered expression and/or phosphorylation levels in the brains of
NMRs as they aged. The NMRs were divided into four age cohorts: young,
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intermediate, old, and oldest. The brain proteins identified suggest mechanisms
by which the NMR brain responds to and adapts to the aging process and
conceivably are clues to better understand how the NMR brain adapted to resist
age-related degeneration. These 14 proteins that are significantly altered during
aging are involved in glycolysis, the pentose-phosphate shunt, the malateaspartate shuttle, the TCA cycle, and the electron transport chain.
Levels of pyruvate kinase (PK) were increased in the old NMR age group
as compared to the youngest age group. PK is a key enzyme that generates ATP
and modulates glycolytic activity. The expression of a specific isoform of PK,
pyruvate kinase M (PKM), was lower in the intermediate age group relative to the
youngest NMR group studied, and the phosphorylation state was decreased in
both the intermediate and oldest age group in relation to the youngest. PKM is an
essential glycolytic enzyme that exists as both a dimer and tetramer, and the
ratio between these two forms determines whether glycolytic flux is directed
towards catabolic or anabolic pathways (Iqbal, Gupta et al. 2014). Moreover,
dephosphorylation of PKM has been shown to increase activity of PKM
(Anastasiou, Yu et al. 2012). Increased PKM activity reportedly promotes antitumor activity by inhibiting tumor cell growth (Stetak, Veress et al. 2007,
Anastasiou, Yu et al. 2012). Therefore, it is conceivable that the decreased
phosphorylation state of PKM likely increases PKM activity in older NMRs and
may contribute to their cancer resistance. In addition, PKM is a known coactivator of hypoxia-inducible factor 1α (HIF-1α), which modulates HIF-1α
transcriptional activity, thereby regulating glucose transport and glycolytic
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enzymes, among other pathways (Luo, Hu et al. 2011) . Old NMRs have been
previously shown to exhibit high levels of HIF-1α, compared to attenuated
expression of HIF-1α in aged mice (unpublished data R.B.). Further, it is
hypothesized that increased expression of HIF-1α is an adaptive response to
modulate neurodegeneration by providing energy to sustain the cell through
glycolysis in hypoxic conditions (Ogunshola and Antoniou 2009). Thus, the
increased expression of PK in the old age cohort as well as the decreased
phosphorylation of PKM in the oldest group, are mechanisms that conceivably
contribute to sustaining the required energy demand during old age to maintain
efficient cellular functioning.
Cytosolic acyl CoA thioester hydrolase, also known as brain acyl-CoA
hydrolase (BACH), catalyzes the cleavage of acyl-CoA producing a fatty acid and
coenzyme A (CoA-SH), thereby modulating many cellular processes. Activity of
BACH is higher in the brain than in any other organ, and acyl-CoA, fatty acids
and CoA-SH are involved in: cellular signaling, β-oxidation, inflammation, ion
fluxes, protein and vesicle trafficking, allosteric regulation of enzymes, gene
expression, lipid synthesis, and energy metabolism and regulation (Hunt and
Alexson 2002, Yamada, Kuramochi et al. 2002, Yamada 2005). BACH’s role in
regulating lipid metabolism may be a crucial factor affecting the aging rate by
providing cell and membrane stability (Hulbert, Pamplona et al. 2007). The brain
is rich in lipid content, and BACH is reportedly essential in the prevention of
neurotoxicity by the dysregulation of neuronal fatty acid metabolism (Ellis, Wong
et al. 2013). Additionally, BACH can scavenge free fatty acids in the cytosol by
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linking CoA-SH to form fatty acyl-CoA. This fatty acyl-CoA can then be imported
into the mitochondria, via the mitochondrial carnitine system, to participate in the
TCA cycle (Kerner and Hoppel 2000). Analysis of BACH levels showed a
significant increase from young to old NMR, which then significantly decreased in
brains of the oldest age group. Expression of BACH isoform 2 was increased in
the two oldest age groups relative to the youngest NMR, with a decrease in the
phosphorylation state in the oldest age group. It is not yet clear what effect
phosphorylation has on the activity of BACH; however, this is an important area
to explore as BACH activity regulates the proper ratios of activated fatty acylCoA, free fatty acids and CoA-SH (Brocker, Carpenter et al. 2010). Such studies
are underway in our laboratories.
Glucose-6-phosphate isomerase (GPI; a.k.a. neuroleukin; autocrine
motility factor) is a pleiotropic protein performing different functions inside the cell
and in the extracellular space. In the cytoplasm, GPI catalyzes the second step in
glycolysis, converting glucose-6-phosphate to fructose-6-phosphate, regulates
gp78-dependent mitochondrial fission and mitophagy (Fu, St-Pierre et al. 2013,
Shankar, Kojic et al. 2013), and is reported to protect against ER stress and
apoptosis by regulation of ER calcium release (Fu, Li et al. 2011). Outside the
cell, GPI acts as a neurotropic factor for spinal and sensory neurons, contributing
to maintenance of neuronal integrity (Haga, Niinaka et al. 2000). A decrease in
phosphorylation of GPI has been reported to lead to an increase in activity
(Yanagawa, Funasaka et al. 2005). Hence, the increased levels of GPI relative to
the earliest age group and the decreased phosphorylation levels in the oldest
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age cohort as compared to the intermediate, demonstrate a potential
neuroprotective mechanism that may contribute to the NMR’s sustained lifespan
and healthspan.
Two additional glycolytic enzymes were identified as being significantly
altered in the NMR brain: fructose-bisphosphate aldolase (ALDO) and alpha
enolase (ENO1). ALDO is a pleiotropic protein that not only catalyzes a key
reaction in glycolysis but is also involved in: endocytosis, assembly and
regulation of vacuolar H+-ATPase proton pump, mRNA stability, and assembly of
the actin cytoskeleton (Kao, Noda et al. 1999, Lundmark and Carlsson 2004,
Canete-Soler, Reddy et al. 2005, Lu, Ammar et al. 2007). Additionally, ALDO has
been reported to act as a scaffolding protein, mediating the association of F-actin
with GLUT4, an insulin-responsive transporter of glucose (Kao, Noda et al.
1999). Furthermore, the presence of ALDO’s substrates reportedly regulates
glucose transport via GLUT4 by disrupting the aldolase-actin interaction (Kao,
Noda et al. 1999). In this current study, the phosphorylation state of ALDO was
decreased in the oldest age group as compared to the youngest. Considering the
aforementioned roles of ALDO, it is tempting to speculate that an increase in
ALDO activity via a decreased phosphorylation state may contribute to salubrious
longevity in the NMR; yet, the functional effects of ALDO phosphorylation have
yet to be elucidated. However, as ALDOC was previously reported to have an
increase in phosphorylation of 4.1-fold in the hippocampus of Alzheimer disease
(AD) brain (Di Domenico, Sultana et al. 2011) and NMR brains have very high
levels of both beta amyloid (Edrey, Medina et al. 2013) and phosphorylated tau
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(Orr, Salinas et al. 2014) (pathological hallmarks of AD), elevated ALDO
phosphorylation in AD may be pathological and the decrease with age in this
protein in NMR brains may reflect a potential mechanism used by NMRs in an
attempt to better cope with these potentially toxic proteins.
ENO1 is primarily known in glycolysis and gluconeogenesis as the
enzyme that catalyzes the conversion between 2-phosphoglycerate and
phosphoenolpyruvate. However, enolase has been reported to have multiple
regulatory functions, acting as: a neurotrophic factor, a hypoxic stress protein, a
transcription factor in tumor formation and metastasis, a plasminogen binding
protein in human diseases, an activator of plasminogen, and others (Butterfield
and Lange 2009, Sedoris, Thomas et al. 2010, Yamada, Marutsuka et al. 2014).
Previously, we have shown ENO1 to be oxidatively modified and differentially
expressed in several age-related neurodegenerative disorders (Castegna,
Aksenov et al. 2002, Perluigi, Fai Poon et al. 2005, Perluigi, Poon et al. 2005,
Poon, Frasier et al. 2005). Further, ENO1 was shown to have an increased
phosphorylation by 2.5-fold in the AD brain (Di Domenico, Sultana et al. 2011).
Conversely, in the present study, the phosphorylation of ENO1 was shown to be
decreased by 68% in the oldest NMR age group relative to the youngest age
group. Therefore, we speculate that decreased phosphorylation of ENO1 may be
a contributing factor to increased lifespan and healthspan in the NMR.
Lactate dehydrogenase (LDH) catalyzes the interconversion between
pyruvate and lactate in an anaerobic environment. There are five different
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isoforms of LDH, and LDHB activity preferentially favors the oxidation of lactate
to pyruvate, generating energy (Newington, Harris et al. 2013). Moreover, levels
of LDH are reportedly increased in senescent human fibroblasts (Zwerschke,
Mazurek et al. 2003), and high amounts of lactate in brain, as a consequence of
decreased LDHB, have been suggested to be an aging hallmark (Ross, Oberg et
al. 2010). Therefore, given that NMRs live in a hypoxic environment in the wild,
the increase in LDHB levels in the oldest NMR cohort as compared to both the
intermediate and old cohorts conceivably may be a neuroprotective mechanism
to increase energy output.
Malate dehydrogenase (MDH2) is a mitochondrial TCA enzyme that
catalyzes the conversion of oxaloacetate to malate producing NADH. When
compared to the youngest NMR, MDH2 levels were significantly increased in the
oldest age group with a decrease in phosphorylation state. Phosphorylation of
MDH has been reported to decrease its activity (Minard and McAlister-Henn
1994), suggesting that aged NMR brains may be effectively regulating the high
levels of MDH2 through inhibitory phosphorylation and thereby maintain a
physiologic level of activity. Malate dehydrogenase in the cytosol (MDH1) is a
metabolic protein of the malate-aspartate shuttle that is necessary in the
transference of reducing equivalents of NADH into the mitochondria for the use
by complex I of the electron transport chain (ETC). MDH1 levels were greater in
the old age group with a decrease in phosphorylation in the two oldest age
groups, all as compared to the youngest cohort. An increased level of this key
enzyme would result in increased mitochondrial ATP synthesis. Consequently,
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the elevated levels of MDH1 and MDH2, along with their decreased
phosphorylation states in brains from the oldest group of NMR are consistent
with an increase in energy metabolism that may contribute to NMR health and
longevity. Congruous with our results, MDH1 is reportedly decreased in aged
human fibroblasts (Lee, Dho et al. 2012); and, in MDH1 knockdown cells, sirtuin
1 deacetylase, a regulator of cellular senescence, is decreased, suggesting
MDH1 plays a role in the regulation of senescence (Lee, Dho et al. 2012) and
could contribute to increased lifespan of these rodents.
Aspartate aminotransferase (AAT) is another enzyme involved in the
malate-aspartate shuttle involved in the transfer of NADH reducing equivalents
produced in glycolysis to the ETC in mitochondria (Panteghini 1990) . AAT also
plays a key role in amino acid metabolism by catalyzing an essential step in the
biosynthesis of purines, pyrimidines, amino acids, and their derivatives (Wrenger,
Muller et al. 2012), as well as the reversible transamination of α-ketoglutarate (αKG) to glutamate. These steps are essential for the production of DNA and RNA,
increased synthesis of ATP, and the formation of the major excitatory
neurotransmitter, glutamate. The precise role of the altered phosphorylation state
is unclear, but it was increased in the brain of the oldest NMR group relative to
the youngest age group; and this increase may be consistent with the need for
elevation of glutamate in extended aging and increased neuroplasticity (Segovia,
Porras et al. 2001, Mattson 2008).
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Isocitrate dehydrogenase [NADP+] cytoplasmic (IDH1) catalyzes the
oxidative decarboxylation of isocitrate that produces α-KG. Further, this reaction
regenerates NADPH, which contributes to cellular defense against reactive
oxygen species (Bleeker, Atai et al. 2010). In the brain of NMR, the
phosphorylation state of IDH1 was significantly decreased in the oldest age
group, relative to the youngest age group, and a decreased phosphorylation
state has been shown to increase the activity of the enzyme (LaPorte 1993). This
is consistent with the notion that decreased phosphorylation of IDH1 contributes
to the increased lifespan of NMRs. In contrast to the increased IDH1 activity in
the senescent and disease-resistant NMR brain, the activities of IDHs are
reported to be markedly decreased in aged cells (Samokhvalov, Ignatov et al.
2004), resulting in impaired insulin secretion (Reitman and Yan 2010).
Glucose-6-phosphate 1 dehydrogenase (G6PD) shunts glucose-6phosphate from the glycolytic pathway to the pentose phosphate pathway, also
producing NADPH as well as pentose phosphates for fatty acid and nucleic acid
synthesis. G6PD levels were higher in the oldest age group as compared to both
the intermediate and old age groups. Therefore, the upregulation of G6PD may
promote a reduced cellular state to encourage a neuroprotective environment.
ATP synthase subunit alpha (ATP5A1) is among the catalytic subunits of
complex V of the ETC. In the oldest NMR cohort, ATP5A1 (isoform 2) was found
to have decreased inhibitory phosphorylation relative to both the young and
intermediate age groups. Phosphorylation of ATP5A1 has been reported to
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decrease activity as a consequence of decreased binding affinity to ATP
(Alzamora, Thali et al. 2010). Therefore, our results are consistent with the notion
that as NMRs age, ATP production is increased, perhaps as a compensatory
mechanism.
Because this study involved both male and female and both breeding and
non-breeding animals, a potential caveat for these results may be the
contribution of breeding status, which could possibly introduce sample variation
due to hormonal differences (Margulis, Saltzman et al. 1995). Future studies,
with many more animals, will be necessary to estimate the contribution of
breeding status to the results obtained. Further, it is tempting to speculate that
the significant differences found between the youngest cohort and the other ages
may represent an immature brain in its final steps of development. Studies
dedicated to understanding and characterizing NMR brain development are
needed to clarify this potential caveat common among this and many prior NMR
studies.
In summary, this current study has identified significant alterations in
protein levels and phosphorylation states of key metabolic proteins. The
metabolic pathways in which these proteins are involved are illustrated in Figure
6.1.5.
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Figure 6.1.5 Metabolism-associated pathways with differential protein
levels and/or phosphorylation levels with age in NMR brain. Summary
schematic diagram of expression proteomics and phosphoproteomics profiles of
metabolic protein changes in the brain of the NMR as a function of age. Proteins
with altered levels and/or phosphorylation states are highlighted in red.

Many of these proteins are pleiotropic, having many other interesting
functions that may contribute to the exceptional longevity and disease resistance
of the NMR. The results obtained using proteomics and phosphoproteomics have
revealed important potential mechanisms for increased lifespan and increased
healthspan of NMRs. Improved understanding of potential mechanisms that
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facilitate an extended lifespan and an extended healthspan in the NMR
conceivably may lead in humans to insights into the prevention of age-related
diseases and may lead to therapies that aid in the delay of the onset and
progression of the aging process.

Copyright © Judy Carol Triplet 2015
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CHAPTER 6.2
AGE-RELATED CHANGES IN THE PROTEOSTASIS NETWORK IN THE
BRAIN OF THE NAKED MOLE-RAT: IMPLICATIONS PROMOTING HEALTHY
LONGEVITY
6.2.1 Overview
The naked mole-rat (NMR) is a remarkably long-lived rodent that
possesses several exceptional traits: marked cancer resistance, negligible
senescence, prolonged genomic integrity, pronounced proteostasis, and
sustained healthspans. The underlying molecular mechanisms that contribute to
these extraordinary attributes are currently under investigation to gain insights
that conceivably may promote and extended human lifespan and healthspan.
The ubiquitin-proteasome and autophagy-lysosomal systems play a vital role in
eliminating cellular detritus to maintain proteostasis and have been previously
shown to be more robust in NMRs when compared to shorter-lived rodents.
Using a 2-D PAGE proteomics approach, differential expression and
phosphorylation levels of proteins involved in proteostasis networks were
evaluated in the brains of NMRs in an age-dependent manner. We identified 9
proteins with significantly altered levels and/or phosphorylation states that have
key roles involved in proteostasis networks. To further investigate the possible
role that autophagy may play in maintaining cellular proteostasis, we examined
aspects of the PI3K/Akt/mammalian target of rapamycin (mTOR) axis as well as
levels of Beclin-1, LC3-I, and LC3-II in the brain of the NMR as a function of age.
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Together, these results show that NMRs maintain high levels of autophagy
throughout the majority of their lifespan.
6.2.2 Introduction
The bathyergid rodent, Heterocephalus glaber, more commonly known as
the naked mole-rat (NMR) or sand puppy, is a strictly subterranean rodent
indigenous to North East Africa. These rodents are arguably best known because
of their unusually long, healthy life spans (15-30 years) when compared to that of
the traditional rodent models such as mice and rats (1-3 years) (Buffenstein
2005, Buffenstein 2008, Edrey, Hanes et al. 2011, Ables, Brown-Borg et al.
2014). This prolonged healthspan has led to research involving many cellular
systems thought to contribute to the aging process including: oxidative stress or
damage of biomolecules such as proteins and nucleotides, mitochondrial
dysfunction, and the autophagy/proteostasis network (Andziak, O'Connor et al.
2006, Lambert, Boysen et al. 2007, Lewis, Andziak et al. 2013, Edrey, Oddo et
al. 2014, Zhao, Lin et al. 2014). The ability of the NMR to withstand the chronic
insult of protein unfolding stressors has been attributed to the efficiency with
which the rodent maintains the integrity of its proteome by way of a high
functioning ubiquitin-proteasome system (UPS) and cellular autophagy (Perez,
Buffenstein et al. 2009, Rodriguez, Wywial et al. 2011, Grimes, Chiao et al. 2012,
Rodriguez, Edrey et al. 2012, Pride, Yu et al. 2015).
The UPS functions to maintain cellular proteostasis by degrading
unwanted, misfolded or damaged proteins that could otherwise aggregate into
potentially cytotoxic moieties, and UPS dysfunction has been implicated in
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multiple neurodegenerative disorders (Leroy, Boyer et al. 1998, FernandezFunez, Nino-Rosales et al. 2000, Castegna, Thongboonkerd et al. 2004, Bennett,
Shaler et al. 2007, Triplett, Zhang et al. 2015). The proteasome cleaves
damaged proteins into smaller peptide fragments by the proteolytic center that
contains trypsin-like (T-L), post-glutamyl peptide-hydrolyzing (PGPH), and
chymotrypsin-like (ChT-L) specificities (Hanna and Finley 2007, Rodriguez,
Osmulski et al. 2014). Liver and brain samples from NMRs when compared to
mouse controls, have shown increased ChT-L and T-L activities, suggesting a
more efficient UPS that may contribute to their inherent resistance to aging and
age-related diseases (Rodriguez, Edrey et al. 2012, Edrey, Oddo et al. 2014).
Moreover, human, mouse, and yeast proteasomes were demonstrated to have
an increased activity when exposed to proteasome depleted cytosolic fractions
containing a novel HSP-containing complex from NMR samples (Rodriguez,
Osmulski et al. 2014).
The autophagy-lysosomal pathway (ALP) is an evolutionarily conserved
catabolic process by which the cell removes and recycles complexes, protein
aggregates and damaged organelles (Mizushima 2007). Often seen as a
mechanism to address starvation to reduce energy output, autophagy provides
the cell many important functions such as cellular differentiation, growth control,
defense from xenobiotics, and general housekeeping and maintenance (Cecconi
and Levine 2008). Thus, autophagy is generally thought of as a survival
mechanism. ALP involves a number of proteins such as Beclin-1 and LC3 that
are crucial in the initiation and recruitment of the autophagosome, which once
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formed, engulfs the target prior to fusing with the lysosome for recycling (Klionsky
2005). Further, the PI3K/Akt/mTOR axis plays a central role in cellular
proteostasis as mTOR activation inhibits autophagy, and mTOR is a direct target
of the kinase Akt, which is regulated by PI3K. Dysregulation of these pathways
has been linked to neurodegenerative diseases (Aguado, Sarkar et al. 2010,
Glick, Barth et al. 2010, Martinez-Vicente, Talloczy et al. 2010, Winslow, Chen et
al. 2010, Nixon and Yang 2011, Nixon 2013, Tramutola, Triplett et al. 2015).
A failing proteostasis network in the brain in particular increases
vulnerability to dysfunctions in UPS and ALP due to the unique shape of neurons
and their non-mitotic nature (Grimm, Hoehn et al. 2011). Further, these protein
degradation mechanisms are essential in neuron function including
neurotransmission and synaptic remodeling (Willeumier, Pulst et al. 2006, Yi and
Ehlers 2007). Dysregulation of these proteostasis maintenance systems can lead
to neurodegeneration, diminished quality of life and reduced lifespans (Tanaka
and Matsuda 2014).
In the current age-related study of the NMR proteome and
phosphoproteome, a large number of significantly altered brain proteins were
identified, whose functions were related to metabolism, proteostasis networks,
cellular signaling, structure, and neuronal plasticity. Too many proteins were
identified to be efficiently discussed and expounded upon in a single manuscript;
consequently, we facilitated discussion of the results by means of protein
functionality. Here, we report on significant changes in proteins related to
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proteostasis and autophagy systems in the NMR brain and their impact upon the
unusually long and salubrious lifespan of the NMR.
6.2.3 Materials and Methods
6.2.3.1 Materials
Criterion precast polyacrylamide gels, TGS and MOPS electrophoresis
running buffers, ReadyStrip IPG strips, mineral oil, Precision Plus Protein All Blue
Standards, Sypro Ruby protein stain, biolytes, urea, dithiothreitol (DTT),
iodoacetamide (IA), and nitrocellulose membranes were purchased from Bio-Rad
(Hercules, CA, USA). Pro-Q Diamond phosphoprotein stain, and antiphosphotyrosine, anti-phosphoserine, and anti-phosphothreonine antibodies
were procured from Invitrogen (Grand Island, NY, USA). Protein A/G beads
Amersham ECL IgG horseradish peroxidase-linked secondary antibodies, and
ECL Plus Western blotting detection reagents were purchased from GE
Healthcare (Pittsburgh, PA, USA). C18 ZipTips and Re-Blot Plus Strong stripping
solution were obtained from Millipore (Billerica, MA, USA). Modified trypsin
solution was purchased from Promega (Madison, WI, USA). Pierce BCA protein
assay reagents A and B were purchased from Thermo Scientific (Waltham, MA,
USA). Anti-p-PI3K (Tyr508) and anti-BAP1 (Ub carboxyl-terminal hydrolase)
antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Anti-Beclin-1, anti-p-mTOR (Ser2448), anti-mTOR, anti-AKT, and anti-p-AKT
(Ser473) antibodies were obtained from Cell Signaling Technology (Danvers, MA,
USA). Anti-LC3-I and anti-LC3-II antibodies were purchased from Novus
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(Littleton, CO, USA). Anti-VDAC2 antibody was purchased from Abcam
(Cambridge, MA, USA). All other chemicals used in this study were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
6.2.3.2 Animals
Brains from NMRs were obtained from well-characterized colonies
(Buffenstein 2005) maintained by Dr. Rochelle Buffenstein at the University of
Texas Health Science Center, San Antonio. The NMRs were housed in
fabricated burrow systems under climate conditions that mimicked their natural
habitat (30˚C and 30-50% relative humidity). The NMRs were fed ad libitum a
diet that consisted of fresh fruits and vegetables, which was supplemented with a
high protein and vitamin enriched feed (Pronutro, South Africa). NMRs were
anesthetized with isofluorane, euthanized by cardiac exsanguination and the
brains were immediately harvested and flash frozen in liquid nitrogen. All animal
procedures were approved by the Institutional Animal Care and Use Committee
at the University of Texas Health Science Center at San Antonio, TX.
Experimental animal groups consisted of 5-9 individual brains from both male
and female individuals and of both subordinate and breeding status. NMRs were
divided into four age groups for analysis: 2-3 year-olds (age group 1; young), 4-6
year-olds (age group 2; intermediate), 7-12 year-olds (age group 3; old) and 1524 year-olds (age group 4; oldest).
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6.2.3.3 Sample preparation
Naked mole-rat brain homogenates were prepared using a Wheaton glass
homogenizer (~40 passes) and diluted with ice-cold isolation buffer [0.32 M
sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5 µg/mL
aprotinin, 4 µg/mL leupeptin, 4 µg/mL pepstatin, and 10 µg/mL phosphatase
inhibitor cocktail 2]. Homogenate protein concentrations were ascertained by the
Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al. 1985).
6.2.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
Isoelectric focusing (IEF). 2-D PAGE experiments were performed as
previously described (Sultana, Boyd-Kimball et al. 2007). In brief, 200 µg of each
homogenate, suspended in 200 µL of rehydration buffer [8 M urea, 2 M thiourea,
50 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, 0.01% bromophenol Blue], were
sonicated and applied to 11 cm pH 3-10 ReadyStrip IPG strips. The strips were
actively rehydrated and isoelectricly focused. At the end of the run, IPG strips
were immediately stored at -80 °C.
SDS PAGE. IEF strips were thawed and equilibrated in DTT and IAcontaining buffers. IEF strips were rinsed in TGS running buffer before
placement into 11 cm Criterion precast linear gradient polyacrylamide gels (8–
16% Tris–HCl). Precision Plus Protein All Blue molecular standards and samples
were run at a constant voltage of 200 V for approximately 65 min at 22˚C in
Tris/Glycine/SDS running buffer.
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6.2.3.5 Sypro Ruby and Pro-Q Diamond staining
After 2D-PAGE, gel staining was carried out according to manufacturer’s
directions and as described previously (Di Domenico, Sultana et al. 2011).
Briefly, gels were incubated in 50 mL of fixing solution [10% (v/v) acetic acid,
50% (v/v) methanol], washed in deionized (DI) water, and stained with 60 mL of
Pro-Q Diamond for 90 min. Gels were then destained four times in 100 mL of
solution [20% acetonitrile (ACN), 50 mM sodium acetate, pH 4] for 30 min each.
The gels were washed three times in DI water (30 min each) and then scanned
at 580 nm using a Bio-Rad ChemiDoc XRS+ imaging system (Bio-Rad, Hercules,
CA, USA). Next, 50 mL of Sypro Ruby protein gel stain was added and allowed
to incubate overnight (15 h). Gels were then rinsed in DI water, scanned at 450
nm with the ChemiDoc imager, and stored in DI water at 4 °C until protein spot
extraction.
6.2.3.6 Image Analysis
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2Dgel images of NMR brain samples were quantified according to the total spot
density using PDQuest 2-D Analysis Software (Bio-Rd, Hercules, CA, USA).
Intensities of individual spots were normalized to the total gel densities.
Normalized spot densities of the four age groups (2-3 year-olds, 4-6 year-olds, 712 year-olds, and 15-24 year-olds) were compared. Only spots with statistically
significant differences (p<0.05) were considered for in-gel trypsin digestion and
protein identification by MS/MS.
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Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel
images of the NMR brain samples were quantified and matched as described
previously (Di Domenico, Sultana et al. 2011). Next, a high match analysis
between the master gels from the Sypro Ruby matching and Pro-Q Diamond
matching was conducted. The phosphoprotein spot densities were normalized to
the Sypro Ruby spot densities and the resultant normalized spot densities in four
age groups were compared and spots that were statistically significant (p<0.05)
were considered for in-gel trypsin digestion and protein identification by MS/MS.
6.2.3.7 In-gel trypsin digestion/peptide extraction
Protein spots identifies as significantly altered from the earliest age group
were excised from 2D-gels and transferred to individual Eppendorf
microcentrifuge tubes for trypsin digestion as described previously
(Thongboonkerd, McLeish et al. 2002). In brief, DTT and IA was used to break
and cap disulfide bonds and the gel plug was incubated overnight at 37°C with
shaking in modified trypsin solution. Salts and contaminants were removed from
the tryptic peptide solutions using C18 ZipTips. Tryptic peptide solutions were
reconstituted in 10 µL of a 5% ACN/0.1% formic acid (FA) solution and stored at 80˚C until MS/MS analysis.
6.2.3.8 NanoLC-MS with Data Dependent Scan
Tryptic peptide solutions were analyzed by a nanoAcquity (Waters,
Milford, MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) platform with a
data dependent scan mode. An in-house packed capillary column (0.1 x 130 mm
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column packed with 3.6 µm, 200Å XB-C18) was used for separation with a
gradient using 0.1% FA and ACN/0.1% FA at 200 nL/min. The spectra obtained
by MS were measured by the orbitrap at 30,000 resolution; and the MS/MS
spectra of the six most intense parent ions in the MS scan were acquired by the
orbitrap at 7,500 resolution. The latest version of the Swiss-Prot database by
SEQUEST (Proteome Discoverer v1.4, Thermo Scientific) was used to
interrogate the data files of each sample. At least two high-confidence peptide
matches were used for protein identification where the false discovery rate <1%.
Proteins that were matched with the same peptides were reported as one protein
group. Protein data reported from these analyses includes: the SwissProt
accession number, the percentage of the protein sequence identified by
matching peptides, the number of peptide sequences detected by the MS/MS
analysis, the confidence score of the protein, the expected molecular weight and
predicted isoelectric point (pI).
6.2.3.9 Immunoprecipitation and Western blotting
Immunoprecipitation (IP). Individual NMR brain homogenates (250 µg)
were suspended in 500 µL of IP buffer [0.05% NP-40, aproprotin 5 µg/mL,
leupeptin 4 µg/mL, pepstatin 4 µg/mL, and phosphatase inhibitor cocktail 10
µg/mL] in a phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M
Na2HPO4, and 0.24 M KH2PO4]. Samples were precleared by incubation with
Protein A/G agarose beads for 1.5 h at 4˚C. Next, each sample was incubated
overnight with anti-VDAC 2 antibody (1:50 dilution) at 4˚C. Samples were then
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incubated with Protein A/G agarose beads for 1.5 h at 4˚C and washed 5 times
with IP buffer, preserving the beads for a 1D-PAGE experiment.
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Sample
homogenates (50 µg) or beads from VDAC2 immunoprecipitation experiment
were suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol,
8% SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue] (diluted to 1X with
DI water) and then heated at 95°C for 5 min. Samples were cooled on ice and
then loaded into Criterion precast 18 well polyacrylamide gels (4-12% Bis-Tris) or
Criterion 12% TGX stain-free polyacrylamide 18 well gels. Using XT MOPS or
TGS running buffer, gels were run at 80 V for 15 min and then at 120 V for
approximately 100 min. Stain-free gels were scanned using a Bio-Rad ChemiDoc
XRS+ imaging system to measure the total protein load before protein transfer to
Western blots.
1D-Western blotting. In-gel proteins were transferred to a nitrocellulose
membrane (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad,
Hercules, CA, USA) at 25 V for 30 min. After the transfer, membranes were
incubated in blocking solution (3% bovine serum albumin (BSA) in TBS-T [8 M
NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h. The membrane was then
incubated with primary antibodies: VDAC2 and UCH (1:3000 dilution), tubulin
(1:5000), and phosphoserine, phosphothreonine and phosphotyrosine antibodies
(1:6000) and mTOR, p-mTOR (Ser2448), Akt, p-AKT (Ser473), p-PI3K (Tyr508)
(1:1000 dilution), which were added to the blocking solution with gentle rocking
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for 2 h. The blots were washed three times with TBS-T (5 min each) and
incubated with a horseradish peroxidase secondary antibody in TBS-T (1:5000)
with gentle rocking. The membranes were then washed three more times in TBST (10 min each). Using Clarity Western ECL substrate, membranes were
chemiluminescently developed in the dark for 5 min, scanned using the
ChemiDoc XRS+ imaging system, and quantified using Image Lab software (BioRad, Hercules, CA, USA). Blots were stripped up to two times with Re-Blot Plus
Strong solution (15 min each) followed by three rinses with TBS-T (5 min each).
Proteins were normalized either to total protein load, tubulin, or the protein itself
in cases of phosphorylation measurements.
6.2.3.10 Statistical analysis
A conservative analysis was carried out on PDQuest data using both a
two-tailed Student’s t-test and a Mann-Whitney U statistical test, independently
comparing each age group to the youngest age cohort. Protein spots were
considered statistically significant if p<0.05 in both tests. To further determine
significant differences (p<0.05) between all of the various age groups, a one-way
ANOVA with post hoc Bonferroni t-test was used. Protein spot fold-change
values were calculated by dividing the average, normalized spot intensities of the
gels of older age group by the average, normalized spot intensities of the gels of
the younger age group in the comparison. For Western blot data, a one-way
ANOVA with either a post hoc Bonferroni or Dunnett’s multiple comparisons test
was used. All data are presented as mean+SEM. To ensure a rigorously
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conservative approach, spots were extracted for MS/MS analysis only if the fold
change was 40% or greater or smaller in normalized spot density. Identifications
of proteins acquired with the SEQUEST search algorithm were considered to be
statistically significant if p<0.01. At least two peptide sequences were used to
identify each protein. To ensure correct identification of the proteins, a visual
comparison was made between the expected molecular weight and isoelectric
point of the identified protein to the spot of the extracted 2-D gel plug.
6.2.4 Results
6.2.4.1 Age-related changes in proteins of the proteostasis network

Figure 6.2.1 Proteins associated with the proteostasis network with altered
expression with age in the NMR brain. Representative Sypro Ruby-stained 2D gel images of isolated proteins from the brains of NMRs, aged 2-3 years (A), 4-
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6 years (B), 7-12 years (C), and 15-24 years (D). Proteins whose expression
and/or phosphorylation state was significantly altered (p<0.05) in the particular
age group are labeled in the images.

Figure 6.2.2 Proteins associated with the proteostasis network with altered
phosphorylation levels with age in the NMR brain. Representative Pro-Q
Diamond-stained 2-D gel images of isolated proteins from the brains of NMRs,
aged 2-3 years (A), 4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins
with significantly altered phosphorylation levels (p<0.05) in the particular age
group are labeled in the images.
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Proteostasis network-related proteins with statistically significant changes
with age in protein levels and phosphorylation states are labeled in the 2-D gel
images of Figures 6.2.1 & 6.2.2, respectively. PDQuest analyses of all 2-D gels
found 9 proteostasis network-related proteins with significant changes in the
NMR brain as a function of age (Table 6.2.1).
Table 6.2.1 Proteins associated with the proteostasis network with
significantly altered levels and/or phosphorylation states with age in the
NMR brain. PDQuest and MS/MS results of NMR brain proteins involved in
proteostasis networks with significant altered expression and/or phosphorylation
states as a function of age.

Many of these proteins are associated with the UPS. Significant elevation
of heat shock protein (HSP) response with age was noted by the increased levels
of HSP70 protein 4 (Figure 6.2.3A) and the decreased phosphorylation levels of
HSP60 (Figure 6.2.3B).
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Figure 6.2.3 HSP70, HSP60 and VDACs with age in the NMR brain. Trends in
median protein levels and/or phosphorylation levels in NMR brain with age for (A)
HSP70 protein 4, (B) HSP60, and (C) VDACs 1-3 (n=5-9 individual brains per
age group comparison).
While the primary function of HSP is to maintain a protein’s native 3-D
conformation, if a protein is terminally misfolded, some HSPs also function to
chaperone the protein for UPS degradation.
The UPS, illustrated in Figure 6.2.4, depicts proteins that have significantly
altered expression and/or phosphorylation levels with increasing age in the brain
of the NMR. Two of these proteins are involved in protein ubiquitinylation: ub-like
modifier-activating enzyme 1 (UBE1) and ub-conjugating enzyme E2 variant 2
(UBE2v2). Both exhibit altered phosphorylation levels in the older age cohorts.
Further supporting the notion of increased UPS activity in the NMR with age is
the increased expression of ub-carboxy-terminal hydrolase (UCH), the protein
responsible for the removal of poly Ub chain, one Ub at a time from the Cterminal end, before entry into the proteasome.
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Figure 6.2.4 Proteins associated with the Ubiquitin-Proteasome System
with altered protein levels and/or phosphorylation levels in brain of NMR
with age. Summary schematic diagram of expression proteomics and
phosphoproteomics profiles of changes in proteins related to the ubiquitinproteasomal system in the brain of the NMR as a function of age. Proteins with
significantly altered protein and/or phosphorylation levels are indicated.

Interestingly, a component of the central proteasome itself, proteasome
subunit beta type 1 (PSβ1), showed decreased phosphorylation levels in the
intermediate and oldest age cohorts (Table 6.2.1).
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Autophagy-related proteins with altered levels and/or phosphorylation
states in one or more age cohorts includes all thee isoforms of the voltagedependent anion channel (VDAC): VDAC1, VDAC2, and VDAC3. VDACs are the
major outer mitochondrial membrane porins and regulators of energy metabolism
and mitophagy. Levels of both VDAC2 and VDAC3 were significantly increased
in the old age group as compared to control (Table 6.2.1), while phosphorylation
levels decreased with age for all VDACs (Figure 6.2.3C).
6.2.4.2 Immunoprecipitation and Western blotting validations
Immunoprecipitation and Western blot experiments were conducted on
selected proteins to confirm MS/MS results. Western blot analysis of UCH
(Figure 6.2.5A) confirmed a significant increase in the level of UCH in the brains
of the oldest age group (p=0.049). Interestingly, the Western blot also showed a
significant increase in UCH levels for the intermediate (p=0.011) and old age
groups (p=0.013) when compared to the youngest age group.
The results of the Western blot analyses of the expression of VDAC2
(Figure 6.2.5B) verified a significant increase in the old age group (p=0.005),
while also showing increased levels of VDAC2 in the oldest age group (p=0.025)
both as compared to the youngest age group. Analyses of the
immunoprecipitation of VDAC2 with anti-phosphoserine, anti-phosphothreonine
and anti-phosphotyrosine antibodies confirmed a significant decrease in the
phosphorylation of VDAC2 in the brain of the NMR for the intermediate age
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group (p=0.04), the old age group (p=0.01), and in the oldest age group
(p=0.048) as compared to the youngest age group (Figure 6.2.5C).

Figure 6.2.5 UCH and VDAC2 in brain of NMR with age. Western blot and
corresponding bar graph representations from the validation experiments of the
changes in the protein levels of (A) Ub carboxy-terminal hydrolase (UCH), (B)
voltage-dependent anion channel 2 (VDAC2), and (C) the immunochemistry
experiment validation of the significant decrease (*p<0.05) in the phosphorylation
of VDAC2 in the brains of NMRs (n=4-6 for each age group). Immunoreactivity
with specific antibodies was detected by chemiluminescence.
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6.2.4.3 PI3K/Akt/mTOR axis in NMR brain with age

Figure 6.2.6 The PI3K/Akt/mTor axis and autophagy. Diagram summarizing
the PI3K/Akt/mTOR axis signaling pathway leading to the nucleation and
formation of the phagophore to initiate the autophagy-lysosomal pathway.
To further investigate the role that autophagy (illustrated in Figure 6.2.6)
may play in the brain of the NMR with age, the PI3K/Akt/mTOR axis was
examined. Western blots were probed for p-PI3K (Tyr508), Akt, p-Akt (Ser473),
mTOR, and p-mTOR (Ser2448) (Figure 6.2.7). Analyses revealed that the p-PI3K
protein level was found to be significantly increased from the early to
intermediate age group (p=0.0001) and then significantly decreased from the
intermediate to the old age group (p=0.0007). Additionally, there was a significant
decrease from the intermediate to the oldest age group (p<0.0001).
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Figure 6.2.7 PI3K/Akt/mTOR axis in NMR brain with age. Western blots and
corresponding bar graph representations from the evaluation of the
PI3K/Akt/mTOR axis in the brain of the NMR (n=5-8 for each age group, *p<0.05,
**p<0.001, ***p<0.0001). Proteins were normalized to the total load of the gel.
Immunoreactivity with specific antibodies was detected by chemiluminescence.

The p-Akt/Akt ratio was decreased from the intermediate age group to the
old age group (p=0.031). Similar to the other proteins in the PI3K/Akt/mTOR axis,
the p-Akt/Akt ratio increases from the youngest to the intermediate age group
(data trended toward significance). There were no significant changes in the
protein levels of mTOR; however the p-mTOR/mTOR ratio follows a
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corresponding trend to that of p-PI3K, in which there is a significant increase
from the early to intermediate age group (p=0.013) and a significant decrease
from the intermediate age grouop to the old and oldest age groups (p=0.0009)
and (p=0.0013), respectively.

Figure 6.2.8 Beclin-1 and LC3 in NMR brain with age. Western blots and
corresponding bar graph representations of Beclin1 and the LC3-II/LC3-I ratio in
the brain of the NMR (n=6-8 for each age group, ***p<0.0001). Proteins were
normalized to the total load of the gel. Immunoreactivity with specific antibodies
was detected by chemiluminescence.
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We further analyzed the quantitative index of autophagy, the LC3-II/LC3-I
ratio in all age groups. The LC3 ratio showed no significant changes with age
(Figure 6.2.8). Additionally, we analyzed levels of the autophagy initiator protein,
Beclin-1, which showed a significant decrease in the oldest age group (p<0.0001)
(Figure 6.2.8).
6.2.5 Discussion
Not only are NMRs the longest-lived rodent, but they also maintain an
extended healthspan. This extraordinary salubrious lifespan has been attributed
to, in part, by mechanisms that contribute to maintaining proteostasis (Zhao, Lin
et al. 2014). Processes that promote sustained cellular homeostasis, such as
unfolded protein response and proteasome and autophagy pathways, remove
damaged or unwanted proteins, macromolecules and organelles which can be
cytotoxic and lead to neuronal death (Di Domenico, Head et al. 2014).
Additionally, these proteostasis systems play a critical role in maintaining health
by modulating protein levels in response to fluctuating physiological
environments (Di Domenico, Head et al. 2014). Previous studies have shown
that NMRs exhibit a more robust proteostasis as compared to shorter-lived
rodents (Perez, Buffenstein et al. 2009, Rodriguez, Wywial et al. 2011, Grimes,
Chiao et al. 2012, Rodriguez, Edrey et al. 2012, Zhao, Lin et al. 2014, Pride, Yu
et al. 2015). In this current study, we evaluated age-related changes in the NMR
proteome and phosphoproteome involved in proteostasis networks. These
findings suggest that the NMR is able to maintain this health-sustaining, robust
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proteostasis throughout the majority of their lifespan. Here, we discuss the
implications of proteins with significant differential levels and phosphorylation
states from the respective proteomics analyses (Table 6.2.1) as well as selected
autophagy-related proteins evaluated via Western blot analyses.
Typically, susceptibility to age-related diseases correlates to a declining
capacity to generate a stress response (Gutsmann-Conrad, Heydari et al. 1998,
Njemini, Abeele et al. 2002). Consistent with this notion, in the brain of the NMR,
levels of HSP70 (protein 4) were increased and phosphorylation of HSP60
decreased with age. HSP70 is a highly conserved pleiotropic protein that
executes many cellular functions including: folding of newly synthesized proteins,
prevention of protein aggregation, aiding in endocytosis, signal transduction,
protein targeting, and relaying proteins to the ubiquitin-proteasome system and
autophagy-lysosomal pathways (reviewed in (Meimaridou, Gooljar et al. 2009)).
Moreover, HSP70 mediates proteasome assembly during stress (Grune, Catalgol
et al. 2011), and together with its co-chaperone, HSP40, HSP70 is involved in
mitigation of proteotoxic insults to the proteasome (Rodriguez, Osmulski et al.
2014). Further, overexpression of HSP70 has been shown to impede apoptotic
mechanisms (Mayer and Bukau 2005, Arya, Mallik et al. 2007) and to curtail
neurodegeneration and senescence (Bonini 2002, Klucken, Shin et al. 2004).
Previously, HSP70 levels in NMRs have been shown to be higher in liver lysates
compared to those in mice (Rodriguez, Osmulski et al. 2014), consistent with the
idea that the increased levels of this important chaperone with age in the brain
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observed in the current study may suggest a more robust and global proteostasis
in these long-lived animals.
HSP60 primarily functions in the mitochondria to properly fold proteins. In
addition, HSP60 has been reported to have anti-apoptotic properties as it can
bind and inhibit pro-apoptotic proteins, Bax and Bak, to prevent
neurodegeneration (Arya, Mallik et al. 2007, Chandra, Choy et al. 2007).
Dephosphorylation of HSP60 has been reported to enhance chaperone functions
(Khan, Wallin et al. 1998). Therefore, the data from our current study suggest
that HSP60 may contribute to proper mitochondrial function in older NMR brains
by preventing protein aggregation and by suppressing apoptotic mechanisms to
impede neuronal loss.
Ubiquitinylation directs proteins to specific cellular targets, such as
proteasomes or DNA, as well as regulating protein interactions and activity
(David, Ziv et al. 2010). Protein ubiquitylation requires the activation and transfer
of Ub to a protein in a three-step process. Two proteins involved in this
ubiquitinylation process, UBE1 and UBE2v2, were found to have altered levels
and/or phosphorylation states in the brains of NMR in different age groups. In the
old age group, protein phosphorylation levels of UBE1 were found to be
increased compared to the youngest age group. UBE1 not only catalyzes the first
step in the Ub-proteasomal pathway, but it is also essential for the protein
ubiquitinylation that modulates DNA double-strand break repair, suggesting an
important role in policing genomic integrity and preventing disease pathogenesis
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(Moudry, Lukas et al. 2012). Posttranslational modifications to UBE1 isoforms
are still poorly understood (Schulman and Harper 2009). Known putative roles of
UBE1 phosphorylation include targeting this protein to different subcellular
locations and modulation of nucleotide excision repair (Stephen, Trausch-Azar et
al. 1996, Nouspikel and Hanawalt 2006). However, with multiple UBE1 isoforms
containing multiple phosphorylation sights in various domains of the protein, the
implications of increased phosphorylation of UBE1 in this current study are as of
yet, uncertain. However, as this critical enzyme is reported to be the apex of
downstream signaling (Schulman and Harper 2009), we opine that UBE1 may be
involved in maintaining a healthy genome and conceivably may be related to the
dearth of cancer in this long-lived rodent.
Ubiquitinylation is a dynamic process and protein eventual protein
destination depends on the lysine to which it is attached and whether it is
monoubiquitinylated, homo-polyubiquitinylated, or hetero-polyubiquitinylated
(Johnson, Ma et al. 1995, Shang, Deng et al. 2005). The UBE2v2 preferentially
ubiquitinylates Lys63, which is reported to participate in chaperoning proteins for
DNA repair, lysosomal degradation of epidermal growth factor receptors, and NFκB activation by degradation of class I major histocompatibility complex
molecules (Hofmann and Pickart 1999, Duncan, Piper et al. 2006, Huang,
Kirkpatrick et al. 2006, Wu, Conze et al. 2006). Here, protein levels of UBE2v2
were increased in the intermediate age group, while phosphorylation levels were
decreased in the intermediate and oldest age groups. The intricacies of UBE2
structure and function are complex; and as such, the implications of altered
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phosphorylation states have yet to be elucidated, though we speculate that this
protein may be involved in promoting the ability for NMR to maintain a healthy
genome.
UCHs are a family of proteins responsible for the removal of the poly-Ub
tags. Dysregulation of UCH may result in the accumulation of poly-Ub proteins;
and this accumulation is reported in many chronic neurodegenerative diseases,
as they are present in the senile plaques and neurofibrillary tangles in Alzheimer
disease (AD) and in the Lewy bodies of Parkinson disease (Schwartz and
Ciechanover 1999). Further, in AD, it is hypothesized that the UPS-mediated
degradation of amyloid-beta (Aβ) is impaired, which leads to ubiquitinylated Aβ
aggregating into neurotoxic plaques (Hong, Huang et al. 2014). Previously, we
have shown that a particular UCH variant, UCHL1, is oxidized in AD brain, which
could conceivably inhibit Aβ degradation (Castegna, Aksenov et al. 2002,
Sultana, Boyd-Kimball et al. 2006). However, it has been reported that even
though NMRs exhibit Aβ levels similar to that of 3xTg-AD mice, there is no
accumulation of senile plaques in the NMR brain (Edrey, Medina et al. 2013,
Edrey, Oddo et al. 2014). Moreover, in mice ubiquitinylated proteins accumulate
with age; however, in NMRs levels of ubiquitinylated proteins of 2 year-old and
26 year-old rodents were similar (Perez, Buffenstein et al. 2009). Therefore, the
increase of UCH levels in the brain of the oldest age group may function to
maintain prolonged cellular proteostasis via availability to mediate disposal of
increasing levels of neurotoxic proteins, such as Aβ.
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When attached to the 26S proteasome and after the removal of Ub by
UCH, the protein is degraded by threonine proteases in the core of the 26S
proteasome (Voges, Zwickl et al. 1999). In this current study, PSB1, which is
responsible for PGPH activity, was found to have decreased levels of
phosphorylation in the intermediate and oldest age groups as compared to the
youngest age group. Decreases in proteasomal function and/or expression have
been reported in multiple neurodegenerative diseases including: AD, PD,
Huntington disease, amyotrophic lateral sclerosis, and prion diseases (Keller,
Hanni et al. 2000, Ciechanover and Brundin 2003, Bukhatwa, Zeng et al. 2010,
Ebrahimi-Fakhari, Wahlster et al. 2012, Martins-Branco, Esteves et al. 2012).
Moreover, PSB1, the variant identified in this current study, has been reported to
promote anti-apoptotic activity of plasminogen activator inhibitor 2 (PAI2) (Fan,
Zhang et al. 2004). While the consequences of the phosphorylation of this
subunit are unclear, it has been shown that phosphorylation of β-subunits in the
prokaryote M. tuberculosis can inhibit proteasomal assembly (Anandan, Han et
al. 2014). While there are multiple β-subunits in eukaryotes, unlike prokaryotes
that have only one type, the reduced phosphorylated states in the oldest NMR
brains could suggest that there is an increased affinity towards proteome
assembly and therefore, an increased degradation of unwanted or damaged
proteins, clearing the cell of detritus to promote healthy cellular function. This
observation would be consistent with the observed high levels of proteasome
activity reported for brain lysates of the NMR (Edrey, Oddo et al. 2014).
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Voltage dependent anion channels (VDACs) are outer mitochondrial
membrane porins that are involved in mitochondrial metabolic processes by
opening at low membrane potentials to regulate metabolic flux of small
hydrophilic molecules and ions (Blachly-Dyson and Forte 2001, ShoshanBarmatz and Gincel 2003). VDACs also participate in mitochondrial autophagy
by recruiting Parkin to docking sites for the removal of defective mitochondria,
targeting the organelle for degradation by lysosomes (Geisler, Holmstrom et al.
2010, Sheldon, Maldonado et al. 2011, Sun, Vashisht et al. 2012). Decreased
levels of VDACs could lead to an increased presence of malfunctioning
mitochondria, leading to increased protein oxidation and cellular detritus and
ensuing neuronal dysregulation. However, in this study, the increased levels of
VDACs suggest that the metabolic flux and the policing of mitochondrial function
are improved in the aging brain of the NMR. VDACs are known to be
phosphorylated by multiple kinases including: PKA, GSK3β, PKC, p38 MAP
kinase, Nek1, and endostatin reduced hexokinase 2 (Chen, Gaczynska et al.
2010, Sheldon, Maldonado et al. 2011). Phosphorylation of VDAC1 by Nek1 has
been reported to open the channel (Chen, Gaczynska et al. 2010). VDAC
phosphorylation by GSK3β or PKA increases the interaction between VDAC and
tubulin, blocking the channel (Sheldon, Maldonado et al. 2011). The
consequences of the decreased phosphorylation levels of VDAC2 and VDAC3 in
the aged NMR brain are unclear. Further investigations are needed to elucidate
the implications of this reported global decrease in phosphorylation in brains of
NMR rodents with age.
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To further assess the role that autophagy may contribute to the sustained
healthspan of the NMR by regulating cellular proteostasis, the PI3K/Akt/mTOR
axis, Beclin-1 and LC3 were examined in the NMR brain as a function of age.
Previous data suggested that the NMR, under basal conditions, maintains higher
levels of autophagy, thereby removing potentially toxic proteins before they can
negatively impact organ functionality (Rodriguez, Wywial et al. 2011) and that
macroautophagy was shown to be substantially higher in NMRs than in shorterlived mice (Rodriguez, Wywial et al. 2011, Pride, Yu et al. 2015). Further, when
the autophagy markers LC3-I, LC3-II and Beclin-1 were measured in one-day-old
NMRs and one-day-old mice, the NMRs were shown to have a higher LC3II/LC3-I ratio, even though their Beclin-1 levels were lower, suggesting that
NMRs have a significantly higher basal levels of autophagy than mice (Zhao, Lin
et al. 2014). Although Beclin-1 plays a critical role in the regulation of
autophagosome formation, it is also a shorter-lived protein involved in the
formation of pre-autophagosomal structures. Consequently, it is generally
accepted that the LC3-II/LC3-I levels usually correlate more reliably with the
number of autophagosomes and can be used to monitor autophagosome
formation (Klionsky, Abeliovich et al. 2008). Here, we measured the levels of
Beclin-1 in the brain of the NMR as a function of age. Beclin-1 was significantly
decreased in the oldest age group relative to the youngest age group. When the
LC3-II/LC3-I ratio was measured, the levels of this quantitative index of
autophagy did not significantly change, suggesting that NMRs do maintain a high
level of autophagy throughout a vast majority of their lives.
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The serine/threonine kinase, mTOR, is a major modulator of autophagy
that receives inputs from many different signaling pathways (Cuyas, CorominasFaja et al. 2014). One of the most important upstream positive regulators of
mTOR is Akt. The hyperphosphorylation of Akt induces a complete inhibition of
TSC2 and activation of mTOR through direct phosphorylation. In turn, the
mechanism of activation of Akt is induced by another kinase, PI3K. All together,
these proteins are recognized as the PI3K/Akt/mTOR axis, which plays a central
role in controlling one of the processes of proteostasis, autophagy. Our results
showed increased phosphorylation of Akt and PI3K (p85 subunit) at Ser473 and
Tyr508, respectively, in the intermediate NMR age group. Surprisingly, the
hyperphosphorylation of these two proteins do not appear to affect NMR aging
negatively. Indeed, the increase of PI3K/Akt activity in intermediate-aged NMRs
in this study could reflect the diversity of one of the several main downstream
targets, mTOR. Consistent with this notion, our data showed a
hyperphosphorylation of mTOR at Ser2448 in the brain of the intermediate age
group.
Taken together, these results demonstrate a plausible mechanism by
which NMRs resist development of age-related diseases, even though they
show high levels of oxidative damage to visceral tissues, even at young ages
(Andziak and Buffenstein 2006, Andziak, O'Connor et al. 2006). Given that NMRs
endogenously produce high levels of Aβ at a young age, yet live more than two
decades with these high levels, it appears that this species is exceedingly
tolerant of high Aβ levels and has evolved mechanisms to counter its
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neurotoxicity (Edrey, Medina et al. 2013, Edrey, Oddo et al. 2014). One possible
explanation could be the sustained activity of the autophagy pathway in the older
age groups. Moreover, the slight elevation of mTOR activity in the intermediate
age group could be a response to these increased levels of Aβ. In fact, a recent
paper published from our lab, supporting earlier findings by LaFerla, Oddo and
others, showed increased activity of the autophagy pathway in AD and down
syndrome subjects, suggesting that Aβ could be one of the major causes causing
hyperactivation of the pathway (Perluigi, Pupo et al. 2014).
Our results of this age-related study in the brain of the NMR expose
significant alterations in protein levels and phosphorylation states of proteins
involved in the functioning of the proteostasis network. Mechanisms that remove
cellular detritus promote an efficient, functional environment. Additionally, by
using long-lived species to identify specific proteins involved in these processes,
targets for potential therapies are identified that may aid in the delay of the onset
and progression of the aging process in humans.
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CHAPTER 6.3

The Extraordinary, Long-lived Naked Mole-Rat: Quantitative Proteomic and
Phosphoproteomic Insights into Mechanisms Promoting Healthspan
Involve Neurite Outgrowth and Neurotransmission
6.3.1 Overview
Aging is the greatest risk factor for developing neurodegenerative
diseases, which are associated with diminished neurotransmission and neuronal
brain structure and function. However, in the brain of the remarkable naked molerat (NMR), several salubrious traits have evolved to avert or delay age-related
deterioration. Not only does the NMR hold the world record as the longest-lived
rodent, but the NMR also possesses a extended healthspan, lasting 75-80% of
its life span. Further, aged NMRs exhibit negligible senescence, pronounced
genomic integrity, robust proteostasis, and a marked resistance to cancer. Using
a proteomic approach, statistically significant changes with age in expression and
phosphorylation levels of proteins associated with neurite outgrowth and
neurotransmission were identified in the brain of the NMR. We hypothesize that
such changes contribute to the extended lifespan and healthspan of the NMR
6.3.2 Introduction
The naked mole-rat (NMR; sand puppy) is a subterranean rodent
indigenous to the sub-Saharan region of North East Africa. Living in large,
eusocial colonies in an underground and thermally stable ecological niche, NMRs
have evolved several remarkable traits that have made this rodent an intriguing
animal research model to investigate, some of which include: extremely long
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lifespan, sustained heathspan, negligible senescence, resistance to cancer,
protein stability, high tolerance to hypoxia and oxidative stress, tightly regulated
metabolism, and efficient removal of cellular detritus, among others (Hulbert,
Pamplona et al. 2007, Buffenstein 2008, Perez, Buffenstein et al. 2009,
Rodriguez, Wywial et al. 2011, Lewis, Mele et al. 2012). The current study
focuses on brain proteins and underlying mechanisms that promote neurite
outgrowth and neurotransmission in the NMR with age.
Mitochondrial dysfunction and resultant decreased ATP production is
implicated in various neuronal degenerative diseases and leads to decreased
neuroplasticity and neurite outgrowth (Cheng, Hou et al. 2010). Moreover, in AD
up to 50% of synapses are lost throughout the brain (Masliah, Terry et al. 1989).
Uncovering proteins and related mechanism that prevent such catastrophic
neuronal loss may conceivably identify potential therapeutic targets to halt or
even ameliorate neurodegenerative damage.
Making new synaptic connections in the brain is dependent upon neurite
outgrowth and neuronal pathfinding, processes in which the axon is extended to
target cells by the growth cone. The growth cone is a highly motile, actin-based
structure located at the tip of neuronal processes that contain lamellipodia and
filopodia projections that respond to surrounding environmental cues to direct
growth cone movement (Dent and Gertler 2003, Lowery and Van Vactor 2009).
Once the growth cone has finalized an axon terminal formation at the
synapse, neurotransmitters can be repeatedly released, triggering enlargement
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of the axonal spines. In order to maintain rapid neurotransmitter activity, efficient
priming, releasing and recycling of synaptic vesicles is essential.
In this study, significant changes in the NMR brain proteome and
phosphoproteome with age were identified. A large number of altered brain
proteins were determined by proteomics and/or phosphoproteomics. To facilitate
discussion of the various proteins that may be involved in promoting healthy
longevity in the NMR, proteins were grouped according to their functionality. In
this report, we report on significant changes with age in neuroplastic-related brain
proteins and phosphoproteins in the NMR and their contribution to underlying
mechanisms that may contribute to the unusually long and salubrious lifespan of
this rodent.
6.3.3 Materials and Methods
6.3.3.1 Materials
All chemicals used in this study were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless otherwise noted. Criterion precast polyacrylamide gels,
ReadyStrip IPG strips, TGS and MOPS electrophoresis running buffers, mineral
oil, Precision Plus Protein All Blue Standards, Sypro Ruby protein stain, biolytes,
urea, dithiothreitol (DTT), iodoacetamide (IA), and nitrocellulose membranes
were purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond
phosphoprotein gel stain, and anti-phosphoserine, anti-phosphothreonine, and
anti-phosphotyrosine antibodies were purchased from Invitrogen (Grand Island,
NY, USA). Protein A/G beads, Amersham ECL IgG horseradish peroxidase173

linked secondary antibodies, and ECL Plus Western blotting detection reagents
were procured from GE Healthcare (Pittsburgh, PA, USA). C18 ZipTips and ReBlot Plus Strong stripping solution were obtained from Millipore (Billerica, MA,
USA). Modified trypsin solution was purchased from Promega (Madison, WI,
USA). Pierce BCA protein assay reagents A & B were purchased from Thermo
Scientific (Waltham, MA, USA). Anti-septin7, anti-CRMP2 and anti-cofilin1
antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
6.3.3.2 Animals
Brains from NMRs, aged 2-24 years, were acquired from the wellcharacterized colonies (Buffenstein 2005) of Dr. Rochelle Buffenstein at the
University of Texas Health Science Center, San Antonio. The fabricated burrow
systems, which housed the NMRs, mimicked conditions of their natural habitat
and were maintained at 30˚C with 30-50% relative humidity. The NMR diet
consisted of fresh fruits and vegetables (fed ad libitum), supplemented with a
high protein and vitamin enriched feed (Pronutro, South Africa). NMRs of
different ages were anesthetized with isofluorane and euthanized by cardiac
exsanguination. Brains were immediately harvested and flash frozen in liquid
nitrogen. All animal procedures were approved by the Institutional Animal Care
and Use Committee at the University of Texas Health Science Center at San
Antonio, TX. Experimental animal groups consisted of 5-9 individual brains from
both male and female individuals, of both subordinate and breeding status.
NMRs were divided into the following four age groups for analysis: 2-3 year-olds
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(age group 1; young), 4-6 year-olds (age group 2; intermediate), 7-12 year-olds
(age group 3; old) and 15-24 year-olds (age group 4; oldest).
6.3.3.3 Sample preparation
NMR brains were homogenized using a Wheaton glass homogenizer (~40
passes) with ice-cold isolation buffer [0.32 M sucrose, 2 mM EDTA, 2 mM
EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5 µg/mL aprotinin, 4 µg/mL leupeptin,
4 µg/mL pepstatin, and 10 µg/mL phosphatase inhibitor cocktail 2] and then
sonicated for 10 s on ice. Protein concentrations of homogenates were
determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al.
1985).
6.3.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
Isoelectric focusing (IEF). 2-D PAGE experiments were performed as
previously described (Sultana, Boyd-Kimball et al. 2007). Briefly, 200 µg of each
sample was suspended in 200 µL of rehydration buffer [8 M urea, 2 M thiourea,
50 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, 0.01% bromophenol Blue],
applied to IPG strips (pH 3-10), actively rehydrated and isoelectricly focused.
After completion of the run, IPG strips were immediately stored at -80 °C.
SDS PAGE. IPG strips were thawed and equilibrated in DTT and IAcontaining buffers. Strips were rinsed in TGS running buffer and placed into
Criterion precast polyacrylamide gels (8–16% Tris–HCl). Precision Plus Protein
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All Blue molecular standards and samples were run at a constant voltage of 200
V for approximately 65 min at 22˚C in Tris/Glycine/SDS running buffer.
6.3.3.5 Sypro Ruby and Pro-Q Diamond staining
After completion of 2D-PAGE, gels were stained according to
manufacturer’s directions and as described previously (Di Domenico, Sultana et
al. 2011). In brief, gels were fixed [10% (v/v) acetic acid, 50% (v/v) methanol]
and stained with 60 mL of Pro-Q Diamond for exactly 90 min. Gels were
incubated four times in destaining solution [20% acetonitrile (ACN), 50 mM
sodium acetate, pH 4] (100 mL, 30 min each). The gels were scanned at 580 nm
using ChemiDoc XRS+ imaging system (Bio-Rad). Next, gels were incubated
overnight (15 h) in 50 mL of Sypro Ruby protein gel stain. Gels were imaged at
450 nm and stored in DI water in covered containers at 4 °C until protein spot
extraction.
6.3.3.6 Image Analysis
Expression Proteomics. Spot intensities from SYPRO Ruby-stained gel
images were quantified according to total spot density and normalized to total gel
density using PDQuest analysis software (Bio-Rad). Normalized spot densities of
the four age groups were compared and only spots with statistically significant
differences in protein spot densities between age groups (p<0.05) were
considered for in-gel trypsin digestion and protein identification by MS/MS.
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Phosphoproteomics. Spot intensities from Pro-Q Diamond-stained gel
images were quantified and matched as described previously (Di Domenico,
Sultana et al. 2011). A high match analysis between the Sypro Ruby and Pro-Q
Diamond-stained gels was conducted. Phosphoprotein spot densities were
normalized to Sypro Ruby spot densities in order to differentiate between a lightly
phosphorylated protein that is highly abundant and a protein of low abundance
that is highly phosphorylated. The normalized spot densities were compared
between the four age groups, and spots that were statistically significant (p<0.05)
were considered for in-gel trypsin digestion and protein identification by MS/MS.
6.3.3.7 In-gel trypsin digestion/peptide extraction
Significantly differential protein spots were excised from 2D-gels and
transferred to individual Eppendorf microcentrifuge tubes for trypsin digestion as
previously described (Thongboonkerd, McLeish et al. 2002). In brief, DTT and IA
were used to break and cap disulfide bonds and the excised gel plugs were
incubated overnight (17 h) in modified trypsin solution with shaking at 37°C. Salts
and contaminants were removed from the tryptic peptide solutions using C 18
ZipTips. Tryptic peptide solutions were reconstituted in 10 µL of a 5% ACN/0.1%
formic acid (FA) solution and stored at -80˚C until MS/MS analysis.
6.3.3.8 NanoLC-MS with Data Dependent Scan
Reconstituted tryptic peptide solutions were analyzed by a nanoAcquity
(Waters, Milford, MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA)
platform using a data dependent scan mode and separated by a capillary column
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(0.1 x 130 mm column packed in-house with 3.6 µm, 200Å XB-C18) with a
gradient using 0.1% FA and ACN/0.1% FA at 200 nL/min. Spectra obtained by
MS were measured by the orbitrap at 30,000 resolution; and the MS/MS spectra
of the six most intense parent ions were acquired by the orbitrap at 7,500
resolution. Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4,
Thermo Scientific) was used to interrogate the data files for sample identification.
Proteins were identified by at least two high-confidence peptide-matched
sequences with a false discovery rate <1%. Proteins matched with the same
peptides were reported as one protein group. Tabular data reported from these
analyses includes: the SwissProt accession number, the percentage of the
protein sequence identified by matching peptides, the number of peptide
sequences sequnced in the MS/MS analysis, the confidence score of the protein,
the protein’s expected molecular weight (MW) and isoelectric point (pI).
6.3.3.9 Immunoprecipitation and Western blotting
Immunoprecipitation (IP). Brain homogenates (250 µg) were suspended
individually in 500 µL of IP buffer [0.05% NP-40, aproprotin 5 µg/mL, leupeptin 4
µg/mL, pepstatin 4 µg/mL, and phosphatase inhibitor cocktail 10 µg/mL] in a
phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na 2HPO4, and
0.24 M KH2PO4]. Samples were incubated with Protein A/G agarose beads in
500 mL of IP buffer for 1.5 h at 4˚C. Each sample was incubated overnight with
anti-cofilin1 antibody (1:50 dilution) at 4˚C. The next day, samples were
incubated with Protein A/G agarose beads for 1.5 h at 4˚C and washed with IP
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buffer (500 mL, 5 times), preserving the protein-linked beads for a 1D-PAGE
experiment.
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Sample
homogenates (50 µg) or beads from immunoprecipitation were suspended in 4X
sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% βmercaptoethanol, 0.01% Bromophenol Blue] (diluted to 1X with DI water).
Samples were heated at 95°C for 5 min, cooled on ice and loaded into Criterion
precast 18 well polyacrylamide gels (4-12% Bis-Tris). Using MOPS running
buffer, gels were run at 80 V for 15 min and then at 120 V for approximately 100
min.
1D-Western blotting. In-gel proteins were transferred to nitrocellulose
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V
for 30 min. Membranes were blocked in solution (3% bovine serum albumin
(BSA) in TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h.
Membranes were then separately incubated with primary antibodies: CRMP2 and
septin7 (1:3000 dilution), tubulin (1:5000), and phosphoserine, phosphothreonine
and phosphotyrosine antibodies (1:6000) for 2 h. The blots were washed with
TBS-T (3 times, 5 min each), incubated (1 h) with a horseradish peroxidase
secondary antibody in TBS-T (1:5000), and washed again in TBS-T (3 times, 10
min each). Western blots were chemiluminescently developed (in dark, 5 min)
with Clarity Western ECL substrate, scanned with the ChemiDoc and quantified
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using Image Lab software (Bio-Rad). Blots were stripped up to two times with
Re-Blot Plus Strong solution (15 min each) for further probing.
6.3.3.10 Statistical analysis
An initial, conservative analysis was carried out on PDQuest data using
both a two-tailed Student’s t-test and a Mann-Whitney U statistical test,
independently comparing each age group to the youngest age group. Protein
spots were considered significant if p<0.05 in both tests. Significant differences
(p<0.05) between the age groups for PDQuest data were determined using oneway ANOVA with post hoc Bonferroni t-test. Fold-change values of proteins were
calculated by dividing the average, normalized spot intensity of older age group
by the average, normalized spot intensity of the younger age group in the
comparison. For Western blot data, a one-way ANOVA with a post hoc Tukey
multiple comparisons test was used. All data are presented as mean +SEM.
Proteins identified by the SEQUEST search algorithm were considered
statistically significant if p<0.01. At least two peptide sequences were used to
identify each protein and a visual comparison was made between the expected
MW and pI of the identified protein to the spot of the extracted 2-D gel plug.
6.3.4 Results
Age-related changes in neuroplasticity-related proteins
Neuroplasticity-related proteins with statistically significant alterations in protein
and phosphorylation levels in the four cohorts are labeled Figures 6.3.1 & 6.3.2.
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Figure 6.3.1 Proteins associated with neurite outgrowth and
neurotransmission with altered expression and/or phosphorylation levels
with age in the NMR brain. Representative Sypro Ruby-stained 2-D gel images
of isolated proteins from the brains of NMRs, aged 2-3 years (A), 4-6 years (B),
7-12 years (C), and 15-24 years (D). Proteins whose expression and/or
phosphorylation state was significantly altered (p<0.05) in the particular age
group are labeled in the images.
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Figure 6.3.2 Proteins associated with neurite outgrowth and
neurotransmission with altered phosphorylation levels with age in the NMR
brain. Representative Pro-Q Diamond-stained 2-D gel images of isolated
proteins from the brains of NMRs, aged 2-3 years (A), 4-6 years (B), 7-12 years
(C), and 15-24 years (D). Proteins with significantly altered phosphorylation
levels (p<0.05) in the particular age group are labeled in the images.

PDQuest analyses of gels from all age groups identified 9 proteins related
to neurite outgrowth and neurotransmission with significant changes in the NMR
brain as a function of age (Table 6.3.1).

182

Table 6.3.1 Proteins associated with neurite outgrowth and
neurotransmission with significantly altered levels and/or phosphorylation
states with age in the NMR brain. PDQuest and MS/MS results of NMR brain
proteins related to plasticity, structure and neurotransmission with significant
altered expression and/or phosphorylation states as a function of age.

These altered proteins were: cofilin-1; isoform 2 of dihydropyrimidinaserelated protein 2, aka collapsin response mediator protein 2; destrin, aka actin
depolymerizing factor; isoform 3 of spectrin alpha chain; septin-7; Syntaxinbinding protein 1; synapsin-2 isoform IIB; and both isoform 3 and 4 of dynamin1.
Immunoprecipitation and Western blotting validations
Immunoprecipitation and Western blot experiments were carried out on
selected proteins to confirm MS/MS results and provide confidence of all
proteomic or phosphoproteomic identifications. Western blot analysis of CRMP2
(Figure 6.3.3A) confirmed a significant increase in CRMP2 levels in the brain of
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the oldest age group compared to the two younger age groups (p=0.008) and
(p=0.011), respectively. The Western blot analyses of the levels of septin-7
(Figure 6.3.3B) verified a significant increase in the old age group (p=0.038)
compared to the youngest, while also showing increased levels of septin-7 in the
intermediate age group (p=0.034) also compared to the youngest age group.
Analyses of the immunoprecipitation of cofilin-1 with anti-phosphoserine, antiphosphothreonine and anti-phosphotyrosine antibodies confirmed a significant
decrease in the phosphorylation of cofilin-1 in the brain of the NMR for the
intermediate age group (p=0.039), the old age group (p=0.037), and in the oldest
age group (p=0.037) all relative to the youngest age group (Figure 6.3.3C).

Figure 6.3.3 CRMP2, septin-7, and cofilin-1 in NMR brain with age.
Immunoprecipitation and Western blot analyses of (A) significant elevation of
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CRMP2 protein levels in oldest age group (B) increased septin-7 protein levels in
the middle age groups, and (C) levels of phosphorylated Ser/Tyr/Thr residues
normalized to total cofilin-1 protein levels after immunoprecipitation showing
significant decrease (*p<0.05) in the phosphorylation of cofilin-1 in the brains of
NMRs (n=4-6 for each age group). Immunoreactivity with specific antibodies was
detected by chemiluminescence.

6.3.5 Discussion
Evaluation of the proteins and phosphoproteins that significantly change
with age in the brain of the NMR, which are related to mechanisms associated
with neuroplasticity, fall into two different yet connected processes: neurite
outgrowth and neurotransmission.
Neurite outgrowth
Rapid assembly and disassembly of the actin cytoskeleton at the leading
edge of the cone is required for motility of the growth cone (Lin and Forscher
1995, Minamide, Striegl et al. 2000). Actin depolymerizing factor (ADF; destrin)
and cofilin-1, members of the ADF/cofilin family, modulate actin dynamics in the
growth cone by binding and depolimerizing F-actin at the negative end of the
filaments (Lappalainen and Drubin 1997, Gungabissoon and Bamburg 2003),
and ADF/cofilin regulate the rate at which these monomers separate from the
actin filament (Maciver and Hussey 2002). Further, overexpression of cofilin has
been reported to increase neurite outgrowth (Meberg and Bamburg 2000). In
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fact, cofilin activity reportedly is essential for neurite extension by the growth
cone (Endo, Ohashi et al. 2003). Interestingly, cofilins also are involved in cellular
stress responses to heat shock and chemical stress, in which actin becomes
saturated with cofilin inducing actin rod bundling (known as cofilin/actin rods),
thereby halting actin polymerization and depolymerization (Munsie and Truant
2012). Upon dissipation of environmental stressors, the cofilin/actin rods
dissipate. However, if the stressed environment persists, as in
neurodegenerative diseases, the cofilin/actin rods block neuronal trafficking and
lead to disruption of synapses and eventual apoptosis (Minamide, Striegl et al.
2000, Cichon, Sun et al. 2012). In the current study, NMRs exhibited increased
ADF/cofilin-1 levels with significant elevation of ADF levels in the two oldest age
cohorts compared to the youngest age group and increased cofilin-1 levels in the
old age group. Additionally, ADF phosphorylation was decreased in the oldest
age group, while cofilin-1 phosphorylation was decreased in all age groups as
compared to the youngest. Phosphorylation at Ser-3 reportedly inactivates
ADF/cofilin, while dephosphorylation activates actin depolymerization (Toshima,
Toshima et al. 2001, Endo, Ohashi et al. 2003). Taken together, the increased
levels and activity of ADF/cofilin suggest a possible mechanism by which the
NMR brain maintains a high numbers of synapses, consistent with salubrious
aging.
Dihydropyrimidinase-related protein 2 (DRP2; collapsin response mediator
protein 2, CRMP2) is a pleiotropic protein that participates in a wide array of
activity in and out of the growth cone, including: organization of the dendritic field,
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guidance and collapse of the growth cone, neurite outgrowth, synaptic assembly,
neurotransmitter release, endocytosis, and Ca2+ homeostasis (Goshima,
Nakamura et al. 1995, Byk, Dobransky et al. 1996, Uchida, Ohshima et al. 2005,
Brittain, Piekarz et al. 2009, Hensley, Venkova et al. 2011, Ju, Li et al. 2013). In
previous studies, we have shown that CRMP2 is oxidatively modified in brain of
subjects with Alzheimer disease (AD) (Castegna, Aksenov et al. 2002) and that
phosphorylation levels of CRMP2 are increased in the hippocampus of AD brain
(Di Domenico, Sultana et al. 2011). In this current study, levels of CRMP2 were
significantly increased in the oldest NMRs compared to both the intermediate and
old age groups. This increase in CRPM2 suggests that older NMR brains have
increased neuronal plasticity and provides another mechanism by which the
NMR is able to ward away cognitive decline with age.
Members of the septin family are highly conserved cytoskeletal GTPases
involved in various cellular functions, including: dendritic field maturation, spine
dynamics, synaptic transmission, vesicle trafficking, DNA response to
cytoskeletal damage, protein scaffolding, membrane compartmentalization, cell
division, and apoptosis (Barral, Mermall et al. 2000, Kremer, Adang et al. 2007,
Tada, Simonetta et al. 2007, Xie, Vessey et al. 2007, Spiliotis, Hunt et al. 2008,
Hagiwara, Tanaka et al. 2011). Septin7, in particular, is reportedly essential in
the regulation of dendritic branching and spine morphology (Xie, Vessey et al.
2007). Additionally, septins can function cooperatively, forming hetero-filaments
of 3 or more septins, the most notable of which being septin2/septin6/septin7
(Barral and Kinoshita 2008). Furthermore, septins have abnormal function in
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several neurological disorders including AD and Parkinson disease (Kinoshita,
Kinoshita et al. 1998, Cheon, Fountoulakis et al. 2001, Barr, Young et al. 2004,
Ihara, Yamasaki et al. 2007). In this study of the NMR brain, expression of
septin7 was significantly increased in the old age group with respect to the
youngest age group, suggesting increased brain plasticity is a survival
mechanism with aging of NMRs.
Neurotransmission
Rapid release and recycling of synaptic vesicles is one facet required for
efficient neurotransmission. In the brain of the NMR, four proteins involved in this
process were altered with age.
Syntaxin-binding protein 1 (stxbp1) apparently plays a role in both neurite
extension and neurotransmission. Not only is stxbp1 reported to regulate the
filopodia of the growth cone to modulate plasticity (Broeke, Roelandse et al.
2010), but stxbp1 also can bind to syntaxin and modulate the formation of the
SNARE complex and subsequent neurotransmitter release (Misura, Scheller et
al. 2000, Yang, Steegmaier et al. 2000). In the current study, the expression of
stxbp1 was increased in the oldest age group compared to the youngest, and
phosphorylation levels of stxbp1 were decreased in the two oldest groups relative
to the youngest. Protein kinase C phosphorylation on Ser-306 and Ser-313 of
stxbp1 reportedly modulates neurotransmission by increasing rapid vesicle
cycling and vesicle release (Barclay, Craig et al. 2003, Craig, Evans et al. 2003).
However, since PhosphoSite lists over 30 residues of stxbp1 that can be
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phosphorylated, it is conceivable that the global phosphorylation events
measured here may be responsible for modulation of other cellular activities,
such as changing affinity to binding partners or cellular localization or other
activities. Furthermore, based on the NMR’s long healthspan well into old age in
addition to the implications of other proteins identified in this study, it may not be
likely that the decreased phosphorylation of stxbp1 seen here would decrease
synaptic activity. Further investigations into decreases of phosphorylation at
particular phosphorylation sites are warranted.
Dynamin-1 (dnm1) is a brain-specific GTP-dependent motor protein that is
abundant in the post-synaptic synapse (Raimondi, Ferguson et al. 2011).
Interestingly, dnms are the only known molecular motor proteins to utilize a
twisting motion, and dnm1 does so by pinching off synaptic vesicles from the
plasma membrane during endocytosis (Soulet, Yarar et al. 2005, Roux, Uyhazi et
al. 2006, Raimondi, Ferguson et al. 2011). Dnm1 phosphorylation plays a key
role in regulating synaptic vesicle endocytosis (reviewed in (Smillie and Cousin
2005)). Dnm1 is activated by the dephosphorylation that occurs upon
depolarization of the axon terminal, and then is deactivated by phosphorylation
upon repolarization. We speculate that upregulation of dnm1 activity observed in
the current study among the two oldest NMR age-groups compared to the
youngest age group, may be the result of the brain’s defensive mechanism to
ameliorate reduced neurotransmission by increasing the uptake of excitatory
neurotransmitters into the post-synaptic synapse.
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Spectrin is an α-β heterodimer that makes up to 2-3% of all proteins in the
brain and is responsible for cross-linking actin filaments to form a resilient 3-D
cellular matrix to increase stability of the cytoskeleton as well as to stabilize
transmembrane proteins (Yan, Winograd et al. 1993, Zhang, Zhang et al. 2013).
In addition to actin, spectrin also can cross-link membrane lipids and proteins
(Baines 2009). Spectrin is found at greater concentrations at the presynaptic
membrane and are thought play a role in synaptic transmission and organization,
since spectrin mutations in Drosophila disrupted neurotransmission and resulted
in aberrant synaptic protein localization (Featherstone, Davis et al. 2001). In the
current study, expression of spectrin alpha chain, isoform 3 is increased in the
brain of old-aged NMRs relative to the youngest, and in addition, the
phosphorylation level of this protein is decreased in the brains of the two oldest
NMR groups. Spectrin is known to be phosphorylated at numerous residues;
however, the consequences of spectrin phosphorylation are not yet clear (Baines
2009). However, based upon the reputation of the NMR in terms of successful
aging, we speculate decreased phosphorylation may contribute to the long
healthspan and lifespan of the NMR.
In summary, the NMR, with its many unique traits associated with
salubrious aging, is an exceptional model organism in the study of proteins to
target for therapeutic interventions in the aging process. The findings of the
current age-related study of brain from NMRs identifies changes in protein
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expression and/or phosphorylation levels of key proteins involved in mechanisms
that may be responsible for the increase in neuronal plasticity and the lack of
senescence noted in the NMR.

Figure 6.3.4 Proteins associated with neurite outgrowths that are increased
in levels and/or activity in brain in older NMR age groups. NMR brain
proteins associated with neurite outgrowths that have significantly altered
phosphorylation levels and/or protein levels with age.

These identified brain proteins are illustrated in figures 6.3.4 and 6.3.5. Further
investigations into these proteomics-identified proteins may be warranted to
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identify targets for potential therapies that conceivably may aid in the delay of
aging onset and progression in humans.

Figure 6.3.5 Proteins associated with neurotransmission that are increased
in levels and/or activity in brain in older NMR age groups. Proteins that play
a role in neurotransmission that were significantly altered in phosphorylation
and/or levels in the brain of the naked mole-rat with age.
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CHAPTER 7
CONCLUSIONS AND FUTURE STUDIES
7.1 Conclusions
The studies in this dissertation examined the proteome and
phosphoproteome in brain from the PINK1 KO model of familial PD, the IPL of
PCAD, amnestic MCI and AD subjects, and changes with age in brain of the
long-lived naked mole-rat. The majority of the significantly altered proteins
identified in this dissertation work are involved in vital processes such as: energy
production, disposal and recycling of cellular detritus, stress response, and
neuroplasticity. Furthermore, the proteins identified with altered expression or
phosphorylation in the neurodegenerative brain reflect increased oxidative stress,
altered energy metabolism, diminished proteostasis networks, and decreases in
neurotransmission and neurite outgrowth. Conversely, in the NMR brain, many
alterations in protein levels and protein activities seemingly support underlying
biochemical mechanisms that promote a healthy and efficient cellular state.
Depletion of ATP is a major factor in the cascade leading to apoptosis. In
brain of AD subjects and PINK1 KO mice, declines in levels and/or activity of
energy-related proteins associated with the mitochondria, such as MDH1, and
VDACs were observed. Interestingly, VDACs were consistently identified as
significantly altered in all of the studies put forth in this dissertation. VDACs are
critical regulators not only of mitochondrial flux but of mitophagy as well.
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Therefore dysregulation of VDACs may result in a considerable shift in
metabolism and homeostasis that promotes a neurodegenerative environment.
Accumulation of cellular detritus, including the aggregation of proteins, is
detrimental to proteostasis. In the IPL of AD brain and in brain of PINK1 KO
mice, proteins involved in proteostasis networks are diminished in levels and/or
activity, including heat shock proteins and proteasomal subunits to name a few.
In contrast, in the brain of the senescent-resistant NMR, proteins associated with
autophagy and proteasomal pathways are increased in expression and activity.
In the NMR, these processes are thought to be a primary contributing factor in
promoting a healthy lifespan.
Brain plasticity is critical to healthy brain functioning. In addition to PINK1’s
role in policing mitochondrial integrity, it also contributes to neurite outgrowth.
Consistent with this notion, the ablation of PINK1 leads to decreased levels of
proteins associated with mechanisms of neuroplasticity, such as EF2 which
mediates protein production in the growth cone, and CRMP2 which is a
pleiotropic protein that plays roles in growth cone guidance and in
neurotransmitter release and recycling, among other functions. Dysregulation of
CRMP2 was also evident in the AD brain and associated with the decreased
synapses present in AD brain, where in the NMR brain, increased CRMP2
activities were associated with negligible senescence.
Taken together, the work in this dissertation study has identified global
mechanisms and specific key proteins involved not only in promoting
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neurodegenerative environments, but also in encouraging sustained good health
and a long lifespan. Further investigations into these key proteins may
conceivably provide targets for potential global combatting of neurodegenerative
diseases as well as providing insights into the prevention of age-related disease
for an extended, healthy human lifespan.
7.2 Future Studies
Based on the results of the studies in this dissertation, future
investigations may be warranted in the following areas:
1. For a great number of proteins identified with significantly altered
phosphorylation levels, the implications of the global trends in
phosphorylation were unclear. Further investigations are warranted
to establish not only the identity of the exact amino acid residues
with altered phosphorylation but also to determine how the
phosphorylation or dephosphorylation of that residue impacts the
function of the protein in order to determine if targeting upstream
kinases and phosphatase could be a potential therapeutic strategy.
2. Mitochondrial dysfunction is present in numerous degenerative
diseases, and as such, the PINK1 KO mouse model is a good
general model organism to evaluate consequences of mitochondrial
impairment. Therefore, it would be interesting to evaluate pathways
associated with PINK1 in the NMR brain to examine if PINK1 is
involved in promoting the healthy lifespan of the naked mole-rat.
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3. Compare the changing levels of proteins and protein
phosphorylation states that were seen in the brain of the NMR to
the levels of proteins and protein phosphorylation in wild-type mice
or in neurodegenerative animal models. Evaluating alterations in
proteomes and phosphoproteomes with age within a species, such
as rodents, may be key in discovering underlying mechanisms for
the substantial difference in average lifespans within a species,
such as between a mouse and a naked mole-rat.
4. NMRs reportedly have uncommonly high levels of oxidative
stress, even at an early age compared to mice and these levels do
not seem to be significantly altered over their lifespan. However it
would be interesting to investigate whether individual proteins in the
NMR brain have significant levels of oxidative modification.
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36.41775

0.128883

20.33233

15-24

889.5203

42.9233

0.974026

57.77162

54.16918

0.919913

75.36409

5.951662

25.189

31.776

15-24
average

646.4217

Bonferroni's multiple
comparisons test for
HSP70

28.42
17.785
Mean
Diff.

95% CI of diff.

Significant?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

-133.2

-685.3 to 418.9

No

ns

> 0.9999

2-3 vs. 7-12

-672.1

-1243 to -101.2

Yes

*

0.0150

2-3 vs. 15-24

-546.4

-1084 to -8.878

Yes

*

0.0448

4-6 vs. 7-12

-538.9

-1063 to -14.30

Yes

*

0.0417

4-6 vs. 15-24

-413.2

-901.2 to 74.81

No

ns

0.1350

7-12 vs. 15-24

125.7

-383.5 to 634.9

No

ns

> 0.9999

Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of diff.

Significant
?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

88.76

4.143 to 173.4

Yes

*

0.0359

2-3 vs. 7-12

70.66

-13.96 to 155.3

No

ns

0.1461

2-3 vs. 15-24

71.58

-10.81 to 154.0

No

ns

0.1180

4-6 vs. 7-12

-18.11

-95.35 to 59.14

No

ns

> 0.9999

4-6 vs. 15-24

-17.18

-91.98 to 57.61

No

ns

> 0.9999

7-12 vs. 15-24

0.9218

-73.87 to 75.72

No

ns

> 0.9999

Mean
Diff.

95% CI of diff.

Significant?

Summar
y

Adjusted P
Value

For HSP60

Bonferroni's multiple
comparisons test for
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p-VDAC1
2-3 years vs. 4-6 years

0.1319

-0.03835 to
0.3022

No

ns

0.2133

2-3 years vs. 7-12 years

0.1824

0.01212 to
0.3527

Yes

*

0.0308

2-3 years vs. 15-24
years

0.1519

-0.01026 to
0.3141

No

ns

0.0762

4-6 years vs. 7-12 years

0.05047

-0.1050 to
0.2059

No

ns

> 0.9999

4-6 years vs. 15-24
years

0.02002

-0.1265 to
0.1666

No

ns

> 0.9999

7-12 years vs. 15-24
years

0.03045

-0.1770 to
0.1161

No

ns

> 0.9999

Bonferroni's multiple
comparisons test of

Mean
Diff.

95% CI of diff.

Significant?

Summar
y

Adjusted P
Value

2-3 years vs. 4-6 years

0.2559

0.1017 to 0.4101

Yes

***

0.0004

2-3 years vs. 7-12 years

0.2593

0.1051 to 0.4135

Yes

***

0.0004

2-3 years vs. 15-24
years

0.2322

0.08529 to
0.3791

Yes

***

0.0008

4-6 years vs. 7-12 years

0.00338
6

-0.1374 to
0.1442

No

ns

> 0.9999

4-6 years vs. 15-24
years

0.02372

-0.1564 to
0.1090

No

ns

> 0.9999

7-12 years vs. 15-24
years

0.02711

-0.1598 to
0.1056

No

ns

> 0.9999

Bonferroni's multiple
comparisons test of

Mean
Diff.

95% CI of diff.

Significant?

Summar
y

Adjusted P
Value

2-3 years vs. 4-6 years

0.09454

-0.1998 to
0.3889

No

ns

> 0.9999

2-3 years vs. 7-12 years

0.3154

0.02104 to
0.6098

Yes

*

0.0307

p-VDAC2

p-VDAC3
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2-3 years vs. 15-24
years

0.2258

-0.05460 to
0.5062

No

ns

0.1768

4-6 years vs. 7-12 years

0.2209

-0.04785 to
0.4896

No

ns

0.1594

4-6 years vs. 15-24
years

0.1313

-0.1221 to
0.3846

No

ns

0.8960

7-12 years vs. 15-24
years

0.08961

-0.3430 to
0.1638

No

ns

> 0.9999

Figure 6.2.5
Age Group
(Years)

UCH Density

Tubulin
Density

2-3

2851686

44505952

87.61379

2-3

2759994

45814200

82.37528

2-3

3604284

46936732

105.00140

2-3

4555672

49830838

125.00950

4-6

5124438

47750646

146.7425

4-6

4663548

51077178

124.8471

4-6

4908006

51205880

131.0612

4-6

5784966

53079396

149.0266

7-12

5354748

52102270

140.5307

7-12

6036012

52537734

157.0969

7-12

4785048

50003598

130.8501

7-12

4856598

52662550

126.1012

15-24

5832432

52280214

152.5461

15-24

4545396

50018736

124.2590

15-24

4200280

50529060

113.6648
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Normalized
UCH / Tubulin

15-24

4309260

Dunnett's multiple
comparisons test

50477702

116.7326

Mean
Diff.

95% CI of diff.

Significa
nt?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

-37.92

-66.81 to 9.030

Yes

*

0.0111

2-3 vs. 7-12

-38.64

-67.53 to 9.756

Yes

**

0.0098

2-3 vs. 15-24

-30.05

-58.94 to 1.162

Yes

*

0.0413

Age Group
(Years)

VDAC2

Tubulin

2-3

11370942

44140320

96.22315

2-3

12029837

41349105

108.67060

2-3

11608083

42878619

101.1203

2-3

11424412

45403533

93.98592

4-6

11408708

42828849

99.49900

4-6

12654145

45058419

104.90000

4-6

12501523

40796532

114.46120

4-6

13941916

46549251

111.87380

7-12

13679860

44917299

113.7592

7-12

14047446

45207603

116.0659

7-12

15104759

42399819

133.0664

7-12

15805771

44166276

133.6729

15-24

16433705

48851208

125.6547

15-24

16788237

52365474

119.7509

15-24

20508688

62373906

122.8156

213

VDAC2
/Tubulin

15-24

20679550

Dunnett's multiple
comparisons test

73103360

105.6629

Mean
Diff.

95% CI of diff.

Significant
?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

-13.18

-29.75 to
3.384

No

ns

0.1290

2-3 vs. 7-12

-24.64

-41.21 to 8.074

Yes

**

0.0048

2-3 vs. 15-24

-18.97

-35.54 to 2.404

Yes

*

0.0249

Age Group
(Years)

p-(S/T/Y)

VDAC2

2-3

25070355

23862224

87.670840

2-3

23857290

20204054

98.534470

2-3

21015465

16304812

107.554600

2-3

20745590

16294564

106.240100

4-6

15912785

18574561

71.488010

4-6

10264595

20668630

81.441520

4-6

13422590

16548263

67.684540

4-6

18079380

15836576

95.263790

7-12

16780335

16762373

83.535430

7-12

17740360

18093088

81.819220

7-12

15535520

15947413

81.290750

7-12

10481460

12070680

72.459550

15-24

17145040

18298536

78.185780

15-24

16154435

16884556

79.837650

15-24

16618855

16661357

83.233150
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p-(S/T/Y)
/VDAC2

15-24

20159150

18506790

90.096410

Dunnett's multiple
comparisons test

Mean
Diff.

95% CI of
diff.

Significan
t?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

17.78

0.7602 to
34.80

Yes

*

0.0404

2-3 vs. 7-12

22.72

5.703 to
39.74

Yes

**

0.0099

2-3 vs. 15-24

17.16

0.1414 to
34.18

Yes

*

0.0481

Figure 6.2
2-3 Years

4-6 Years

7-12
Years

Normalized

15-24 Years

113.

316.

648.

93.

105.

344.

241.

58.

96.

308.

126.

69.

94.

379.

109.

63.

86.

103.

98.

100.

106.

93.

101.

127.

77.

87.

p-PI3K

52.
Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of diff.

Significan
t?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

-190.0

-291.2 to 88.85

Yes

***

0.0001

2-3 vs. 7-12

-25.33

-121.8 to
71.11

No

ns

> 0.9999

2-3 vs. 15-24

18.88

-71.34 to
109.1

No

ns

> 0.9999

4-6 vs. 7-12

164.7

63.52 to
265.8

Yes

***

0.0007
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4-6 vs. 15-24

208.9

113.6 to
304.1

Yes

****

< 0.0001

7-12 vs. 15-24

44.21

-46.01 to
134.4

No

ns

> 0.9999

2-3 Years

4-6 Years

7-12
Years

Normalized

15-24 Years

141.

219.

129.

84.

148.

239.

115.

128.

70.

129.

60.

273.

73.

195.

53.

103.

67.

109.

25.

70.

p-Akt

56.*

87.
93.

Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of
diff.

Significant?

Summ
ary

Adjusted P
Value

4-6 vs. 2-3

78.40

-15.24 to
172.0

No

ns

0.1210

4-6 vs. 7-12

101.8

8.165 to
195.4

Yes

*

0.0306

4-6 vs. 15-24

58.49

-28.20 to
145.2

No

ns

0.2756

2-3 Years

4-6 Years

7-12
Years

Normalized

15-24 Years

76.

265.

152.*

121.

136.

202.

57.

58.

62.

167.

126.

72.

95.

174.

65.

69.

p-PI3K
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103.

47.*

43.

154.*

128.

106.

42.

41.
97.

Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of diff.

Significan
t?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

-82.80

-151.4 to 14.16

Yes

*

0.0130

2-3 vs. 7-12

33.40

-35.24 to
102.0

No

ns

0.9994

2-3 vs. 15-24

23.67

-41.78 to
89.11

No

ns

> 0.9999

4-6 vs. 7-12

116.2

44.51 to
187.9

Yes

***

0.0009

4-6 vs. 15-24

106.5

37.83 to
175.1

Yes

**

0.0013

7-12 vs. 15-24

-9.733

-78.37 to
58.91

No

ns

> 0.9999

Figure 6.2.8
2-3 Years
Normalized
Beclin-1

4-6 Years

7-12
Years

15-24 Years

109.

98.

84.

45.

100.

100.

86.

38.

97.

101.

76.

25.

86.

89.

66.

41.

106.

88.

83.

100.

102.

92.

71.

116.*

96.

84.

59.
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Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of
diff.

Significant?

Summ
ary

Adjusted P
Value

2-3 vs. 4-6

5.143

-17.38 to
27.67

No

ns

> 0.9999

2-3 vs. 7-12

21.43

-1.095 to
43.95

No

ns

0.0689

2-3 vs. 15-24

48.67

25.29 to
72.04

Yes

****

< 0.0001

4-6 vs. 7-12

16.29

-5.354 to
37.93

No

ns

0.2408

4-6 vs. 15-24

43.52

21.00 to
66.05

Yes

****

< 0.0001

7-12 vs. 15-24

27.24

4.714 to
49.76

Yes

*

0.0120

2-3 Years
LC3-II/LC3-I

4-6 Years

7-12 Years

15-24 Years

87.

80.

105.

82.

94.

76.

104.

83.

102.

106.

84.

80.

95.

85.

103.

79.

108.

95.

84.

100.

111.

103.

113.

90.
91.
Bonferroni's multiple
comparisons test

Mean
Diff.

95% CI of
diff.

Significant
?

Summar
y

Adjusted P
Value

2-3 vs. 4-6

11.43

-7.067 to
29.93

No

ns

0.5178

2-3 vs. 7-12

1.333

-16.31 to
18.97

No

ns

> 0.9999

2-3 vs. 15-24

11.33

-5.167 to
27.83

No

ns

0.3515
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4-6 vs. 7-12

-10.10

-28.60 to
8.400

No

ns

0.7609

4-6 vs. 15-24

-0.1000

-17.52 to
17.32

No

ns

> 0.9999

10.00

-6.500 to
26.50

No

ns

0.5527

7-12 vs. 15-24

Figure 6.3.3
CRMP2
Age
Group

2-3

4-6

7-12

15-24

112.02810 91.20329 85.89200 116.70740
103.42720 83.99056 88.99440 101.48190
98.89340

74.40849 72.86880 104.06040

85.65129

83.06218 89.11713 104.64650

SS
DF
1640
3
822.5
12
2463
15
Tukey's multiple comparisons
test
2-3 vs. 4-6
2-3 vs. 7-12
2-3 vs. 15-24
4-6 vs. 7-12
4-6 vs. 15-24
7-12 vs. 15-24

MS
546.8
68.54

F (DFn, DFd)
P value
F (3, 12) = 7.977 P = 0.0034

Mean Diff.
16.83
15.78
-6.724
-1.052
-23.56
-22.51

95% CI of diff.
-0.5464 to 34.21
-1.598 to 33.16
-24.10 to 10.66
-18.43 to 16.33
-40.94 to -6.178
-39.89 to -5.126

Significant?
No
No
No
No
Yes
Yes

Summary Adjusted P Value
ns
0.0587
ns
0.0797
ns
0.6682
ns
0.9978
**
0.0079
*
0.0108

Septin-7
Age Group

2-3

4-6

7-12

15-24

60.11256

144.154
2

145.034
9

161.08360

105.6591
0

165.870
5

158.037
6

149.56410
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100.2287
0

155.489
9

159.520
5

105.29490

133.9996
0

143.832
2

149.282
5

94.47577

SS
7562

DF
3

MS
2521

6455
14017

12
15

537.9

ANOVA table
Treatment (between
columns)
Residual (within columns)
Total
Tukey's multiple comparisons
test
2-3 vs. 4-6
2-3 vs. 7-12
2-3 vs. 15-24
4-6 vs. 7-12
4-6 vs. 15-24
7-12 vs. 15-24

Mean Diff.
-52.34
-52.97
-27.60
-0.6322
24.73
25.36

95% CI of diff.
-101.0 to -3.647
-101.7 to -4.279
-76.29 to 21.08
-49.32 to 48.06
-23.96 to 73.42
-23.33 to 74.05

F (DFn, DFd)
F (3, 12) =
4.686

Significant?
Yes
Yes
No
No
No
No

P value
P=
0.0217

Summary Adjusted P Value
*
0.0340
*
0.0318
ns
0.3733
ns
> 0.9999
ns
0.4628
ns
0.4422

Cofilin-1
Age Group

ANOVA table
Treatment (between
columns)
Residual (within columns)
Total
Tukey's multiple comparisons
test
2-3 vs. 4-6
2-3 vs. 7-12
2-3 vs. 15-24
4-6 vs. 7-12
4-6 vs. 15-24

2-3

4-6

7-12

15-24

96.44344

73.0699
1

61.9647
4

66.76112

81.95702

40.2358
7

72.7016
6

87.00309

121.8742
0

82.9013
2

64.8332
3

60.22153

99.72531

76.0143
0

71.2137
8

56.64687

SS
3111

DF
3

MS
1037

2530
5641

12
15

210.8

Mean Diff.
31.94
32.32
32.34
0.3770
0.3972

95% CI of diff.
1.464 to 62.42
1.841 to 62.80
1.862 to 62.82
-30.10 to 30.86
-30.08 to 30.88

220

F (DFn, DFd)
F (3, 12) =
4.920

Significant?
Yes
Yes
Yes
No
No

P value
P=
0.0187

Summary Adjusted P Value
*
0.0390
*
0.0366
*
0.0365
ns
> 0.9999
ns
> 0.9999

7-12 vs. 15-24

0.02020

-30.46 to 30.50
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No

ns

> 0.9999
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